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ABSTRACT OF DISSERTATION

PERMISSIVENESS OF SELECTED CELL LINES TO EQUINE ARTERITIS VIRUS:
ESTABLISHMENT, CHARACTERIZATION, AND SIGNIFICANCE OF
PERSISTENT INFECTION IN HELA CELLS

A major goal of this research was to evaluate a variety of cell lines for their
permissiveness to equine arteritis virus (EAV) infection and then identify the mechanism
that restricts EAV infection in certain cell lines. The cell lines BHK-21, RK-13, and
C2C12 were found to support productive infection with EAV strain VBS53, whereas
Hela, Hep-2, and L-M cell lines exhibited limited susceptibility to infection with this
virus. In the course of the study, it was found that the Hela cell line became more
susceptible to infection with EAV strain VBS53 after extended serial passage. The
respective cell lines were referred to as Hela High (passage 170-221) and Hela Low
(passage 95-115) lines. While the Hela High cell line was more susceptible than the Hela
Low cell line, it was still considerably less susceptible than the BHK-21 cell line to EAV
infection. Subsequent studies demonstrated that infection with EAV strain VBS53 was
restricted at the entry step in Hela, Hep-2, and L-M cell lines.
The second major goal of this research was to establish an in vitro model of
persistent EAV infection using cell culture and then use the persistently infected cultures
as a tool to study virus-host cell interactions, and to investigate virus and host cell
evolution. Persistent infection was successfully established in the Hela High cell line with
the VBS53 strain of EAV. Properties of the persistently infected Hela High cell line were
characterized. Virus evolution with respect to virus growth characteristics, ability of the
virus to initiate secondary persistent infection, and genetic changes during persistent

EAV infection in Hela cells was investigated. Neutralization phenotypic changes of
viruses were observed during the course of persistent EAV infection in Hela cells.
Reverse genetics studies identified that amino acid 98 of the GP5 protein is a new
neutralization determinant of EAV. Using an in vitro assay, it was found that EAV
probably became progressively less virulent during the course of persistent infection in
Hela cells. The potential changes in pathogenicity of EAV during persistent infection of
Hela cells need to be verified by inoculation of horses.
KEYWORDS: Equine Arteritis Virus, Hela Cells, Persistent Infection, Neutralization
Determinants, Virus Virulence
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Chapter One: General Introduction
I. INTRODUCTION
Equine viral arteritis (EVA) is a globally distributed infectious disease of equids
caused by equine arteritis virus (EAV). EAV was first isolated from the lung of an
aborted fetus in the course of an outbreak of respiratory disease and abortion in
Standardbred horses at Bucyrus, Ohio, USA, in 1953 (Doll et al. 1957a; 1957b). The
majority of horses develop a subclinical infection following natural exposure to EAV.
Occasionally, clinical disease can occur: influenza-like illnesses in adult horses, abortion
in pregnant mares, and interstitial pneumonia, or enteritis, or pneumonoenteritis in young
foals (Glaser et al. 1997; Timoney and McCollum 1993). Up to 30% to 70% of stallions
infected with EAV can subsequently become carriers which constantly shed the virus in
semen (Timoney and McCollum 1993). Persistently infected stallions are the principal
reservoir of EAV and are responsible for perpetuation and dissemination of EAV in
equine populations (Timoney et al. 1987; Timoney and McCollum 1993). Carrier
stallions are also thought to be a significant natural source of genetic and phenotypic
diversity of EAV (Balasuriya et al. 1999a; 2004a; Hedges et al. 1999a).
Persistent infection of cell culture has been documented with many viruses. Such
infections have been used to study virus-host cell interactions and they have also been
shown to be a useful tool for investigating virus and cell evolutions (Ahmed et al. 1981;
Colbere-Garapin et al. 1989; de la Torre et al. 1988a; Kaplan et al. 1989). Persistent
infection in cell culture could possibly serve as a model system for elucidating
mechanisms of viral persistence in vivo.
In this introductory chapter, the molecular biology of EAV is addressed in section II
with EAV infection and persistently infected stallions discussed in section III. Persistent
infections of cell cultures with RNA viruses will be reviewed in section IV followed by
the research objectives of this study in section V.

II. EQUINE ARTERITIS VIRUS
1. Classification and genome organization
Based on similarities in genomic organization and protein expression strategies, the
Arteriviridae (genus Arterivirus), Coronaviridae (genera Coronavirus and Torovirus),
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and Roniviridae (genus Okavirus) were grouped together in the order Nidovirales (Table
1.1; Cavanagh 1997; de Vries et al. 1997). Arteriviruses comprise four members: equine
arteritis virus (EAV), porcine respiratory and reproductive syndrome virus (PRRSV),
lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV)
(Snijder and Meulenberg 1998). Coronaviruses can be grouped into three clusters on the
basis of serological and genetic properties (Lai and Cavanagh 1997; Stephensen et al.
1999). Grouping of newly discovered SARS-CoV has been of controversy. Phylogenetic
analysis of different SARS-CoV proteins using unrooted trees showed that SARS-CoV
does not segregate into any of the three established coronavirus groups and it was
suggested that SARS-CoV may be classified as the prototype of a novel, fourth group of
coronaviruses (Marra et al. 2003; Rota et al. 2003). However, phylogenetic analysis of
coronavirus replicase genes using a rooted tree (the equine torovirus was used as an
outgroup for coronaviruses) indicated that the SARS-CoV lineage was an early split-off
from the coronavirus group 2 branch and it was suggested that SARS-CoV could be
classified as the prototype of subgroup 2b if the established group 2 coronaviruses would
be referred to as subgroup 2a (Snijder et al. 2003). Four torovirus species have been
recognized: equine torovirus (Berne virus), bovine torovirus (Breda virus), human
torovirus, and porcine torovirus (Koopmans and Horzinek 1994; Kroneman et al. 1998).
The recently discovered okaviruses that infect prawns comprise two members thus far:
gill-associated virus and yellow head virus (Cowley et al. 2002a; Cowley and Walker
2002b; Sittidilokratna et al. 2002).
Nidoviruses have in common a characteristic genome organization: the most 5’ end
open reading frames (ORF), 1a and 1b, encode the viral replicase polyproteins that are
subsequently proteolytically processed; the 3’-terminals of the genome encode structural
proteins (Snijder and Meulenberg 1998). Nidoviruses have a unique mechanism to
regulate structural protein gene expression. The structural protein genes are not directly
expressed from the genome, but from a nested set of 3’-coterminal subgenomic mRNAs
(sg mRNAs). In the case of arteriviruses and coronaviruses, subgenomic mRNAs also
contain a common 5’ leader sequence derived from the 5’ end of the genome (Lai and
Cavanagh 1997; Snijder and Meulenberg 1998). On the other hand, subgenomic mRNAs
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of okaviruses do not have a common 5’ leader sequence (Cowley et al. 2002c), neither do
torovirus sg mRNAs with exception of sg mRNA2 (Snijder et al. 1990).
The EAV genome is a single-stranded, positive-sense RNA molecule of 12,704
nucleotides [sizes excluding the 3’ poly(A) tail] in length. The 3’ end of the genome is
polyadenylated (van Berlo et al. 1982) and the 5’ end is believed to be capped (Snijder
and Meulenberg 1998). Its genomic organization is depicted in Fig 1.1 and Table 1.2. The
coding regions of the EAV genome are flanked by 5’ and 3’ non-translated regions
(NTRs) of 224 nucleotides (nt) and 59 nt, respectively (Table 1.2). Nucleotides (1-211)
are often referred to as the 5’ leader sequence which is present in genomic RNA and in
all sg mRNAs. An intraleader ORF (nt 14-127, encoding a hypothetical 37 aa peptide)
was suggested by Kheyar et al. (1996). However, the expression of this ORF has never
been observed and the role of this putative intraleader ORF has yet to be determined. The
EAV genome includes nine functional ORFs. The replicase gene comprises the 5’terminal three-quarters of the genome and includes two large ORFs (1a and 1b), which
are both expressed directly from the genomic RNA. The translation of ORF1a generates a
multi-domain precursor polyprotein: the 1727-amino-acid ORF1a polyprotein (187 kD).
Following ORF1a translation, a -1 ribosome frameshift into ORF1b occurs with an
estimated efficiency of 15 to 20% (den Boon et al. 1991). This results in the generation of
a 3175-amino-acid ORF1ab polyprotein (345 kD). Two large replicase polyproteins
(polyprotein 1a and polyprotein 1ab) are proteolytically processed by three ORF1aencoded proteases (Snijder et al. 1992; 1995; 1996) and produce 12 nonstructural
proteins (nsp1-12; Table 1.2) and multiple processing intermediates (den Boon et al.
1995a; Snijder et al. 1993, 1994; van Dinten et al. 1996; 1999; Wassenaar et al. 1997).
The 3’ one-quarter of the genome is composed of seven ORFs (2a, 2b, 3-7), which
encode structural proteins E, GP2b (Gs), GP3, GP4, GP5 (GL), M, and N, respectively.
Most of these ORFs that encode structural proteins have both 5’- and 3’- terminal
sequences that overlap with neighboring genes (Fig 1.1A and Table 1.2; de Vries et al.
1992; Snijder and Meulenberg 1998; Snijder et al. 1999). These structural proteins are
expressed from a 3’-coterminal nested set of six subgenomic mRNAs that also contain a
common 5’ leader sequence, which is derived from the 5’ end of the viral genome (Fig
1.1A; de Vries et al. 1990; van Berlo et al. 1982). The following 13, 3.2, 2.7, 2.2, 1.9, 1.2,

3

and 0.8 kb [including a poly(A) tail] were estimated for EAV genomic RNA and sg
mRNAs 2-7, respectively (den Boon et al. 1991). In sg mRNAs, the leader sequence is
linked to different sequences derived from the 3’ region of the genome, which are
referred to as “mRNA bodies”. The leader sequences are connected to the mRNA bodies
by a short, conserved transcription-regulating sequence (TRS) which is present both at
the 3’ end of the leader sequence and at the 5’ end of the mRNA bodies (Fig 1.1A).
2. Virion architecture and properties
Equine arteritis virus is a small, spherical, enveloped, positive-strand RNA virus.
The virus particles are 40-60 nm in diameter (Horzinek et al. 1971) and have a buoyant
density of 1.17 to 1.20 g/ml in sucrose, 1.18 to 1.22 g/ml in cesium chloride (Hyllseth
1970). The sedimentation coefficient of EAV particles has been reported to be between
216S and 232S (van der Zeijst and Horzinek 1975). The stability of EAV is influenced by
temperature and pH and EAV can be stored at -70ºC for years without significant loss of
the infectivity (Burki 1966; Harry and McCollum 1981; McCollum et al. 1961). Equine
arteritis virus can be inactivated by lipid solvents (ether and chloroform) and by
disinfectants and detergents (Burki 1965; Zeegers et al. 1976).
A schematic representation of the EAV virion architecture is shown in Fig 1.1B.
Virions consist of an icosahedral nucleocapsid (25-35 nm in diameter) which is
surrounded by a lipid-containing envelope with tiny surface projections (Horzinek et al.
1971). The viral nucleocapsid is composed of the linear viral genomic RNA (12.7 kb) and
a 14-kDa phosphorylated nucleocapsid (N) protein (de Vries et al. 1992; Hyllseth 1973;
Zeegers et al. 1976). The virion envelope contains six envelope proteins. The two major
envelope proteins are 16-kDa nonglycosylated membrane protein (M) and the relatively
large envelope glycoprotein GP5 (previously named GL) of 30 to 42 kDa (de Vries et al.
1992). The M and GP5 proteins occur in the virion as disulfide-linked heterodimers (de
Vries et al. 1995b). The unglycosylated envelope protein E of 8 kDa is of intermediate
abundance in the virion (Snijder et al. 1999). The three minor envelope proteins of EAV
are 25-kDa glycoprotein GP2b (previously named Gs), the heterogeneously Nglycosylated GP3 glycoprotein of 36 to 42 kDa, and the 28-kDa GP4 glycoprotein,
respectively (de Vries et al. 1992; 1995a; Hedges et al. 1999b; Wieringa et al. 2002). The
GP2b, GP3, and GP4 proteins occur in the virion as heterotrimers (Wieringa et al. 2003a).
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The EAV nucleocapsid protein, encoded by ORF7, is a small protein with a high
content of basic amino acids and a hydrophilic nature (de Vries et al. 1992). The N
protein is expressed abundantly in infected cells and constitutes about 35 to 40% of the
protein moiety in the virion (de Vries et al. 1992). The N protein was shown to be
phosphorylated and present in the virion as a monomer (Snijder and Meulenberg 1998).
The N protein is necessary for virus assembly and the production of infectious virus
particles (Molenkamp et al. 2000; Wieringa et al. 2004). It is predicted that the N protein
plays an important role in encapsidating viral genomic RNA and in the interactions with
envelope proteins during virus assembly. However, the regions of the N protein
responsible for RNA encapsidation and interactions with envelope proteins have not yet
been determined. The EAV virion biogenesis is assumed to be a strictly cytoplasmic
event, however, besides existing in the cytoplasm, small quantities of the N protein have
also been observed in the nucleus (Molenkamp et al. 2000; Tijms et al. 2002). The
mechanism and significance of the nuclear translocation of EAV N protein remain
unknown.
The GP5 and M proteins are the two major envelope proteins and are encoded by
ORF5 and 6, respectively (de Vries et al. 1992). The M and GP5 proteins are present in
virions in equimolar amounts and appear as disulfide-linked heterodimers which
constitute the basic protein matrix of the envelope (de Vries et al. 1992; 1995b). In cells
infected with EAV, disulfide-linked M protein homodimers were also observed but these
were not incorporated into virions (Snijder and Meulenberg 1998). The M protein, like
the N protein, lacks potential N-glycosylation sites and lacks a potential amino-terminal
signal sequence (de Vries et al. 1992). The M protein is assumed to span the viral
envelope three times with its internal transmembrane segments, leaving a short stretch of
10-18-amino-acid N-terminal domain (ectodomain) exposed at the outside of the virion
and an approximately 72-residue C-terminal domain buried at the inside (de Vries et al.
1992; 1995b; Snijder and Meulenberg 1998). The single Cys residue (Cys-8) in the M
ectodomain is crucial for the formation of both the GP5-M heterodimer and the M-M
homodimer (Snijder et al. 2003). The GP5 protein (255 aa) is a heterogeneously
glycosylated protein that contains an N-terminal signal sequence (aa 1-18) which is
cleaved off during transport through the endoplasmic reticulum (ER). The hydropathy
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profile of the GP5 protein would suggest that amino acid residues 19-116 constitute the
hydrophilic ectodomain of the protein, while the C-terminal half consists of three
membrane-spanning domains followed by an endodomain of about 64 amino acids
(Balasuriya and MacLachlan 2004c; de Vries et al. 1992; Snijder et al. 2003). The
ectodomain of the GP5 protein possesses one or two N-glycosylation sites (Asn-56 is a
N-glycosylation site which is conserved amongst all strains of EAV and Asn-81 is
another potential N-glycosylation site occurring in some field and laboratory strains of
EAV) to which variable numbers of lactosamine side chains were added (Balasuriya et al.
1995a; de Vries et al. 1992). The ectodomain of the GP5 protein also contains five
conserved Cys residues: Cys-34, Cys-57, Cys-63, Cys-66, and Cys-80. The Cys-34 in the
GP5 ectodomain and the Cys-8 in the M ectodomain form a disulfide bond which
mediates GP5-M heterodimerization (Snijder et al. 2003). The GP5 and M proteins are
indispensable for both virus assembly (Wieringa et al. 2004) and the production of
infectious virus particles (Molenkamp et al. 2000; Snijder et al. 2003; Wieringa et al.
2004). The GP5 protein expresses neutralization determinants of the virus. All of the
neutralization determinants of EAV identified to date are located on the ectodomain of
the GP5 protein (Balasuriya et al. 1993; 1995b; 1997; 2004b; Chirnside et al. 1995;
Deregt et al. 1994; Glaser et al. 1995).
Besides the three major structural proteins, the EAV virion contains four other
envelope proteins: small hydrophobic envelope protein E, and minor envelope proteins
GP2b, GP3, and GP4 which occur as heterotrimers (Snijder et al. 2003; Wieringa et al.
2002). Also, it has been recently demonstrated that incorporation of the E protein is
somehow linked to that of GP2b/GP4/GP3, suggesting the existence of a
GP2b/GP4/GP3/(E) complex (Wieringa et al. 2004). The small envelope protein E (67
aa), encoded by EAV ORF2a, is an integral membrane protein with a central hydrophobic
domain of 40 residues and a cluster of basic amino acid residues in the hydrophilic Cterminal domain (Snijder et al. 1999). The EAV E protein does not have a N-terminal
signal sequence and lacks potential N-glycosylation sites (Snijder et al. 1999). The E
protein proved to be stable and did not form covalently linked multimers (Snijder et al.
1999). The E protein was found to associate with intracellular membranes (both the ER
and Golgi complex) in EAV-infected cells or upon independent expression(Snijder et al.
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1999). Minor envelope proteins GP2b, GP3, and GP4, encoded by EAV ORF2b, 3, 4,
respectively, are abundantly expressed in EAV-infected cells, but only a small fraction of
them is assembled into the virion. In the virion, the molar ratio of GP2b to GP5 and M is
approximately 1:25 (de Vries et al. 1992; 1995a; Wieringa et al. 2003a). Both GP2b and
GP4 proteins are type I integral membrane proteins, containing one and three functional
N-glycosylation sites, respectively (de Vries et al. 1995a; Wieringa et al. 2002). Both
GP2b and GP4 proteins contain a 22-24 amino acid residue of an N-terminal signal
sequence which is cleaved off during transport through the ER (de Vries et al. 1995a;
Wieringa et al. 2002). The GP3 protein is a heavily glycosylated integral membrane
protein with six N-glycosylation sites. It contains an uncleaved hydrophobic aminoterminal signal sequence and a hydrophobic C-terminus (Hedges et al. 1999b; Wieringa
et al. 2002). The GP3 protein is anchored to the membrane by either one or both of its
hydrophobic terminal domains; no part of its structure is detectably exposed
cytoplasmically (Hedges et al. 1999b; Wieringa et al. 2002). It has been shown that the
EAV E, GP2b, GP3, and GP4 proteins are dispensable for the formation of virus-like
particles (Wieringa et al. 2004) while they are essential for the production of infectious
virus particles (Molenkamp et al. 2000). It implies that the GP2b/GP4/GP3/(E) complex
may be involved in the virus attachment and cell entry process.
3. The replication cycle of equine arteritis virus
Equine arteritis virus can be propagated in a variety of primary cultures such as
equine macrophages (Moore et al. 2003a), equine endothelial cells (Moore et al. 2003b),
equine kidney cells (McCollum et al. 1961), hamster kidney cells (Wilson et al. 1962),
and so on. The virus can also replicate efficiently in several continuous cell lines such as
rabbit kidney (RK-13; McCollum et al. 1962), baby hamster kidney (BHK-21; Hyllseth
1969), African green monkey kidney (Vero; Konishi et al. 1975) and so on. EAV
infection of primary cells and continuous cell lines is highly cytocidal. The appearance of
cytopathic effect (CPE) and the titer of infectious virus produced in different cell lines
vary. The cytopathic effect exhibited in EAV-infected cells is characterized by rounding
of cells and cell detachment from the culture plate surface (Hyllseth 1969; McCollum et
al. 1962). Like other viruses, EAV infection of cells involves virus attachment and entry,
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biosynthesis (viral genome replication, mRNA transcription, and viral protein synthesis),
virus assembly, budding, and release.
(1) Virus attachment and entry
The first step of virus infection is viral attachment to a specific receptor on a
susceptible cell. In the case of EAV, neither a virus attachment molecule nor a specific
cell receptor has yet been identified. By analogy with many other animal RNA viruses
and in view of its recognition by neutralizing antibodies, the EAV GP5 protein had been
postulated to serve as the virus attachment protein and to mediate receptor recognition.
However, exchange of the ectodomain of the EAV GP5 protein with that of PRRSV or
LDV in the context of an infectious EAV cDNA clone did not alter the cell tropism of the
virus (Dobbe et al. 2001). In that study, the EAV GP5 ectodomain (aa 1-114) in a fulllength EAV cDNA clone was replaced by the GP5 ectodomain (aa 1-64) of PRRSV or
LDV to yield chimeric EAV. It was found that these chimeric viruses were still able to
infect BHK-21 and RK-13 cells. It is well known that these cells can be infected by EAV,
but not by either PRRSV or LDV (Dobbe et al. 2001). The authors concluded that the
ectodomain of GP5 is not the main determinant of EAV tropism in cell culture. Similarly,
PRRSV mutants in which the ectodomain of the M protein was replaced by that of EAV
or LDV still retained their ability to infect porcine alveolar macrophages and did not
acquire tropism to cells susceptible to the respective viruses (e.g. BHK-21 cells for EAV
and mouse macrophages fro LDV) from which the foreign ectodomains were derived
(Verheije et al. 2002). This would suggest that, in the case of arteriviruses, the M protein
is not responsible for receptor binding either. Recently, Wieringa et al. (2003a) have
shown that minor structural proteins are present in EAV virions as disulfide-linked
GP2b/GP4/GP3 heterotrimeric complexes. Also, there are indications that the E protein is
noncovalently associated with the GP2b/GP4/GP3 trimers (Wieringa et al. 2004). It has
also been demonstrated that the E, GP2b, GP3, and GP4 proteins are not required for the
formation of EAV particles, although these proteins are believed essential for ensuring
that the virus particles are infectious (Molenkamp et al. 2000; Wieringa et al. 2004).
These findings would suggest that the GP2b/GP4/GP3/(E) complex might be involved in
the EAV attachment/entry process. However, it must be realized that it is possible that a
virus utilizes more than one attachment molecule for binding to cells. For example,
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Delputte et al. (2002) showed that the PRRSV M protein alone or in a complex with GP5
were involved in virus attachment to the receptor heparan sulfate on porcine alveolar
macrophages; it has also been found that sialic acids on the PRRS virion can mediate
virus attachment to another receptor sialoadhesin on porcine alveolar macrophages
(Delputte and Nauwynck 2004). Sialic acids may be present on one or more viral
glycoproteins. Moreover, viruses do not necessarily utilize the same attachment molecule
to attach to different cells, e.g. PRRSV uses some unidentified molecules other than sialic
acids to attach to Marc-145 cells (Delputte and Nauwynck 2004).
The cell receptor for EAV has not been identified either. Asagoe et al. (1997)
showed that heparin can reduce EAV infection of RK-13 cells and that this inhibition was
due to the direct interaction between heparin and EAV rather than the interaction between
heparin and RK-13 cells. Furthermore, treatment of RK-13 cells with heparinase before
virus inoculation decreased EAV infection of the cells (Asagoe et al. 1997). The data
suggested that a heparin-like molecule on the surface of RK-13 cells might serve as a cell
receptor for EAV. Similar studies have shown that a heparin-like molecule on Marc-145
cells and porcine alveolar macrophages serves as the cell receptor for PRRSV (Delputte
et al. 2002; Jusa et al. 1997). However, heparinase treatment of RK-13 cells could not
completely block EAV infection (Asagoe et al. 1997). Furthermore, EAV infection could
not be reduced below 13% even in the presence of a very high concentration of heparin
(Asagoe et al. 1997). This implied that other molecules on the cell surface might serve as
EAV receptors as well. In fact, for PRRSV, another arterivirus, two receptors have been
identified on porcine macrophages: heparan sulfate and porcine sialoadhesin (Delputte et
al. 2002; Vanderheijden et al. 2003). Both heparan sulfate and sialoadhesin mediate
PRRSV attachment to porcine macrophages, and early attachment is mediated mainly via
an interaction with heparan sulfate, followed by gradual increase of attachment via the
interaction with sialoadhesin (Delputte et al. 2005). It was observed that PRRSV can
attach to but not be internalized into wild-type CHO K1 cells, which express heparan
sulfate but not sialoadhesin, suggesting that heparan sulfate alone is sufficient to mediate
virus attachment but not entry (Delputte et al. 2005). Upon transfection and expression of
recombinant sialoadhesin, CHO A745 and D667 cells which are naturally deficient in
both heparan sulfate and sialoadhesin expression are capable of binding and internalizing
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PRRSV, indicating that sialoadhesin expression is sufficient for both PRRSV attachment
and internalization and heparan sulfate is not essential for internalization (Delputte et al.
2005). However, heparan sulfate may enhance PRRSV binding to porcine sialoadhesin
(Delputte et al. 2005).
EAV is assumed to enter cells through a process of receptor-mediated endocytosis,
since the same family member PRRSV has been shown to enter cells through a
mechanism of clathrin-dependent, receptor-mediated endocytosis in which low pH is
necessary for the fusion between the endosomal membrane and the viral envelope and
subsequent virus uncoating (Kreutz and Ackermann 1996; Nauwynck et al. 1999). It was
observed that PK-15 cells expressing recombinant sialoadhesin can bind and internalize
PRRSV but they are not productively infected (Vanderheijden et al. 2003). It was also
reported that Vero cells, which are non-permissive to PRRSV infection but can support
PRRSV replication after transfection with viral RNA, were able to bind and internalize
the virus almost as efficiently as the permissive cell line Marc-145 (Kreutz 1998). This
may possibly be due to the fact that the fusion of viral and endosomal membranes does
not occur after virus internalization, and virus remains in the endosome and the viral
genome is not released into the cytoplasm. If this should prove to be true, it would
indicate that some cellular factor(s), which are essential for viral and endosomal
membrane fusion and virus uncoating, are lacking in these cells.
EAV attachment and the entry process still need further study. Firstly, the virus
attachment molecule(s) need to be determined. Secondly, EAV specific cell receptor(s)
wait to be defined. Thirdly, mechanism of fusion between EAV envelope and endosomal
membrane need to be studied. It is still unknown how many receptors or coreceptors are
needed for EAV attachment and entry. Also, it is not clear whether EAV utilizes the same
receptor(s) in different cells and whether different EAV strains use the same receptor(s).
(2) Biosynthesis: viral genome replication, mRNA transcription, and viral
protein synthesis
Once the viral RNA is released into the cytoplasm, arteriviruses start their
replication cycle in the cell. The EAV replication cycle commences with translation of
the replicase polyproteins from the genome, followed by genome replication, subgenomic
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RNA transcription, and translation of structural proteins from sg mRNAs (Fig 1.2;
Snijder and Meulenberg 1998).
A. Genome

translation

and

post-translational

processing

of

replicase

polyproteins
There are two general mechanisms for translation initiation: classical cap-dependent
initiation followed by linear ribosome scanning and initiation via internal ribosome entry
site (IRES) element. The EAV genome is assumed to be 5’ capped based on two findings:
another arterivirus SHFV has been shown to contain a type I cap structure (Sagripanti et
al. 1986) and a cap analogue is known to be essential to make in vitro transcribed fulllength infectious RNA (Meulenberg et al. 1998; van Dinten et al. 1997). Therefore, it
was suggested that EAV genome translation is initiated via a cap-dependent mechanism.
van den Born et al. (2005) has further demonstrated that EAV genome translation is not
IRES mediated. The EAV replicase polyprotein 1a is translated directly from ORF1a.
However, ORF1b translation requires a -1 ribosomal frameshift just before ORF1a
translation is terminated (den Boon et al. 1991). The ribosomal frameshift is assumed to
be directed by two signals in the ORF1a/ORF1b overlap region: a ‘shifty’
heptanucleotide sequence 5’ GUUAAAC 3’, and a downstream RNA pseudoknot
structure (Fig 1.3; Snijder and Meulenberg 1998).
Translation of the EAV replicase gene yields two polyproteins: the polyprotein 1a
and the polyprotein 1ab. The EAV polyprotein 1a is cleaved seven times and the
polyprotein 1ab is cleaved ten times by three different viral proteases, which in total,
generates 12 end-products, named nonstructural protein (nsp) 1-12, and multiple
processing intermediates (Fig 1.4A; Table 1.2). Three EAV proteases are located in nsp1,
nsp2, and nsp4. The nsp1 protease has been characterized as a papain-like cysteine
protease (PCP) (Snijder et al. 1992). The nsp1 of PRRSV and LDV contains two active
proteases: PCP1a and PCP1ß (Ziebuhr et al. 2000). However, in the case of EAV, PCP1a
is inactive and only PCP1ß is active (Ziebuhr et al. 2000). The catalytic dyad of the EAV
PCP has been identified as Cys-164 and His-230 (den Boon et al. 1991; Snijder et al.
1992). The EAV PCP has been found to direct an autoproteolytic cleavage at its C
terminus (Gly-260 | Gly-261 site) and to result in the rapid release of nsp1 (aa 1-260)
from the polyprotein (Fig 1.4A and Table 1.2; Snijder et al. 1992). It was observed that
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the EAV PCP mediates probably exclusively in cis cleavage, and attempts to achieve
cleavage in trans were unsuccessful (den Boon et al. 1995a; Snijder et al. 1992). The
second protease of EAV is the cysteine protease of nsp2 (CP2), which mediates the single
cleavage at Gly-831 | Gly-832 to release nsp2 (Snijder et al. 1995). The putative catalytic
residues of the EAV CP2 are Cys-270 and His-332, though the entire nsp2 protein
appears to be essential for the nsp2|3 cleavage (Snijder et al. 1995). The nsp2|3 cleavage
can be performed by the EAV CP2 in cis or in trans, though trans-cleavage activity is
relatively low (Snijder et al. 1995; Ziebuhr et al. 2000). The EAV nsp4 protease has
some unique characteristics. On one hand, the nsp4 protease utilizes the His-Asp-Ser
(His-1103, Asp-1129, and Ser-1184 in EAV) catalytic triad, a typical characteristic of
classical chymotrypsin-like proteases (Snijder et al. 1996). On the other hand, the
putative substrate-binding region of the EAV nsp4 protease contains Thr and His residues
(Thr-1179 and His-1198 in EAV), which are conserved in viral 3C-like cysteine
proteases and determine their specificity for cleavage sites containing a (Glu/Gln) |
(Gly/Ser) dipeptide (Snijder et al. 1996). Based on these characteristics, the EAV nsp4
protease was classified as the prototype of a novel group of chymotrypsin-like enzymes,
the 3C-like serine proteases (3CLSP) (Snijder et al. 1996). The EAV 3CLSP was shown
to mediate eight cleavages in the EAV replicase proteins: five in the polyprotein 1a and
three in the ORF1b-encoded polypeptide (Snijder et al. 1996; van Dinten et al. 1999;
Wassenaar et al. 1997). Four of the known EAV 3CLSP cleavages occur at Glu | Gly
sites (nsp3|4, nsp5|6, nsp7|8/9, and nsp11|12), three at Glu | Ser sites (nsp4|5, nsp6|7, and
nsp9|10), and one at Gln | Ser site (nsp10|11) (Fig 1.4A and Table 1.2; Snijder et al. 1996;
van Dinten et al. 1999; Wassenaar et al. 1997; Ziebuhr et al. 2000). Whether EAV
3CLSP cleaves each site in cis or in trans has not yet been studied in detail. However, it
is clear that EAV 3CLSP has in trans cleavage activity, since a nsp4 expression product
has been shown to efficiently cleave the nsp9|10 and nsp10|11 sites in a separately
expressed, ORF1b-encoded polypeptide (van Dinten et al. 1999).
As mentioned above, the nsp1|2 and nsp2|3 cleavages are mediated by EAV PCP
and EAV CP2, respectively; the other sites in the EAV polyproteins 1a and 1ab are
cleaved by EAV 3CLSP. But these sites are not equally sensitive to processing by EAV
3CLSP. In fact, two alternative pathways have been reported to process the carboxyl-
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terminal part of the EAV polyprotein 1a (Fig 1.4B; Wassenaar et al. 1997). In the major
processing pathway, the EAV 3CLSP first cleaves at the nsp4|5 site, followed by
cleavage of the nsp3|4 and nsp7|8 junctions, and the nsp5-7 remained uncleaved (Fig
1.4B; Snijder et al. 1994; 1996). But it was found that cleavage at the nsp4|5 site requires
the association of cleaved nsp2 with the nsp3-8 precursor (Wassenaar et al. 1997). If the
nsp2 is absent, the nsp4|5 site cannot be processed and an alternative minor processing
pathway is utilized (Wassenaar et al. 1997). In the minor processing pathway, the nsp4|5
site is not cleaved; instead, the nsp5|6 and nsp6|7 sites are cleaved. Subsequently,
cleavages at the nsp3|4 and nsp7|8 sites occur (Fig 1.4B; Wassenaar et al. 1997). It
appears that the two pathways are mutually exclusive (Wassenaar et al. 1997). In either
processing pathway, multiple processing intermediates are generated. In the major
processing pathway, the nsp2 is required for the cleavage at the nsp4|5 site. But nsp2
protease activity is not involved, since it has been demonstrated that the nsp2 mutants in
which the nsp2 cysteine protease is inactivated can still induce the nsp4|5 cleavage
(Wassenaar et al. 1997). Consequently, it was suggested that the association of nsp2 with
nsp3-8 may affect conformation of the nsp2/nsp3-8 complex which allows the cleavage
of the nsp4|5 site by EAV 3CLSP (Wassenaar et al. 1997).
B. Genome replication
The RNA synthesis (including genome replication and mRNA transcription) of
RNA viruses (except retroviruses) relies on viral-encoded RNA-dependent RNA
polymerase (RdRp). Equine arteritis virus replicase proteins are processed into 12 end
products (nsp1-12) and multiple processing intermediates. The nsp1, nsp2, and nsp4
contain viral proteases (Snijder et al. 1992; 1995; 1996). The nsp9 contains the putative
RNA-dependent RNA polymerase activity, the nsp10 comprises a zinc-binding domain
and the nucleoside triphosphate-binding/helicase activity, and the nsp11 harbors a
conserved nidovirus-specific domain with unknown function (Fig 1.4A and Table 1.2;
van Dinten et al. 1996). Immunofluorescence studies have revealed that the nsp9, nsp10
and the majority of replicase polyprotein 1a cleavage products (nsp2, nsp4, nsp7-8, and
nsp8) colocalize in the perinuclear region of EAV-infected cells and the distribution
pattern of these proteins suggest that they are associated with intracellular membranes
(van der Meer et al. 1998; van Dinten et al. 1996). Colocalization of these proteins
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suggests that they might assemble into a large complex which is likely involved in viral
RNA synthesis. In situ labeling of nascent viral RNA with bromouridine triphosphate
(BrUTP) further revealed that viral RNA synthesis colocalizes with the membrane-bound
complex in which the replicase subunits accumulate, demonstrating that the membranebound complex is indeed the site of viral RNA synthesis (van der Meer et al. 1998). A
typical feature of EAV and other arterivirus infections is the formation of paired
membranes and double-membrane vesicles (DMVs) observed under electron microscope
(Breese and McCollum 1970; Pol et al. 1997; Stueckemann et al. 1982; Wood et al.
1970). These double-membrane vesicles appear to be derived from paired endoplasmic
reticulum membranes and they are most likely formed by protrusion and detachment of
vesicular structures with a double membrane (Pedersen et al. 1999). Using replicasespecific antibodies, BrUTP-specific monoclonal antibody, and cryoimmunoelectron
microscopy, Pedersen et al. (1999) have shown that the EAV replicase subunits and RNA
synthesis localize to double-membrane vesicles. This indicates that the EAV replicase
subunits, including nsp9 which contains the putative RNA polymerase function, assemble
into a viral replication complex, which is membrane-associated with DMVs where the
viral RNA synthesis occurs. How are the ORF1b-encoded replicase subunits (nsp9, nsp10,
etc), which do not contain any transmembrane hydrophobic domains, membraneassociated with DMVs? Hydrophobic domains located in nsp2, nsp3, and nsp5 were
postulated to mediate the membrane association of the EAV replication complex (van der
Meer et al. 1998). This also suggests the presence of multiple protein-protein interactions
between replicase subunits in the replication complex. Interestingly, it was observed that
double-membrane vesicles could be induced, in the absence of EAV infection, upon
expression of ORF1a-encoded replicase subunits nsp2 to nsp7 from an alphavirus-based
expression system (Pedersen et al. 1999). Snijder et al. (2001) further demonstrated that
the co-expression of nsp2 and nsp3 is both necessary and sufficient to induce the
formation of double-membrane vesicles. Taken together, these data indicate that EAV
ORF1a replicase proteins play an important role in the formation of a membrane-bound
scaffold for the viral replication/transcription complex (Snijder et al. 2001).
As described above, the EAV replication complex, assembled on the membrane of
virus-induced and host cell-derived DMVs, directs the viral RNA synthesis. The RNA
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polymerase copies (+) genomic strands into full-length (-) genomic strands and then
utilizes (-) genomic strands as templates to synthesize (+) genomic strands. But the cisacting elements essentially involved in EAV replication and transcription have not been
defined. Also, the exact components of the EAV replication complex need to be
elucidated. It has been shown that the EAV replicase is the only viral protein required for
genome replication and none of the structural proteins (E, GP2b, GP3, GP4, GP5, M, and
N) are essential for genomic replication (Molenkamp et al. 2000). Among EAV replicase
proteins, nsp1 was also shown to be dispensable for genome replication (Tijms et al.
2001). However, it is still uncertain whether any host cell proteins are involved in
genomic replication. Recently, four MA-104 cell proteins have been shown to bind to in
vitro-generated transcripts representing the 3’ noncoding region of the genomic negative
strand of several arteriviruses, including EAV (Hwang and Brinton 1998). This region,
which is complementary to the (+) strand genomic leader sequence, is assumed to be
important for the initiation of (+) strand RNA synthesis. Archambault et al. (2005) have
also shown that some proteins in Vero cell cytoplasmic extracts can bind to the (+) and (-)
strands of the EAV leader sequence. These suggest that host cell proteins may be utilized
as components of the EAV replication complex. However, this topic definitely needs
further study. Construction of an EAV replicon may be a solution to resolve these issues
concerning EAV replication.
C. Subgenomic RNA transcription
One striking characteristic of the nidovirus replication cycle is the generation of a
nested set of 3’-coterminal sg mRNAs from which the structural proteins are expressed
(Snijder and Meulenberg 1998). For coronaviruses and arteriviruses, these sg mRNAs
also contain a common 5’ leader sequence, which is derived from the 5’ end of the viral
genome (Fig 1.1A and Fig 1.2; Snijder and Meulenberg 1998). These sg mRNAs
comprise leader and body sequences that are not contiguous on the viral genome. It was
observed that coronaviruses and arteriviruses use transcription-regulating sequences to
join the leader and the body of sg mRNAs (Chen et al. 1993; de Vries et al. 1990; den
Boon et al. 1996; Godeny et al. 1998; Makino et al. 1991; Meulenberg et al. 1993; Spaan
et al. 1983; Zeng et al. 1995).
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How is the 5’ leader sequence joined to the sg mRNA bodies? Studies for both
coronaviruses and arteriviruses have ruled out conventional cis-splicing as the major
mechanism for the production of sg mRNAs (den Boon et al. 1995b; Jacobs et al. 1981;
Yokomori et al. 1992). Moreover, nidoviruses replicate in the cytoplasm, while
conventional splicing mainly occurs in the nucleus. Thus, it is generally accepted that
nidovirus sg mRNAs are generated via a discontinuous transcription process. The first
model proposed to explain this discontinuous process was the so-called ‘leader-primed
transcription’ model (Fig 1.5A; Baric et al. 1983; Spaan et al. 1983). In this model,
discontinuous transcription was assumed to occur during positive-strand RNA synthesis
using the full-length negative genomic strand as a template. The sense TRS at the 3’ end
of the leader transcript base pairs with the antisense body TRS in the negative-strand
template, after which the leader transcript is extended to generate a sg mRNA. In this
model, the genome-length negative strand serves as the template for the synthesis of
genomic RNA as well as sg mRNAs. However, the discovery of sg negative-strand
RNAs and the fact that these sg negative-strand RNAs appear to be transcriptionally
active argued against the above model (Baric and Schaad 1995; Brian et al. 1994; den
Boon et al. 1996; Sawicki and Sawicki 1990; Schaad and Baric 1994; Sethna et al. 1989,
1990; 1991). Subsequently, several models were put forward to explain the presence of
sg negative strands. Sethna et al. (1989; 1990) hypothesized that sg mRNAs could be
amplified as independent replicons. According to their hypothesis, leader-primed
transcription could produce the first generation of sg mRNAs and these sg mRNAs could
subsequently function as templates for the synthesis of sg negative strands, which could
in turn be used to generate the second generation of sg mRNAs. In Sethna’s model, sg
mRNAs are generated from two templates: genome-length negative strands and sg
negative strands. However, direct evidence for replication of sg mRNAs has never been
obtained. When sg-length RNA was transfected into coronavirus-infected cells,
amplification of sg RNA was not observed (Chang et al. 1994; Makino et al. 1991).
Sawicki and Sawicki (1990; 1995) proposed another model called ‘discontinuous
negative strand extension’ model (Fig1.5B,C). In their model, discontinuous transcription
was proposed to occur during negative-strand RNA synthesis using the full-length
positive genomic strand as a template. The antisense body TRS at the 3’ end of the
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nascent (-) strand base pairs with the sense leader TRS in the positive genomic template,
thereby allowing the addition of the anti-leader sequence. The sg negative-strand RNAs
further function as templates for sg mRNAs synthesis. In this model, sg negative strands
are produced directly from genome-length positive strand and are the only templates for
sg mRNAs synthesis. More and more studies of arterivirus and coronavirus sg mRNAs
synthesis have provided convincing evidence which is consistent with the discontinuous
negative strand extension model (Baric and Yount 2000; Pasternak et al. 2001; Sawicki et
al. 2001; van Marle et al. 1999a).
The availability of full-length infectious cDNA clones of arteriviruses has provided
a powerful tool to investigate sg mRNAs synthesis. Through genetic manipulation of the
body and leader TRS of an infectious EAV clone, van Marle et al. (1999a) has
experimentally demonstrated that EAV discontinuous mRNA transcription is guided by a
direct base pairing interaction between the sense leader TRS and the antisense body TRS.
Using a number of TRS mutants with partial transcriptional activity, they also showed
that the TRS sequence at the leader-body junction of the sg mRNA is derived exclusively
from the body TRS rather than from the leader TRS, supporting the theory that sg
mRNAs are generated by a ‘discontinuous negative strand extension’ mechanism rather
than by a ‘leader-primed transcription’ mechanism (van Marle et al. 1999a). For
discontinuous transcription, viral RNA polymerase has to stop transcription at one site
and reinitiate transcription at another site. Therefore, it has been proposed that nidovirus
discontinuous negative strand extension resembles similarity-assisted, copy-choice RNA
recombination (Fig 1.5C; Brian and Spaan 1997; Nagy and Simon 1997; van Marle et al.
1999a). During this process, the RdRp complex and nascent (-) strand transcript are
released from the primary site (a body TRS) in the positive-strand genomic template and
translocated to the secondary site (the leader region) of the template where transcription
is reinitiated. Base pairing between the sense leader TRS and the antisense body TRS at
the 3’ end of the nascent (-) strand plays a crucial role in guiding this RNA strand transfer
(Pasternak et al. 2003; van Marle et al. 1999a). Recent studies have shown that, besides
base pairing between sense leader TRS and antisense body TRS, the secondary structure
of the leader is also essential for efficient sg RNAs synthesis (van den Born et al. 2004;
2005). According to the predicted secondary structure of the leader sequence of

17

arteriviruses (in the case of EAV, leader sequence is nt 1-211), the leader TRS is located
in the loop of a hairpin structure and this hairpin is named as leader TRS hairpin (LTH)
(Fig 1.5C; van den Born et al. 2004; van Marle et al. 1999a). By mutagenesis studies of
the leader sequence using an infectious EAV clone, it has been demonstrated that the
leader TRS hairpin and its immediate flanking sequences are essential for efficient sg
RNA synthesis (van den Born et al. 2004; 2005). It is predicated that proably the
antisense body TRS at the 3’ end of the nascent (-) strand can base pair with the sense
leader TRS only when the latter is present in the loop of a hairpin structure (van den Born
et al. 2004; 2005; van Marle et al. 1999a).
Another open question is about the functionality of body TRSs and the
heterogeneity of sg mRNAs. In addition to the leader TRS (5’UCAAC3’), the EAV
genome contains 17 other 5’UCAAC3’ motifs, of which only 6 function as body TRSs
participating in leader-body junction to generate major sg mRNAs2-7 (den Boon et al.
1991) from which structural proteins E/GP2b, GP3, GP4, GP5, M, and N are expressed,
respectively. The proteins E and GP2b are expressed from the same sg mRNA2. Using sg
mRNA-specific RT-PCR approach, studies have shown that there exist subspecies for sg
mRNAs 3, 4, and 5: namely sg mRNA3.1, -3.2, -3.3, sg mRNA4.1, -4.2, sg mRNA5.1,
and -5.2 (den Boon et al. 1996; Pasternak et al. 2000). This heterogeneity of sg mRNAs
originates from the use of alternative body TRSs for the joining of leader and body (den
Boon et al. 1996; Pasternak et al. 2000). The reason that sg mRNA3.3, -4.1, and -5.2
subspecies went unnoticed in previous studies may be due to two facts: a) these
subspecies are minor mRNA subspecies and are in low abundance in infected cells. For
example, sg mRNA5.2 is 125- to 625-fold less abundant than the major sg mRNA5.1
subspecies; body TRS4.1 is 40 times less active than body TRS4.2. b) The size
differences of subspecies for respective mRNA are very small. For example, sg
mRNA3.1 is 32 nt larger than sg mRNA3.2 which is 42 nt larger than sg mRNA3.3; sg
mRNA4.1 is 17 nt larger than sg mRNA4.2. These small size differences can hardly be
detected by northern hybridization assay used in previous studies. Taken together, it must
be realized that the same sequence motif 5’UCAAC3’ can be actively, less actively, or
not used for leader-body junction to generate sg mRNAs. Thus, the primary sequence
5’UCAAC3’ itself is clearly not sufficient to determine whether it is used for sg mRNA
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transcription or not. Other factors, such as flanking sequences and/or RNA secondary
structure, are likely to contribute to determining the functionality of the sequence motif
5’UCAAC3’. Probably the sequences 5’UCAAC3’ at certain positions are more active
and at other positions are less active or not active.
Just as in viral genomic replication, synthesis of sg mRNAs is also directed by the
RdRp complex. So, it can be assumed that sg mRNA transcription of EAV also occurs on
the membrane of virus-induced and host cell-derived double membrane vesicles. Similar
to viral replication, none of the structural proteins is required for EAV sg mRNA
transcription (Molenkamp et al. 2000). However, the EAV nsp1, which is dispensable for
viral replication, has been found to be essential for sg mRNA transcription (Tijms et al.
2001). How the nsp1 is involved in sg RNA synthesis is still unclear. Interestingly, it has
been found that the EAV nsp1 is able to interact with the cellular transcription co-factor
p100 (Tijms and Snijder 2003). It remains to be determined whether the interaction
between the nsp1 and p100 plays any role in sg mRNA transcription.
EAV structural proteins are expressed from respective sg mRNAs. Since all of the
EAV sg mRNAs are 5’ and 3’ co-terminal as the viral genome, it is reasonable to assume
that translational machinery for genomic RNA and sg mRNAs are the same. With
exception of the sg mRNA7, the EAV sg mRNAs are structurally polycistronic (Fig 1.2).
However, in each of these sg mRNAs, only the most 5’-proximal gene positioned
immediately downstream of the leader sequence is translated, with exception of sg
mRNA2, from which both E and GP2b proteins are translated (Snijder et al. 1999). As
mentioned afore, there exist subspecies for sg mRNAs 3, -4, and -5. But, since all TRSs
used to generate sg mRNA subspecies are located upstream of the translation initiation
codons in respective ORFs (Fig 1.6), sg mRNA subspecies can be used to express the
same corresponding structural protein.
D. The link among translation, replication, and transcription
The EAV replicase is expressed directly from the viral genome as two polyproteins
which subsequently are extensively processed by three viral proteases to generate 12 endproducts and multiple processing intermediates which direct viral replication and sg
mRNA transcription. Equine arteritis virus genomic replication and sg mRNA
transcription are both based on viral replicase proteins and occur at the same intracellular
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location, following the same principles of RNA synthesis. The only difference is that
genomic replication is a continous process and sg mRNA transcription involves a
discontinuous mechanism. The continuity or discontinuity may be directed by some viral
or cellular proteins which are associated with the transcription complex but not the
replication complex.
(3) Virus assembly, budding, and release
Equine arteritis virus acquires its envelope from internal membranes of the infected
cell rather than from the plasma membrane. The assembly of EAV takes place at the
cytoplasmic faces of the endplasmic reticulum (ER), and/or the Golgi complex
(Magnusson et al. 1970).
It has been shown that all seven EAV structural proteins (E, GP2b, GP3, GP4, GP5,
M, and N proteins) are indispensable for the production of infectious progeny virus
(Molenkamp et al. 2000; Snijder et al. 1999; Snijder et al. 2003). However, only the
structural proteins GP5, M, and N are essential for the formation of virus-like particles
(VLPs) (Wieringa et al. 2004). None of the other structural proteins, E, GP2b, GP3, and
GP4, is required to generate virus-like particles (Wieringa et al. 2004). When any one of
GP5, M, and N genes was disrupted in the infectious cDNA clone, the virus particle
formation was abrogated (Wieringa et al. 2004). In contrast, following inactivation of any
of E, GP2b, GP3, and GP4 genes, virus particles were still generated although these
particles were noninfectious (Wieringa et al. 2004). Strangely, all attempts to produce
virus-like particles by the cotransfection of cells with expression plasmids encoding the
EAV GP5, M, and N proteins were unsuccessful (Snijder et al. 1999; Wieringa et al.
2004). This suggests that, besides the GP5, M, and N proteins, there must be additional
factors involved in EAV particle formation. For instance, EAV particle formation may
depend on pre-formation of the nucleocapsid which constitutes of the N protein and the
viral genomic RNA; if the icosahedral nucleocapsid containing viral genomic RNA is not
formed, the subsequent steps of EAV assembly will not take place.
How the EAV N protein interacts with viral genomic RNA to form the icosahedral
nucleocapsid remains unknown. Is the EAV N protein the sole protein required to form
the icosahedral nuclocapsid or does the formation of icosahedral nucleocapsids need the
assistance of other viral or cellular proteins? How many copies of the EAV N protein are
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needed to form the nucleocapsid? Is the EAV nucleocapsid assembly a concerted
assembly or a sequential assembly? In a concerted assembly, the structural units of the
protein shell assemble productively only in association with the viral genome. In the
alternative sequential assembly, the viral genome is inserted into a preformed protein
shell. In EAV-infected cells, there are many forms of RNAs, e.g. full-length (+) and (-)
viral genomic RNAs, (+) and (-) viral sg mRNAs, and cellular RNAs. But only fulllength (+) viral genomic RNA is selectively packaged into the EAV virion (Molenkamp
et al. 2000). How does the EAV N protein distinguish (+) viral genomic RNA from other
forms of RNAs? The RNA sequences required for encapsidation of the EAV genome
have not yet been determined. What parts of the EAV N protein recognize the RNApackaging sequences? All of these questions remain to be answered.
How does the EAV nucleocapsid acquire an envelope? As mentioned above, the
EAV N, GP5, and M proteins are the only structural proteins required for the production
of viral particles (Wieringa et al. 2004). It is generally thought that the disulfide-linked
GP5/M heterodimers constitute the basic protein matrix of the envelope (de Vries et al.
1995b) and are a prerequisite for virus assembly (Snijder et al. 2003). When expressed
individually, EAV GP5 and M proteins were observed to be retained only in the
endoplasmic reticulum (ER); in contrast, when co-expressed, the M protein localized
both in ER and the Golgi complex and the GP5 protein consistently colocalized with the
M protein in the Golgi complex (Balasuriya et al. 2000). The authors concluded that
transport of EAV GP5 and M proteins from ER to the Golgi complex is dependent upon
the formation of a GP5-M heterodimer (Balasuriya et al. 2000). Snijder et al. (2003)
further confirmed this conclusion with their observation that mutations of Cys residues in
GP5 or M, which would block GP5-M heterodimer formation, abrogated the transport of
both GP5 and M to the Golgi complex and resulted in the accumulation of both proteins
in the ER with no infectious virus produced. The authors assumed that the GP5/M
heterodimers are a prerequisite for virus assembly, which obviously needs to be
confirmed. Actually this can be easily affirmed by investigating whether mutations
blocking GP5-M heterodimerization will also abrogate the virus particle formation. The
above data also suggested that the heterodimerization of GP5 and M proteins occur in the
ER. The luminal (ecto-) domains of GP5 and M proteins form a disulfide linkage
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between GP5 Cys-34 and M Cys-8 (Snijder et al. 2003). The cytoplasmically exposed
domains of the disulfide-bonded GP5/M heterodimers may interact with the synthesized
nucleocapsid. Thus, the EAV nucleocapsids bud into the lumen of ER or Golgi network
and acquire lipid membrane carrying viral envelope proteins. Since the EAV E, GP2b,
GP3, and GP4 proteins are also integral membrane proteins and are anchored to the lipid
membrane of ER or Golgi complex, the EAV nucleocapsids also acquire these envelope
proteins when budding into the lumen. However, the formation of GP2b/GP4/GP3
heterotrimers is not simple. In EAV-infected cells, the GP2b protein occurs in four
monomeric conformations due to the formation of different intrachain disulfide bonds
between the cysteine residues (Cys 48, 102, 137), and a disulfide-linked dimer (de Vries
et al. 1995a; Wieringa et al. 2003a; 2003b). The disulfide-linked dimer, previously
identified as homodimer of the GP2b protein (de Vries et al. 1995a), has been redefined
as a covalently linked heterodimer of GP2b and GP4 (Wieringa et al. 2003a). In EAVinfected cells, no disulfide-bonded GP2b/GP3/GP4 heterotrimers could be detected,
despite the fact that such heterotrimers occur in the EAV virion (Wieringa et al. 2003a).
It is speculated that the formation of disulfide-bonded GP2b/GP3/GP4 heterotrimers
involves two disulfide-bond linkages: the disulfide bond between GP2b and GP4 and the
disulfide bond between GP4 and GP3. It is known that GP2b Cys-102 is responsible for
the disulfide bond linkage with GP4 (Wieringa et al. 2003b). However, it is still unknown
which cysteine residue in GP4 interacts with Cys-102 of GP2b. Likewise, the cysteine
residues that are involved in the disulfide bond formation between GP4 and GP3 remain
undefined. So, what is the process of the formation of disulfide-bonded GP2b/GP4/GP3
heterotrimers in the virion? It has been postulated that the GP2b protein and the GP4
protein first form a covalently linked heterodimer, then GP3 protein interacts
noncovalently with the disulfide-bonded GP2b/GP4 heterodimer and the complex is
finally assembled into the virion, but disulfide bond linkage between GP2b/GP4 and GP3
takes place only after virus particles have been released (Wieringa et al. 2003a; 2003b).
Also, it has been recently found that, when one of the GP2b, GP3, or GP4 proteins was
missing, incorporation of the remaining two minor envelope proteins was completely
blocked and incorporation of the E protein was greatly reduced (Wieringa et al. 2004).
The absence of E protein entirely prevented incorporation of the GP2b, GP3, and GP4

22

proteins into the virion (Wieringa et al. 2004). The detailed molecular interactions
between EAV structural proteins are unclear. Wieringa et al. (2004) proposed a model to
describe the interactions between EAV structural proteins. In this model, the E protein is
thought to be the component which, on the one hand interacts with the GP2b/GP4/GP3
heterotrimer, and on the other hand interacts with the GP5/M heterodimer and/or the
nucleocaspid. It is through these interactions that the E protein draws the GP2b/GP4/GP3
complex into nascent particles.
After the EAV nucleocapsids bud into the lumen of ER or Golgi complex and
acquire a lipid membrane carrying viral envelope proteins, virus particles are formed.
Then the virus particles are transported from the intracellular compartments to the plasma
membrane where the virus particles are released via exocytosis. After the virus particles
are released, the noncovalent linkage between the GP3 protein and the GP2b/GP4
heterodimer become covalently linked; thus, the disulfide-bonded GP2b/GP4/GP3
heterotrimers are formed.
4. Neutralization determinants of equine arteritis virus
Long-lived EAV-neutralizing antibodies are induced following natural infection,
experimental infection or vaccination (with the modified live virus vaccine) of horses
(Timoney and McCollum 1993), and neutralizing antibodies can protect horses from
subsequent challenge with EAV (Doll et al. 1968; McCollum 1970, 1976, 1986;
McCollum et al. 1988). Identification and characterization of immunogenic epitopes has
important implications for disease diagnosis and development of improved vaccines.
Neutralizing monoclonal antibodies to EAV have been developed by several laboratories,
and all of them have been shown to recognize the GP5 protein using Western blot and/or
immunoprecipitation assays (Balasuriya et al. 1993; 1995b; 1997; Deregt et al. 1994;
Glaser et al. 1995). The hydropathy profile of the GP5 protein predicts that amino acid
residues 1-18 constitute the putative signal sequence, 19-116 constitute the hydrophilic
ectodomain of the protein, while the C-terminal half consists of three membranespanning domains followed by an endodomain of about 64 amino acids (de Vries et al.
1992; Snijder et al. 2003). Chirnside et al. (1995) have shown that horses developed
EAV-neutralizing antibodies after they were inoculated with either a fusion protein
covering GP5 aa 55-98 or a synthetic peptide corresponding to GP5 aa 75-97. It was
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further demonstrated that an E. coli-expressed recombinant protein comprising the entire
ectodomain (aa 18-122) of EAV GP5 protein induced high levels of neutralizing
antibodies in ponies (Castillo-Olivares et al. 2001). These support the hypothesis that the
ectodomain (aa 19-116) of EAV GP5 protein is immunodominant. By comparing the
sequences of neutralization-sensitive EAV and neutralization-resistant viruses (escape
mutants, EM), Glaser et al. (1995) identified that amino acid residues at 99 and 100 are
critical for virus neutralization. After extensive comparison of GP5 amino acid sequences
and neutralization phenotypes of a large number of field and laboratory EAV strains
using both neutralizing MAbs and EAV strain-specific polyclonal equine antisera,
Balasuriya et al. (1993; 1995b; 1997) have identified four distinct neutralization sites.
These sites include amino acids 49 (site A), 61 (site B), 67-90 (site C), and 99-106 (site D)
in the GP5 protein. In a recent study, the ORF5 of an infectious EAV clone was replaced
with that of different laboratory, field, and vaccine strains of EAV, thus generating
various chimeric viruses (Balasuriya et al. 2004b). The comparative characterization of
neutralization phenotypes of chimeric viruses and parental viruses has further confirmed
the importance of the aforementioned four neutralization sites in the GP5 protein. Taken
together, these studies demonstrated that the ectodomain of the GP5 protein contains
EAV neutralization determinants. Site D includes several overlapping linear epitopes.
The four neutralization sites (A-D) are conformationally interactive (Balasuriya et al.
1997; 2004b). However, it was also observed that a monoclonal antibody (1H7) failed to
neutralize some chimeric viruses but was able to neutralize their respective parental
viruses, though chimeric viruses and parental viruses have the same ORF5 sequences
(Balasuriya et al. 2004b). This suggests that some of the neutralization epitopes are
conformationally dependent and may interact with other structural proteins. Moreover, it
remains to be determined whether there exist additional neutralization determinants in the
EAV GP5 protein. The ectodomain of the EAV GP5 protein possesses one or two Nglycosylation sites: Asn-56 is the conserved N-glycosylation site amongst all strains of
EAV and Asn-81 is another potential N-glycosylation site occurring in some field and
laboratory strains of EAV. There is no evidence that the presence of a second
glycosylation site on EAV GP5 protein interferes with virus neutralization. In the case of
EAV, all of the neutralization determinants identified thus far are located in the GP5
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protein; however, neutralization determinants have been found in both the GP4 and GP5
proteins of PRRSV. Monoclonal antibodies against the GP4 protein of the Lelystad strain
of PRRSV have been reported to be neutralizing (Meulenberg et al. 1997), although
MAbs against the GP5 protein of PRRSV are more effective in virus neutralization than
MAbs against the GP4 protein (Weiland et al. 1999). The primary neutralization
determinants of PRRSV are located in the middle of the GP5 ectodomain (Pirzadeh and
Dea 1997; Plagemann et al. 2002; Zhang et al. 1998), but a neutralization epitope (aa 24)
has also been observed in the predicted signal sequence of the GP5 protein of PRRSV
(Wissink et al. 2003).
5. Genetic and phenotypic diversity of equine arteritis virus
The virus-encoded RNA-dependent RNA polymerases (RdRp) are low fidelity
enzymes with mutation rates as high as the order of 10-3 to 10-5 errors per nucleotide per
replication cycle (Domingo and Holland 1997; Drake 1993). In addition, RNA viruses
have very short replication times and generate very large populations during replication.
Therefore, RNA viruses exist not as a single genotype but rather as a heterogeneous
mixture of related genomes known as a viral quasi-species (Holland et al. 1992). The
quasi-species nature of RNA viruses allows viruses to adapt to environmental changes
more rapidly and facilitates the emergence of viral variants (Castro et al. 2005). Genetic
and phenotypic variation among equine arteritis virus isolates have been demonstrated,
although only one neutralization serotype of EAV has been identified so far (Fukunaga
and McCollum 1977; Golnik et al. 1986). Murphy et al. (1988; 1992) first demonstrated
that genomic variation exists among EAV isolates using RNase T1 oligonucleotide
fingerprinting. Nucelotide sequence comparison of ten EAV isolates revealed that the
leader sequence identity between different isolates and the Bucyrus reference strain
ranged from 94.2 to 98.5% (Kheyar et al. 1998). In the case of the replicase gene, the
nsp2 is highly variable among field isolates of EAV (Balasuriya et al. 2004a). Most
studies of genetic variation of EAV have focused on structural proteins. Nucleotide and
amino acid comparison of various EAV isolates in ORFs 2-7 have been performed
(Archambault et al. 1997; Balasuriya et al. 1995a; 2004a; Chirnside et al. 1994; Hedges
et al. 1996; 2001; Larsen et al. 2001; Lepage et al. 1996; St-Laurent et al. 1997; Stadejek
et al. 1999). These studies revealed that the EAV M and N proteins are more conserved
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than other structural proteins, the ORF4 and ORF2 protein sequences are moderately
conserved, and the ORF3 and ORF5 protein sequences are most variable. Phylogenetic
analysis of EAV ORF5 sequences have suggested classification of various EAV isolates
into two large groups: North American group (group I) and European group (group II)
(Balasuriya et al. 1995a; Stadejek et al. 1999). The geographic origin of the viruses
(where the viruses were isolated) may be different from phylogenetically predicted
relationships. For example, some of the EAV strains were isolated from horses in North
America, but are grouped with European isolates according to phylogenetic analysis,
suggesting dispersal of the virus between continents by movement of horeses. Therefore,
phylogenetic analyses of ORF5 sequences between strains are a useful molecular
epidemiological tool for tracing the origin of an EAV isolate.
As mentioned above, there is only one serotype of EAV (Fukunaga and McCollum
1977; Golnik et al. 1986) and all strains evaluated thus far are neutralized by polyclonal
equine sera raised against the virulent Bucyrus strain of EAV (Balasuriya and
MacLachlan 2004c). However, EAV strains frequently exhibit neutralization phenotypic
differences; e.g., different EAV strains are neutralized to various degrees with different
polyclonal antisera and monoclonal antibodies (Balasuriya et al. 1997; 2004a; 2004b;
Hedges et al. 1999a). In addition, geographically and temporally distinct EAV isolates
vary markedly in the severity of the clinical disease they induce and in their abortigenic
potentials (Balasuriya et al. 1998; 1999b; Balasuriya and MacLachlan 2004c; McCollum
and Timoney 1999; Timoney and McCollum 1993). For example, the virulence of some
EAV strains for horses have been defined: severely virulent (VBS53 and ATCC EAV),
moderately virulent (KY84, CAN86, AZ87, and IL93), mildly virulent (SWZ64, AUT68,
IL94, and CA97), and putatively avirulent (KY63, PA76, KY77, CA95G, and ARVAC
vaccine) strains of EAV (MacLachlan et al. 1996; McCollum 1981; McCollum and
Timoney 1984; McCollum et al. 1995; McCollum and Timoney 1999; Moore et al.
2003b; Patton et al. 1999; Timoney and McCollum 1993). However, the genetic
determinants of viral virulence have not yet been defined.
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III.

EAV INFECTION AND PERSISTENTLY INFECTED STALLIONS

Natural EAV infection occurs in both horses and donkeys, and the virus is
distributed in many equid populations throughout the world (McCollum et al. 1995;
Timoney and McCollum 1993). Most EAV infections are subclinical in nature;
occasionally, infection results in a respiratory type syndrome, abortion in pregnant mares,
and interstitial pneumonia or pneumonoenteritis in young foals (Timoney and McCollum
1993; 1996). Up to 30% to 70% of stallions infected with EAV can subsequently become
persistently infected and constantly shed the virus in semen. On the other hand, neither
mares, geldings, nor foals have been shown to become carriers of the virus (Timoney and
McCollum 1993).
1. Modes of transmission
The two major routes of EAV transmission between horses are the respiratory and
venereal routes (Timoney and McCollum 1993). During the acute phase of the infection,
virus is shed significant amounts in the respiratory tract secretions and transmission to
other susceptible horses occurs through aerosolized respiratory tract secretions (Timoney
and McCollum 1993). Acutely infected horses also shed virus in their urine, feces,
vaginal and other body secretions, although in smaller amounts than via the respiratory
tract (McCollum et al. 1971; Timoney and McCollum 1993). EAV can also be found in
aborted fetuses, placenta, and their membranes and fluids from a mare that has aborted as
a result of EAV infection (Timoney and McCollum 1993). These sources of virus may
also contribute to aerosol transmission of EAV to other horses. Aerosol transmission of
infectious particles is the most important and primary route of EAV dissemination during
outbreak of the disease. However, it should be emphasized that direct and close contact
appears to be necessary for aerosol transmission of EAV (Collins et al. 1987; Timoney
1988). Venereal transmission is another important route of dissemination of EAV. The
virus can be transmitted venereally not only by the acutely infected mare and stallion, but
also by persistently infected stallions (Timoney et al. 1986; 1987). Approximately 85 to
100% of seronegative mares become infected when they are bred to persistenlty infected
stallions or artificially inseminated with infective semen from these carrier animals
(Timoney and McCollum 1993). The infected mares can in turn transmit the virus to
susceptible horses via the respiratory route. Reciprocal venereal transmission from an
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acutely infected mare to a seronegative stallion, though plausible, has not been
documented. Carrier stallions are believed to be the natural reservoir of EAV and are
responsible for perpetuation and dissemination of EAV in equine populations (Timoney
et al. 1987; Timoney and McCollum 1993).
Besides the two aforementioned major routes of transmission, EAV can also be
transmitted less commonly by other means. For example, the foal can congenitally
acquire EAV infection through transplacental transmission when a pregnant mare is
exposed to the virus in late gestation (Vaala et al. 1992). In this case, infected foals may
develop rapidly progressive fulminating interstitial pneumonia and in some cases, also a
fibronecrotic enteritis (Carman et al. 1988; Del Piero et al. 1997; Vaala et al. 1992;
Wilkins et al. 1995). Transmission of EAV through indirect contact with viruscontaminated fomites or by an infected teaser stallion or nurse mare may also occur
infrequently (Timoney and McCollum 1996).
2. Carrier state
A. General information
As early as the latter half of the nineteeth century, it had been observed that healthy
stallions could transmit so called pink-eye or influenza disease, which very likely was
equine viral arteritis, to mares at breeding (Clark 1892; Pottie 1888). At that time, it was
postulated that the causative agent is shed in the semen of those healthy stallions (Clark
1892; Pottie 1888). These are the earliest reports of occurrence of an ‘EAV’ carrier state.
However, not until the 1984 epizootic of equine viral arteritis in Kentucky was the EAV
carrier state extensively studied by Timoney and McCollum (Timoney et al. 1986; 1987).
After natural infection with EAV, up to 30% to 70% of stallions can become persistently
infected with the virus (Timoney and McCollum 1993). Persistently infected stallions
shed EAV constantly in their semen; virus has not been detected in their urine, blood, or
nasopharyngeal secretions (Timoney and McCollum 1993). Equine arteritis virus appears
to be restricted to the reproductive tract of carrier stallions, and the ampulla of the vas
deferens seems to be the primary site of EAV persistence (Neu et al. 1987; Timoney and
McCollum 1993). Virus is present in the sperm-rich fraction of the ejaculate and is not
detected in the preejaculatory fluids (Timoney et al. 1987). There appears to be little
variation of virus titer among semen samples sequentially collected from the same
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stallion over time. Duration of the carrier state varies and it has been arbitrarily divided
into three categories: short-term or convalescent carrier state lasting several weeks;
intermediate carrier state lasting 3 to 7 months; and the long-term or chronic carrier state
lasting for years and even the lifetime of particular stallions (Timoney et al. 1986;
Timoney and McCollum 1993). It has also been observed that some carrier stallions
spontaneously cease to shed virus after years of persistent infection, with no indication of
reversion to a shedding state later on (Timoney and McCollum 1993). A longitudinal
field study provided no evidence that carrier stallions are or can become intermittent
shedders of the virus (Timoney et al. 1991) .
B. The mechanisms of EAV persistence in carrier stallions
The detailed mechanisms of virus persistence in the host have not been clearly
understood. It has been proposed that viral persistence maybe involves two essential
ingredients: an ineffectual immune response, and a unique component or strategy of viral
replication (de la Torre et al. 1991; Oldstone 1989, 1991). EAV persistence in carrier
stallions may also involve the factors in these two aspects.
In carrier stallions, EAV persists exclusively in the reproductive tract and not in
other sites. It seems unlikely that the EAV has obtained a restricted tropism to the
reproductive tract of stallions, since EAV in the reproductive tract of carrier stallions can
be venereally transmitted to susceptible mares in which the virus has an apparent wide
tissue distribution (McCollum et al. 1988; Timoney et al. 1987). It seems more likely that
the immune effectors have eliminated EAV from other sites but have failed to eliminate
the virus from reproductive tract of carrier stallions. The observation that carrier stallions
usually have moderate to high titers of serum neutralizing antibody to EAV (Timoney
and McCollum 1993) further support the conclusion that humoral immunity does not
prevent establishment or maintenance of persistent EAV infection in the reproductive
tract of stallions. How the virus in the reproductive tract of carrier stallions evades
immune clearance by neutralizing antibodies is unknown. It seems unlikely that immune
escape mutants of virus play a significant role, because the emerging virus variants in
carrier stallions can still be neutralized by polyclonal neutralizing antibodies (Balasuriya
and MacLachlan 2004c). Virus persistence may be related to the fact that the
reproductive tract of mature male is an immunologically priviledged site (Johnson 1973).
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The physiologic mechanisms responsible for this privileged site are multifactorial,
develop at puberty, and in some species depend on androgens (Pelletier 1986). Maybe the
virus in the reproductive tract of stallions is inaccessible to circulating neutralizing
antibodies or that neutralizing antibodies can only partially downregulate virus
replication but are inadequate to completely prevent ongoing virus replication. Also, the
role of cellular immune responses in persistent EAV infection is not known.
There is convincing evidence that establishment and maintenance of the carrier state
in the stallion is testosterone-dependent (Little et al. 1991; McCollum et al. 1994). When
persistently infected stallions were castrated and administered testosterone, they
continued to shed virus in semen, whereas castrated stallions given a placebo ceased
shedding virus (Little et al. 1991). Investigation of the persistence of EAV in prepubertal
and peripubertal colts showed that EAV can replicate in the reproductive tract of a
significant proportion of colts for a variable period of time after clinical recovery in the
absence of circulating concentrations of testosterone equivalent to those found in sexually
mature stallions. However, long-term persistent EAV infection does not appear to occur
in colts exposed to the virus before the onset of peripubertal development (Holyoak et al.
1993). The mechanism by which testosterone contributes to the establishment and
maintenance of the persistent EAV infection in stallions remains undetermined. It is
speculated that testosterone may be involved in (i) the development of mature
reproductive tract and (ii) the replication of androgen-dependent cells in the reproductive
tract of stallions to maintain EAV persistence.
It remains to be determined whether other host factor(s) or viral factor(s) contribute
to the establishment and maintenance of persistent EAV infection in stallions. Frequency
of the carrier state varies between different groups of stallions; however, extensive
epidemiological study involving Standardbred and Thoroughbred horses failed to
demonstrate any breed predilection for establishment of persistent EAV infection
(Timoney et al. 1986; 1987). Analysis of two carrier stallions and a number of their male
offspring did not demonstrate a significant association between inherited MHC haplotype
and the carrier state (Albright-Fraser 1998). Moreover, the mechanism accounting for the
spontaneous clearance of EAV from some carrier stallions is not clear. So far, no fully
validated therapy (except castration) has been available to eliminate the EAV carrier state
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in stallions. One group of researchers have investigated the effects of a GnRH antagonist
on testosterone secretion, spermatogenesis, and viral excretion in EAV carrier stallions,
but the results were not conclusive (Fortier et al. 2002).
C. The significance of EAV carrier stallions
Carrier stallions occupy a significant niche in the epidemiology of EAV infection.
Carrier stallions are not only a natural reservoir of EAV responsible for maintenance and
dissemination of EAV in equine populations (Timoney et al. 1987; Timoney and
McCollum 1993), but also a natural source of genetic and phenotypic diversity of EAV
(Balasuriya et al. 2004a; Balasuriya and MacLachlan 2004c; Hedges et al. 1999a).
Equine arteritis virus exists as a quasi-species. It has been observed that EAV
quasispecies was relatively limited and the virus remained relatively genetically stable
during horizontal and vertical transmission in the course of an outbreak of EVA
(Balasuriya et al. 1999a); in contrast, virus quasi-species expanded and genetic and
phenotypic variants of EAV emerged during persistent infection of stallions (Balasuriya
et al. 2004a; Hedges et al. 1999a). Therefore, carrier stallions are probably the major
source of EAV evolution. Some new virus variants generated during the course of
persistent infection may have significant pathogenic potential and give rise to
occurrences of EVA.

IV.

PERSISTENT INFECTION OF CELL CULTURES WITH RNA VIRUSES
Viral infection of various hosts result in an acute infection, which is characterized

by rapid production of infectious virus followed by rapid resolution and clearance of the
infection by the host, or persistent infection, in which viral particles or viral products
continue to be produced for long periods of time. The mechanisms employed by different
viruses for their persistence in vivo vary. One common feature is that the host defense
systems fail to clear the virus from the host. It is generally thought that both host and
viral factors may contribute to the establishment and maintenance of persistent infection.
Persistent viral infections in cell culture are valuable in studying virus-host cell
interactions and in providing insights into how virus persistence is established and
maintained. The following is an attempt to summarize persistent infection in cell culture
by RNA viruses.
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1. Properties of persistent infection
Many RNA viruses have been found capable of establishing persistent infection in
tissue culture cells (Rima and Martin 1976). One virus may establish persistent infections
in a number of cell lines, e.g. poliovirus is able to establish persistent infections in human
neuroblastoma cells (Colbere-Garapin et al. 1989), human erythroblastoid K562 cells
(Lloyd and Bovee 1993), Hep-2 cells (Calvez et al. 1993), and Hela cells. Persistent
infection in Hela cells was established by cotransfecting the cells with poliovirion type 2
RNA and R1, an in vitro-synthesized poliovirus subgenomic replicon which contains a
deletion of nearly all the capsid region (Kaplan et al. 1989). Sindbis virus is able to
initiate persistent infections in BHK-21 cells (Schwobel and Ahl 1972; Weiss et al. 1980)
and mouse L cells (Inglot et al. 1973). Persistently infected cell cultures may have
common properties in some respects, as well as distinct properties in other respects.
A. Cytopathic effect, virus-positive cells, and production of virus
Persistently infected cells may or may not exhibit virus-specific cytopathic effect
despite the fact that they continuously produce infectious virus. For example, CV-1 cells
persistently infected with human parainfluenza virus-3 (Moscona and Galinski 1990) and
rhabdomyosarcoma cells persistently infected with coxsackievirus B4 (Frisk et al. 1999)
continuously produced infectious virus without cellular destruction; however, Hela cells
persistently infected with human rhinovirus-2 and Hela cells persistently infected with
poliovirus continually produced low levels of infectious virus and cell cultures underwent
multiple episodes of partial destruction and subsequent recovery (Gercel et al. 1985;
Kaplan et al. 1989). The percentage of virus-positive cells varies from one persistent
system to another. In some persistent systems, the percentage of virus-positive cells even
undergoes cyclic variation. For instance, in rabies virus/BHK21 cells, the percentage of
cells showing positive immunofluorescence varied from 5% to 100% in cycles of 6-8
subcultures (Wiktor and Clark 1972); in human rhinovirus-2/Hela cells, the percentage of
cells producing infectious centers varied from 0.03% to 23% (Gercel et al. 1985). Most
of the persistently infected cells continuously produce small amounts of infectious virus.
In measles virus/Hela cells, the yield of cell-associated virus was high and similar to that
in lytic infections, whereas the yield of released (extracellular) virus was very small
(Rustigian 1966a). In mumps virus/conjunctiva cells, the yield of cell-associated virus
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was consistently about one log unit lower than that of released virus (Walker and Hinze
1962). The amount of released virus may show cyclic variation coinciding with variation
in the appearance of CPE and cell destruction in some persistent systems such as Sindbis
virus/BHK-21 cells (Schwobel and Ahl 1972), Sindbis virus/mouse L cells (Inglot et al.
1973), lymphocytic choriomeningitis virus (LCMV)/BHK-21 cells (Staneck et al. 1972),
rabies virus/BHK-21 cells (Kawai et al. 1975; Wiktor and Clark 1972) and so on.
Occasionally persistently infected cells may stop producing infectious virus after longterm subculturing. For example, during routine subcultivation of Hela cells persistently
infected with human rhinovirus-2, some spontaneous cures were observed (Gercel et al.
1985). In spontaneously cured cells, no extracellular virus or infectious centers could be
detected and no viral antigen could be detected by immunofluorescence (Gercel et al.
1985). Whether these cells were free of viral RNA was not reported.
B. Effect of antibodies and anti-viral compounds
Addition of virus-specific antibodies or anti-viral compounds to the media of
persistently infected cells may result in distinct outcomes: non-cured or cured. It has been
shown that cloning or subculture of measles virus/Hela cells in the presence of antimeasles serum in the culture medium led to a state in which no infectious virus was
released (non-yielder state), whereas the large majority of these cells were still
immunofluorescence positive (Rustigian 1966b), indicating the existence of viral antigen.
When human influenza C virus/MDCK cells (Goshima and Maeno 1989) or
poliovirus/human erythroblastoid K562 cells (Lloyd and Bovee 1993) were subcultured
with growth medium containing virus-neutralizing antibodies for several continuous
passages, extracellular virus became undetectable. However, further passage in the
absence of antiserum resulted in the return of infectious virus yield. Similarly, addition of
the antiviral compound disoxaril did not cure rhabdomyosarcoma cells persistently
infected with coxsackievirus B4 (Frisk et al. 1999). In contrast, it was observed that three
serial subcultivations of human rhinovirus-2/Hela cells in the presence of antiserum
resulted in a cure (no extracellular virus or infectious centers or viral antigens could be
detected) (Gercel et al. 1985). In addition, after removal of antiserum, no renewed virus
production or viral antigen expression could be detected upon 12 further passages (Gercel
et al. 1985), indicating that the persistently infected cells were cured. Similarly, it has
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been reported that mouse L cells persistently infected with reovirus can be cured by
antireovirus serum (Ahmed et al. 1981). It was also found that anti-viral compound
ribavirin was able to eliminate foot-and-mouth disease virus (FMDV) from persistently
infected BHK-21 cells (de la Torre et al. 1987). In ribavirin-cured cultures, no FMDV
RNA or antigens were detected by dot-blot hybridization to cDNA probes or by indirect
immunofluorescence, respectively. No renewed FMDV production occurred after the
cells underwent at least 20 serial passages in the absence of ribavirin (de la Torre et al.
1987). Curing of FMDV from persistently infected cells by ribavirin involves ribavirin’s
ability to enhance mutagenesis (Airaksinen et al. 2003). RNA viruses replicate with a
high spontaneous mutation frequency which is near the error threshold for maintenance
of genetic information. When the mutation rate of the viral genome increases and exceeds
this error threshold, the viral fitness decreases significantly and the virus may fall into
error catastrophe or lethal mutagenesis leading to virus extinction (Castro et al. 2005;
Domingo et al. 2005; Manrubia et al. 2005). Ribavirin is an RNA virus mutagen which
can increase mutation frequency during virus replication and increase in mutation
frequency may drive RNA viruses to error catastrophe leading to extinction of viruses
(Crotty et al. 2000; 2001; 2002; Pariente et al. 2003).
C. Resistance to superinfection
Another interesting property of persistently infected cells is that they are immune to
superinfection with homologous virus but are still susceptible to infection with
heterologous viruses. In an investigation of human rhinovirus-2 (HRV-2)/Hela cells to
superinfection, normal Hela cells infected with homologous viruses (HRV-2, HRV-2 TS1 mutant, and HRV-4) or heterologous viruses (poliovirus type 2 and vesicular stomatitis
virus (VSV)), HRV-2/Hela cells superinfected with the same homologous or
heterologous viruses, and HRV-2/Hela cells not superinfected with any virus were
compared (Gercel et al. 1985). It was found that the cytopathic effects and virus yields in
HRV-2/Hela cells superinfected with HRV-2, TS-1 mutant, and HRV-4 were similar to
those produced in HRV-2/Hela cells alone (not superinfected) but were less pronounced
than those produced in normal Hela cells infected with the respective virus. In contrast,
virus yields in HRV-2/Hela cells superinfected with poliovirus type 2 or VSV were
comparable to those obtained in normal Hela cells infected with respective virus (Gercel
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et al. 1985). Both yielder (with production of infectious virus) and non-yielder (with no
production of infectious virus but with existence of viral antigen) measles virus/Hela cells
were shown to be resistant to superinfection with measles virus, but these cells supported
normal growth of vaccinia virus, herpes virus and poliovirus (Rustigian 1966a). Similarly,
Sindbis virus/mouse L cells were found to be resistant to superinfection with Sindbis
virus but not with VSV or encephalomyocarditis virus (Inglot et al. 1973). LCMV/BHK21 cells were resistant to superinfection with homologous arenaviruses but not with
dengue virus, rubella virus, Sindbis virus, and VSV (Staneck et al. 1972). Rabies
virus/BHK-21 cells were resistant to superinfection with rabies virus but not with VSV
(Kawai et al. 1975). FMDV/BHK-21 cells were resistant to superinfection with FMDV
but not with encephalomyocarditis virus, VSV, and Semliki Forest virus (de la Torre et al.
1985). Poliovirus/human neuroblastoma IMR-32 cells were resistant to superinfection
with Sabin 1, 2, and 3 poliovirus but sensitive to another enterovirus coxsackievirus B3
(Colbere-Garapin et al. 1989). Above examples uniformly demonstrated that all
persistently infected cells are resistant to superinfection with the same virus that was used
to initiate the persistent infection. The mechanism by which persistently infected cells are
resistant to superinfection with homologous viruses but are sensitive to heterologous
virus infection is not clear. It is speculated that it may be associated with virus-specific
cell receptors or the production level of interferon: i) interference at one of the early steps
of virus growth cycle (e.g. attachment, penetration, or uncoating) is probably involved in
the resistance of persistently infected cells to superinfection by the homologous virus; ii)
in contrast, cell receptors of ‘heterologous’ viruses are distinctly different from that of
homologous virus, thus there are no such interferences with heterologous virus infection;
lack or low levels of interferon produced in these persistently infected cells may also
contribute to the growth of heterologous virus in carrier cultures.
D. Evolution of viruses and cells
A number of studies have shown that the viruses recovered from persistently
infected cells are genetically and phenotypically different from the parental viruses which
were used to establish the persistent infections. Temperature-sensitive (ts) virus mutants
were isolated from mouse L cells persistently infected with Newcastle disease virus
(Preble and Youngner 1972, 1973a, 1973b) and mouse L cells persistently infected with
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VSV (Youngner et al. 1976). The production of defective interfering (DI) viral particles
was reported in mouse L cells persistently infected with LCMV (Lehmann-Grube et al.
1969; Welsh et al. 1972) and BHK-21 cells persistently infected with Parana virus
(Staneck and Peau 1974). Defective interfering viral RNA has also been detected in Vero
cells persistently infected with Murray Valley encephalitis (MVE) virus (Lancaster et al.
1998). Small plaque virus mutants were observed in BHK-21 cells persistently infected
with rabies virus (Kawai et al. 1975) and in mouse neuroblastoma cells persistently
infected with yellow fever 17D virus (Vlaycheva and Chambers 2002). Fusion-defective
mutants of mouse hepatitis virus A59 were produced in persistently infected primary
mouse glial cells and the phenotype was probably due to a mutation at the viral spike
(fusion) protein cleavage signal (Gombold et al. 1993). Genetic and antigenic changes
have been demonstrated in hepatitis A virus (HAV) variants arising during persistent
infection of BS-C-1 cells (Lemon et al. 1991). FMDV is able to initiate persistent
infection in BHK-21 cells (de la Torre et al. 1985) and the virus isolated from persistently
infected culture (carrier culture) was more cytolytic than parental FMDV for BHK-21
cells (de la Torre et al. 1988a). Further studies showed that nine amino acid substitutions
were fixed on the viral capsid protein during persistence and these amino acid
substitutions resulted in altered antigenicity, as revealed by reactivity with monoclonal
antibodies (Diez et al. 1990a). Moreover, FMDV became progressively less virulent for
mice and cattle during the course of persistence in BHK-21 cells (Diez et al. 1990b).
Virus evolution was also observed in carrier cultures of poliovirus. The poliovirus
mutants selected from human neuroblastoma IMR-32 cells persistently infected with the
Sabin strains could reach 1-3 log10 units higher titer in IMR-32 cells than that in nonneural Hep-2 cells, while parental viruses had similar titers in both cell lines (ColbereGarapin et al. 1989). Correlated with this modified cell tropism, the poliovirus mutants
recovered from carrier culture could establish secondary persistent infection in nonneural Hep-2 cells (Pelletier et al. 1991). Interestingly, these poliovirus mutants harbor
major mutations at capsid proteins VP1 and VP2 which are known to be involved in
interactions between poliovirus and its receptor (Borzakian et al. 1993; Calvez et al. 1993;
Colbere-Garapin et al. 1989; Duncan et al. 1998; Pavio et al. 1996; Pelletier et al. 1991;
1998a). Poliovirus type 1 mutants selected from human neuroblastoma cells persistently
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infected with the wild-type Mahoney strain exhibited neurovirulent phenotype in mice,
while the wild-type Mahoney strain is avirulent in mice (Couderc et al. 1994). And this
conversion of mouse-neurovirulent phenotype is caused by several amino acid
substitutions on the viral capsid protein (Couderc et al. 1993; 1994).
Coevolution of viruses and the host cells have been observed in mouse L cells
persistently infected with reovirus (Ahmed et al. 1981), BHK-21 cells persistently
infected with FMDV (de la Torre et al. 1988a), and Hela cells and human neuroblastoma
cells persistently infected with poliovirus (Kaplan et al. 1989; Pavio et al. 2000). In the
study performed by Ahmed et al (1981), persistent infection was established in mouse L
cells with a reovirus stock, more than 90% of which was made up of defective interfering
particles. Mutant mouse L cells and reovirus were isolated from carrier cultures. Reovirus
isolated from carrier culture grew more efficiently than cloned wild-type reovirus in
mutant L cells, indicating the evolution of viruses during persistent infection. On the
other hand, infection of mutant L cells with either wild-type reovirus or reovirus isolated
from carrier cultures led to establishment of persistent infections, while infection of the
original L cells with either wild-type reovirus or reovirus isolated from carrier cultures
resulted in a lytic infection with no surviving cells, demonstrating the evolution of the
host cells during persistent infection. Virus evolution during persistent FMDV infection
of BHK-21 cells has been discussed above. It has also been observed that BHK-21 cell
mutants selected during serial passage of the carrier culture were constitutively more
resistant to the parental FMDV infection than the parental BHK-21 cells (de la Torre et al.
1988a), indicating the evolution of the host cells during persistent infection. The
increased resistance of BHK-21 cell mutants to parental FMDV was not due to an
impairment of attachment, internalization, or uncoating of the viral particles but was
because of some intracellular block that downregulated FMDV RNA synthesis (de la
Torre et al. 1988a). Further studies showed that BHK-21 cells evolved and exhibited
extensive heterogeneity during persistent infection with FMDV (de la Torre et al. 1989).
Analysis of 248 stable cell clones isolated from FMDV carrier culture revealed that at
least six distinct cell phenotypes could be distinguished with regard to cell morphology,
susceptibility to parental FMDV infection, and cell growth characteristics (de la Torre et
al. 1989). These altered phenotypes were maintained as stable genetic traits. Genetic and
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phenotypic variation of the host cells enables the selection of cells with increased
resistance to FMDV and thus contributes to the maintenance of viral persistence (Martin
Hernandez et al. 1994). During persistent poliovirus infection in Hep-2 cells, the
evolution and heterogeneity of the host cells have also been reported (Borzakian et al.
1992). Cell evolution was also observed in other persistent poliovirus infections. After
passage of poliovirus/Hela cells for 6 months, a stable cell line termed SOFIA emerged
that no longer produced infectious virus and did not contain viral proteins or viral RNA
(Kaplan et al. 1989). In SOFIA cells, the poliovirus receptor (PVR) gene did not contain
gross alteration at DNA level; however, the transcription of PVR-specific RNA was
reduced. Therefore, it was suggested that resistance of SOFIA cells to poliovirus
infection appears to result from down-regulation of PVR RNA which leads to lack of
PVR protein expression at the cell surface (Kaplan and Racaniello 1991). During
persistent poliovirus infection in human neuroblastoma IMR-32 cells, cells expressing
mutated poliovirus receptor emerged and the mutations at the N-terminal domain of PVR
increased the resistance of cells to poliovirus-induced lysis (Pavio et al. 2000). Moreover,
when the wild-type PVR and mutated PVR were expressed independently in murine LM
cells which lack the poliovirus receptor gene, it was found that the level of poliovirusinduced apoptosis was lower in cells expressing mutated PVR which was selected during
persistent poliovirus infection in IMR-32 cells than in cells expressing the wild-type
receptor (Gosselin et al. 2003).
2. Virus-specific factors involved in persistent infection
Various viral factors could be involved in the establishment and maintenance of
persistent infection, e.g. temperature-sensitive (ts) viral mutants, defective interfering (DI)
viral particles, alteration of viral RNA or protein synthesis, and so on.
A few studies have shown that viruses released from persistently infected cells
contain ts mutants (Preble and Youngner 1972, 1973a, 1973b; Youngner et al. 1976).
However, there has been no convincing evidence to demonstrate the role of ts mutants in
the establishment or maintenance of persistent infection.
The possible involvement of defective interfering viral particles in some persistent
infections is based upon: i) the presence of DI particles in the viral preparation used to
initiate persistent infection; or ii) the presence of DI particles in the medium of
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persistently infected cells. A number of viruses are usually highly cytolytic in permissive
cells and within a few days after infection all of the cells die. However, when infected
with the viral preparation containing DI particles, cells can survive the infection and
eventually became persistently infected. In 1970s, it was reported that noncytocidal
persistent infection of BHK-21 cells (Holland and Villarreal 1974) or mouse L cells
(Youngner et al. 1976) with wild-type VSV particles could be established only in the
presence of large number of DI particles. During persistent infection, wild-type and DI
VSV particles were continuously produced accompanied with viral protein changes and
RNA sequence alterations (Holland and Villarreal 1974; Holland et al. 1976; 1979;
Rowlands et al. 1980; Semler and Holland 1979; Villarreal and Holland 1976). Similarly,
in the presence of their respective DI particles, wild-type reovirus, Sindbis virus, and
Ebola virus establish persistent infections in mouse L cells, BHK-21 cells, and Vero cells,
respectively (Ahmed et al. 1981; Calain et al. 1999; Weiss et al. 1980). Interestingly,
when Hela cells were cotransfected with poliovirus type 2 RNA plus R1, an in vitrosynthesized poliovirus subgenomic replicon which contains a deletion of nearly all the
capsid region, persistent infection was established, whereas Hela cells transfected only
with poliovirion RNA all died (Kaplan et al. 1989). The detailed mechanism by which DI
particles change a lytic infection to a persistent infection is unclear. DI genomes are
truncated and their replication depends on the replicative enzymes encoded by the helper
virus. Since DI genomes are usually much smaller than the helper virus genome, they are
replicated more efficiently. Because of competition of DI RNAs, synthesis of the helper
virus genome is decreased. It is speculated that the decrease of the helper virus genome
may result in downregulation of determinants of cell killing which have yet to be
identified.
The foregoing discussion of virus evolution during persistent infection would
suggest that viral factors play an important role in establishment and maintenance of
persistent infection. The following are several additional examples supporting the
hypothesis that alteration of viral gene products is involved in persistent infections. It was
observed that persistence of Japanese encephalitis virus (JEV) in several cell lines
(murine neuroblastoma N18 cells, Vero cells, and murine astrocytoma DBT cells) was
associated with expression of truncated viral nonstructural protein 1 (NS1) in host cells
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(Chen et al. 1996). Sindbis virus is highly cytopathic in BHK-21 cells and establishment
of persistent infection with wild-type Sindbis virus needed the presence of high
concentration of DI particles (Weiss et al. 1980). However, Sindbis virus mutants (free of
DI particles) isolated from the carrier culture were able to establish secondary persistent
infection in BHK-21 cells. Through reverse genetics studies, it was found that a single
coding mutation in the nsP2 gene (a predicted change of Pro-726? Ser) was responsible
for the ability of mutated virus to establish persistent infection in BHK-21 cells (Dryga et
al. 1997). It has been suggested that persistence of VSV mutants on fibroblast cells is
associated with shutoff levels of cellular gene expression which may be determined by
the VSV matrix protein (Desforges et al. 2001). Poliovirus mutants selected in the
persistently infected human neuroblastoma cells initiated by either the Sabin 1 strain or
the type 3 wild-type Leon strain can establish secondary persistent infection in non-neural
Hep-2 cells, while both the Sabin 1 strain and the type 3 wild-type Leon strain cause a
lytic infection in Hep-2 cells (Duncan et al. 1998; Pelletier et al. 1991). Further studies
have shown that several amino acid residues in capsid proteins VP1 and VP2 are the viral
determinants which control whether the outcome of an infection in Hep-2 cells is a lytic
infection or a persistent infection (Borzakian et al. 1993; Calvez et al. 1993; Duncan et al.
1998; Pelletier et al. 1998a). It was proposed (Duncan et al. 1998) that these viral
determinants may affect the early steps of the virus life cycle such as virus attachment
and the receptor-mediated conformational changes which are believed to be necessary for
viral penetration and uncoating. Modification of these steps could be the mechanism by
which poliovirus mutants are able to establish persistent infection in Hep-2 cells. It has
also been reported that a single amino acid change (Phe-260? Leu) in viral glycoprotein
markedly increased the capacity of lymphocytic choriomeningitis virus to persist in adult
mice (Matloubian et al. 1990).
3. Host-specific factors involved in persistent infection
Various host factors such as host cell type, host cell mutants, host cell
differentiation stage, production level of interferon and so on may be involved in the
establishment and maintenance of persistent viral infection.
Many viruses show marked differences in interaction with various types of host
cells. For example, Newcastle disease virus (NDV) infection in BHK-21 cells led to large
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amounts of fusion of the cells with production of infectious virus; in NDV-infected Hep2 cells, less cell fusion was observed; while in NDV-inoculated mouse L cells, no
apparent cell fusion was observed and a persistent infection was established (Hecht and
Summers 1974; Poste et al. 1972). Mouse cells are not susceptible to echovirus 1 (EV-1)
infection since they lack the viral receptor, human VLA-2. By transforming mouse L
cells and 3T3 cells with cDNAs of human VLA-2, stable mouse L cell and 3T3 cell
transformants that express human VLA-2 were obtained. Upon infection with EV-1,
cytopathic effect developed on mouse L cell transformants but not on 3T3 cell
transformants and a persistent infection was established on 3T3 cell transformants (Zhang
and Racaniello 1997). The study also revealed that receptor down-regulation is not
involved in the establishment of persistent infection (Zhang and Racaniello 1997).
The contribution of host cell mutants to the maintenance of persistent infection has
been addressed in discussion of cell evolution during persistent infection.
Effects of the state of cell differentiation on viral infection have been documented.
Human erythroleukemia K562 cells can differentiate into several cell lineages. Four cell
strains were analyzed for their responses to poliovirus infection (Benton et al. 1995).
Poliovirus readily establishes persistent infections in K562-Mu cells and K562-ATCC
cells, while the majority of K562-KI cells and K562-We cells were killed after poliovirus
infection (Benton et al. 1995). Surface poliovirus receptor levels are similar in all K562
cell strains and there are no significant differences in viral RNA and protein synthesis
between these cell strains. It was proposed that some host factors related to virusmediated cytopathology may be responsible for the observed phenomenon (Benton et al.
1995). Further studies showed that after hemin-induced differentiation, poliovirus
infection of K562-Mu cells became cytolytic rather than leading to persistent infection
(Benton et al. 1996), demonstrating the influence of cell differentiation on the outcome of
virus infection. It is speculated that hemin treatment alters the expression of specific host
proteins in K562-Mu cells, which changes their response to poliovirus infection from
persistent to lytic (Benton et al. 1996). In addition, it has been observed that upon
poliovirus infection, well differentiated human blood cell lines develop CPE more rapidly
than less differentiated cell lines (Okada et al. 1987).
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In some persistent infections, such as Newcastle disease virus/mouse L cells
(Thacore and Youngner 1969) and human influenza C virus/MDCK cells (Goshima and
Maeno 1989), low levels of interferon were detected. However it is unclear whether
interferon plays a role in the maintenance of persistent infection in these cells. In most
persistent viral infections, such as measles virus/Hela cells (Rustigian 1966a), mumps
virus/conjunctiva cells (Walker and Hinze 1962), human rhinovirus-2/Hela cells (Gercel
et al. 1985), and poliovirus/human neuroblastoma IMR-32 cells (Colbere-Garapin et al.
1989), interferon was below detectable levels. It would appear therefore, that interferon
does not play a significant role in establishment and maintenance of persistent infection.

V.

RESEARCH OBJECTIVES OF THIS DISSERTATION

As discussed previously, neither a virus attachment molecule nor a specific cell
receptor has been identified for EAV. The early steps (e.g. attachment, penetration, and
uncoating) of the EAV infection cycle have not been elucidated. A major goal of this
study is to identify and characterize the cell receptor(s) involved in EAV attachment to
and entry into cells. However, identification of the cellular receptor(s) used by EAV for
attachment and entry has been hampered by the unavailability of a cell line that lacks the
appropriate EAV receptor(s). Identification of EAV non-permissive cell lines in which
EAV infection is restricted at different steps in its replication and comparison of these
non-permissive cell lines with permissive cell lines should help to identify the cellular
factor(s) that are involved in EAV infection. The specific objective of this research is to
evaluate a variety of cell lines for their permissiveness to EAV infection and then identify
the mechanism that restricts EAV infection. To achieve this objective, two hypotheses
and aims are proposed.
Hypothesis 1: Within selected cell lines (RK-13, BHK-21, C2C12, Hela, Hep-2,
and L-M), some cell lines are permissive to VBS53 EAV infection and some cell lines
are non-permissive to VBS53 EAV infection.
Aim 1: to test the permissiveness of various cell lines to EAV infection by one-step
growth of the virus in these cell lines as well as by indirect immunofluorescence assay
using EAV-specific monoclonal antibodies.
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Hypothesis 2: In non-permissive cell lines, EAV infection is restricted at certain
step(s) of the virus life cycle.
Aim 2: to determine whether restriction of EAV infection in non-permissive cell
lines is due to a block at the virus attachment step, a block at the cell entry step, or an
intracellular block.
After EAV infection, up to 30% to 70% of stallions can subsequently become
persistently infected. The detailed mechanism by which EAV establishes persistent
infection in stallions is unknown. Carrier stallions are not only a natural reservoir of EAV
responsible for maintenance and dissemination of EAV in equine populations, but also a
natural source of genetic and phenotypic diversity of EAV. Persistent viral infections in
cell culture have been demonstrated as a valuable tool to study virus-host cell interactions,
virus and host cell evolutions, and to elucidate the mechanisms of viral persistence. In
fact, genetic and phenotypic characterization of virus mutants and host cell mutants
during persistent infection has already greatly helped study virus-receptor interactions,
define virus virulence gene, and identify viral and host cell determinants involved in
persistent viral infection. The second major goal of this study is to establish persistent
EAV infection in cell cultures and then use the persistently infected cultures as a tool to
study virus-host cell interactions, virus and host cell evolutions, and to identify viral and
host cell determinants involved in EAV persistence. Specific hypotheses and objectives
relating to this goal are as follows.
Hypothesis 1: Persistent EAV infection can be established in certain cell lines.
Aim 1: to test a variety of cell lines and determine in which cell lines persistent
EAV infection can be established.
Hypothesis 2: During persistent infection of cell cultures, EAV undergoes genetic
and phenotypic evolution; genetic variations result in phenotypic changes.
Aim 2: to investigate genetic and phenotypic (such as growth characteristics,
neutralization phenotypes, and pathogenicity) variations of the viruses recovered from
different passages of the persistently infected culture; to define genetic variations that are
responsible for corresponding phenotypic changes.
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Table 1.1. The order of Nidovirales
Order
Family
Genus
Species

Nidovirales
Coronaviridae
Coronavirus
Canine coronavirus (CCV)

Torovirus
Equine torovirus (EqTV)

Porcine respiratory and
reproductive syndrome virus
(PRRSV)

Feline coronavirus (FCoV)

Bovine torovirus (BoTV)

Lactate dehydrogenase-elevating
virus (LDV)

Porcine epidemic diarrhea virus (PEDV)

Arteriviridae
Arterivirus
Equine arteritis virus (EAV)

Simian hemorrhagic fever virus
(SHFV)

Human coronavirus 229E (HCoV-229E)

Group 1
species

Porcine torovirus (PoTV)

Transmissible gastroenteritis virus (TGEV)
Bovine coronavirus (BCoV)
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Human coronavirus OC43 (HCoV-OC43)
Mouse hepatitis virus (MHV)

Group 2
species

Porcine hemagglutinating encephalomyelitis
virus (HEV)
Rat coronavirus (RCV)
Infectious bronchitis virus (IBV)
Turkey coronavirus (TCoV)
Severe acute respiratory syndrome
coronavirus (SARS-CoV)

Human torovirus (HuTV)

Group 3
species
Not
grouped

Roniviridae
Okavirus
Gill-associated virus
(GAV)
Yellow head virus
(YHV)

Table 1.2. The ORFs of the EAV genome
Leader or ORFs
(nt location) *
5' NTR (1-224)
5' Leader (1-211)
ORF1a (225-5408)
ORF1ab (225-5405,
5405-9751)

Protein (aa length† and molecular
§
weight kDa)
N/A
N/A
Nonstructural proteins (nsp)
1a polyprotein (1727 aa; 187 kDa)

Putative functional domain‡

1ab polyprotein (3175 aa; 345 kDa)
nsp1: Met1-Gly260 (260 aa; 29 kDa)
nsp2: Gly261-Gly831 (571 aa; 61 kDa)
nsp3: Gly832-Glu1064 (233 aa)
nsp4: Gly1065-Glu1268 (204 aa)
nsp5: Ser1269-Glu1430 (162 aa)
nsp6: Gly1431-Glu1452 (22 aa)
nsp7: Ser1453-Glu1677 (225 aa)
nsp8: Gly1678-Asn1727 (50 aa)
nsp 9: Gly1678-Glu2370 (693 aa; 80 kDa)
nsp10: Ser2371-Gln2837 (467 aa; 50 kDa)
nsp11: Ser2838-Glu3056 (219 aa; 26 kDa)
nsp12: Gly3057-Val3175 (119 aa; 12 kDa)

ORF2a (9751-9954)

Structural proteins
E (67 aa; 8 kDa)

ORF2b (9824-10507)

GP2b (227 aa; 25 kDa)

ORF3 (10306-10797)

GP3 (163 aa; 36-42 kDa)

ORF4 (10700-11158)

GP4 (152 aa; 28 kDa)

ORF5 (11146-11913)

GP5 (255 aa; 30-42 kDa)

ORF6 (11901-12389)

M (162 aa; 16 kDa)

ORF7 (12313-12645)

N (110 aa; 14 kDa)

Zinc finger, PCP1ß
CP2
HD
3CLSP
HD
?
?
?
RdRp
MB, NTPase, HEL
?
?

intermediate envelope protein
minor envelope protein;
1 N-glycosylation
minor envelope protein;
6 N-glycosylation
minor envelope protein;
3 N-glycosylation
major envelope protein;
1 N glycosylation; expressing
neutralization determinants
major envelope protein
nucleocapsid protein;
3 phosphorylation

N/A
3' NTR (12646-12704)
*
Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et al.,
1997).
†
Amino acids of non-structural proteins are numbered according to their locations in polyprotein 1ab.
Amino acids of structural proteins are numbered according to their locations in individual structural
protein. N/A: Not Applicable.
§
Molecular weight (kDa) of structural proteins shown here was the size after modification, e.g.
glycosylation.
‡

PCP1ß: papain-like cysteine proteinase 1ß; CP2: cysteine proteinase of nsp2; HD: hydrophobic
domain; 3CLSP: 3C-like serine proteinase; RdRp: RNA-dependent RNA polymerase; MB: metal ionbinding domain; NTPase: NTPase domain; HEL: helicase domain; ?: function unknown.
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(A)

(B)

Fig. 1.1. (A) Schematic diagram of the genome organization and expression of EAV. The
regions of the genome specifying the leader (L) sequence, the replicase gene (ORFs 1a
and 1b), and the structural protein genes are indicated. The nested set of EAV mRNAs
(genome and sg mRNAs 2 to 7) is depicted below. The black boxes in the genomic RNA
indicate the position of leader and major body TRSs. The figure A is reprinted from van
den Born et al. (2005). (B) Schematic representation of EAV virion, showing an
icosahedral nucleocapsid and an envelope containing six viral membrane proteins which
include a GP5-M heterodimer, an E protein, and a GP2b/GP3/GP4 heterotrimer. The E
protein is proposed to be the component which, on the one hand interacts with the
GP2b/GP4/GP3 heterotrimer, and on the other hand interacts with the GP5/M
heterodimer and/or the nucleocaspid. It is through these interactions that the E protein
draws the GP2b/GP4/GP3 complex into nascent virus particles (Wieringa et al. 2004).
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Fig 1.2. Overview of the replication cycle of EAV. The viral genome and the nested set
of subgenomic mRNAs are indicated, with the small black boxes representing the
common 5’ leader sequence. The white boxes in sg mRNAs represent the translationally
active ORF(s) for each mRNA. The figure is reprinted from Snijder et al. (1999).

Fig 1.3. Schematic diagram of the EAV ORF1a/1b frameshift-directing signals: the
‘shifty’ codons (5’ GUUAAAC 3’) and RNA pseudoknot structure. The codons of the
reading frames 1a including its termination codon and 1b are indicated. The figure is
reprinted from Snijder and Meulenberg (1998) with permission.
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A
1a

1ab

B

Fig 1.4. Overview of the proteolytic processing of the EAV replicase polyproteins. (A)
The processing schemes for the EAV polyproteins 1a and 1ab are depicted. The three
EAV proteases and their corresponding cleavage sites are shown: PCP1ß, nsp1 papainlike cysteine protease 1ß; CP2, nsp2 cysteine protease; 3CLSP, nsp4 3C-like serine
protease; the a* domain represents the inactive PCP1a domain. Hydrophobic domains
(HD) in nsp2, nsp3, and nsp5 are indicated. In the ORF1b-encoded polypeptide, the four
major conserved domains are depicted: RdRp, RNA-dependent RNA polymerase; Z,
putative zinc-binding domain; HEL, helicase domain; C, conserved, nidovirus-specific Cterminal domain. (B) Two alternative processing pathways of the EAV ORF1a protein.
The association of cleaved nsp2 with nsp3-8 was shown to direct cleavage at the nsp4|5
site by the nsp4 3CLSP (major pathway). Alternatively, in the absence of nsp2, the nsp5|6
and 6|7 sites were cleaved and the nsp4|5 junction remained uncleaved. The diagrams are
reprinted from Ziebuhr et al. (2000) with permission.
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A

B

C

Fig 1.5. Transcription models illustrating the discontinuous step during nidoviral
subgenomic mRNA synthesis. (A) ‘Leader-primed transcription’ model. Discontinuous
transcription was proposed to occur during positive-strand RNA synthesis using the fulllength negative genomic strand as a template. The sense TRS at the 3’ end of the leader
transcript base pairs with the antisense body TRS in the negative-strand template, after
which the leader transcript is extended to produce a sg mRNA. (B, C) ‘Discontinuous
negative strand extension’ model. In C, EAV is used as an example. Discontinuous
transcription was proposed to occur during negative-strand RNA synthesis using the fulllength positive genomic strand as a template. After attenuation of the RdRp complex at a
body TRS in the positive-strand genomic template, the nascent (-) strand is translocated
to the leader TRS region. Following base pairing between the antisense body TRS and
sense leader TRS, negative strand RNA synthesis resumes to add the anti-leader sequence.
Subsequently, the sg (-) strand RNA serves as a template for sg mRNA synthesis. The
positive- (white) and negative- (black) strand RNAs are shown. The sense leader and
body TRS (black boxes) in positive strand RNA and antisense leader and body TRS
(white boxes) in negative strand RNA are indicated. The diagrams A and B are modified
from Snijder and Meulenberg (1998) and the diagram C is reprinted from van den Born et
al. (2005) with permission.
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Fig 1.6. EAV sg mRNA3, -4, and -5 body TRS regions. The sequences are aligned with
respect to the translation initiation for the corresponding structural protein. The body
TRSs and translation initiation codon are shown in bold. The figure is reprinted from
Pasternak et al. (2000).
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Chapter Two
Determination of the Permissiveness of Various Cell Lines to Equine Arteritis Virus
Infection and Demonstration That Equine Arteritis Virus Infection Is Restricted at
the Entry Step in Non-Permissive Cell Lines

ABSTRACT
Neither the virus attachment molecule nor the specific cell receptor has been
identified for EAV. The early cell-EAV interactions (e.g. attachment, penetration, and
uncoating) have not been elucidated. Although several permissive cell lines have been
identified which support productive EAV infection, it is unknown which cell lines are
non-permissive to EAV infection and at which steps EAV infection is blocked in these
cell lines. In this study, a variety of cell lines of different species and tissue origin were
tested for their permissiveness to infection with EAV strain VBS53, and the mechanisms
that restrict EAV infection in non-permissive cell lines were investigated. The cell lines
baby hamster kidney (BHK-21; ATCC CCL-10), rabbit kidney (RK-13; KY & ATCC
CCL-37) and mouse muscle (C2C12; ATCC CRL-1772) were found to support
productive infection with EAV strain VBS53 as demonstrated by infectious virus yield
and indirect immunofluorescence assay using EAV-specific monoclonal antibodies. On
the other hand, human cervix (Hela; ATCC CCL-2), human epidermoid larynx (Hep-2;
ATCC CCL-23), and mouse connective tissue (L-M; ATCC CCL-1.2) cell lines exhibited
limited susceptibility to infection with EAV strain VBS53. Interestingly, Hela cells
became more susceptible to the virus infection after extended serial passage. The
respective cell lines were referred to as Hela ‘High’ (passage 170-221) and Hela ‘Low’
(passage 95-115). While Hela ‘High’ cell line was more susceptible than Hela ‘Low’ cell
line, it was still considerably less susceptible than BHK-21 cell line to EAV infection.
Karyotypic analysis of Hela ‘High’ and Hela ‘Low’ cell lines using G-banding technique
revealed chromosomal differences. Transfection of Hela ‘High’, Hela ‘Low’, Hep-2, and
L-M cell lines with viral RNA in vitro-transcribed from a full-length EAV cDNA clone
induced virus replication, assembly, and release. Virus levels were comparable to those in
transfected BHK-21 cells 24 h post transfection, indicating that these cells fully support
EAV replication when the attachment and entry steps are bypassed. Thus, interference
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with the attachment or entry steps might account for resistance of these cells to infection
with EAV. Attachment of EAV strain VBS53 to the cells was determined by directly
titrating the virus bound to the cells. It was found that EAV was able to bind to Hela
‘High’, Hela ‘Low’, Hep-2, and L-M cell lines almost as efficiently as it did to the fully
permissive cell line BHK-21. Attachment of EAV strain VBS53 to each cell line was
further confirmed using a fluorescence-activated cell sorter (FACS) assay in which
binding of biotinylated EAV was detected with streptavidin-FITC. All of the cell lines
under study bound EAV in a dose-dependent manner and nonbiotinylated EAV
competitively inhibited binding, indicating that the binding was specific. Virus entry
studies showed that the efficiency of EAV strain VBS53 entry into Hela ‘High’, Hela
‘Low’, Hep-2, and L-M cell lines was significantly lower than that of entry into BHK-21
cells. In addition, it was observed that the entry of EAV into Hela ‘High’ cell line was
more efficient than virus entry into Hela ‘Low’, Hep-2, and L-M cell lines. In conclusion,
we have identified several cell lines that exhibit varying susceptibility to infection with
EAV strain VBS53 and have found that permissiveness of a cell line to EAV is
determined at the entry step. Results of this study would suggest that interaction of EAV
with its attachment receptor on the cell surface may be necessary, but of itself not
sufficient to initiate a productive infection.

52

INTRODUCTION
Equine arteritis virus (EAV) is the prototype member of the family Arteriviridae
which also contains porcine respiratory and reproductive syndrome virus (PRRSV),
lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV)
(Snijder and Meulenberg 1998). The EAV genome is a single-stranded, positive-sense
RNA molecule of 12.7 kb, which includes nine functional open reading frames (ORFs)
(Snijder and Meulenberg 1998; Snijder et al. 1999). The replicase gene comprises the 5’terminal three-quarters of the genome and includes two ORFs (1a and 1b). ORFs 1a and
1b are expressed directly from the genomic RNA and encode replicase proteins involved
in viral replication and transcription (den Boon et al. 1991; 1995a; Snijder et al. 1992,
1994; 1995; 1996; van Dinten et al. 1996; 1999; Wassenaar et al. 1997). The 3’ terminal
one-quarter length of the genome is composed of seven ORFs (2a, 2b, and 3-7), which
encode structural proteins E, GP2b (Gs), GP3, GP4, GP5 (G L), M, and N, respectively
(den Boon et al. 1991; Snijder and Meulenberg 1998; Snijder et al. 1999). These
structural proteins are expressed from 5’- and 3’-coterminal nested set of six subgenomic
mRNAs.
EAV virions consist of an icosahedral nucleocapsid which is surrounded by a lipidcontaining envelope with tiny surface projections (Horzinek et al. 1971). The viral
nucleocapsid is composed of the linear viral genomic RNA and a phosphorylated
nucleocapsid (N) protein (de Vries et al. 1992; Hyllseth 1973; Zeegers et al. 1976). The
virion envelope contains six envelope proteins. The two major envelope proteins include
the nonglycosylated membrane protein (M) and the relatively large envelope glycoprotein
GP5 (de Vries et al. 1992). The M and GP5 proteins occur as disulfide-linked
heterodimers (de Vries et al. 1995b). The unglycosylated envelope protein E is of
intermediate abundance in the virion (Snijder et al. 1999). The three minor envelope
proteins of EAV are glycoproteins GP2b, GP3, and GP4, which occur as heterotrimers in
the virion (de Vries et al. 1992; 1995a; Hedges et al. 1999b; Wieringa et al. 2002; 2003a).
The first step in virus infection is viral attachment to a specific receptor on a
susceptible cell. In the case of EAV, neither the virus attachment molecule nor a specific
cell receptor has yet been clearly identified. By analogy with many other animal RNA
viruses and in view of its recognition by neutralizing antibodies, the EAV GP5 protein
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had been postulated to serve as the virus attachment protein and to mediate receptor
recognition. However, exchange of the ectodomain of the EAV GP5 protein with that of
PRRSV or LDV in the context of an infectious EAV cDNA clone did not alter the cell
tropism of the virus, suggesting that the ectodomain of GP5 is not the main determinant
of EAV tropism in cell culture (Dobbe et al., 2001). Similarly, PRRSV mutants in which
the ectodomain of the M protein was replaced by that of EAV or LDV still retained their
ability to infect porcine alveolar macrophages and did not acquire tropism for cells
susceptible to the respective viruses (e.g. BHK-21 cells for EAV and mouse macrophages
for LDV) from which the foreign ectodomains were derived (Verheije et al. 2002). This
would suggest that, in the case of arteriviruses, the M protein is not responsible for
receptor binding either. Recently, Wieringa et al. (2003a) have shown that minor
structural proteins are present in EAV virions as disulfide-bonded GP2b/GP4/GP3
heterotrimeric complexes. Also, there are indications that the E protein is noncovalently
associated with the GP2b/GP4/GP3 trimers (Wieringa et al. 2004). It has also been
demonstrated that the E, GP2b, GP3, and GP4 proteins are not required for the formation
of EAV particles, although these proteins are believed essential for ensuring that the virus
particles are infectious (Molenkamp et al. 2000; Wieringa et al. 2004). These findings
would suggest that the GP2b/GP4/GP3/(E) complex might be involved in the EAV
attachment/entry process.
The cell receptor for EAV has not been identified either. Asagoe et al. (1997)
showed that heparin can reduce EAV infection of RK-13 cells and that this inhibition was
due to the direct interaction between heparin and EAV rather than the interaction between
heparin and RK-13 cells. Furthermore, treatment of RK-13 cells with heparinase before
virus inoculation decreased EAV infection of the cells (Asagoe et al. 1997). The data
suggested that a heparin-like molecule on the surface of RK-13 cells might serve as cell
receptor for EAV. However, heparinase treatment of cells could not completely block
EAV infection and EAV infection could not be reduced below 13% even in the presence
of a very high concentration of heparin (Asagoe et al. 1997), implying that other
molecules on the cell surface might serve as EAV receptors as well.
Identification of the receptor used by EAV for cell attachment and entry has been
hampered by the unavailability of a known cell line that lacks the appropriate EAV
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receptor(s). Identification of EAV non-permissive cell lines in which EAV infection is
restricted at different steps and comparison of these non-permissive cell lines with
permissive cell lines should help to identify the cellular factor(s) that are involved in each
step of EAV infection. In this study, a variety of cell lines of different species and tissue
origin were assessed for their permissiveness to infection with the strain VBS53 of EAV
and the mechanism that restricts EAV infection in the non-permissive cell lines was
investigated.

MATERIALS AND METHODS
Cells and viruses. The origin and morphological description of the cell lines used
in this study are listed in Table 2.1. The RK-13 (ATCC CCL37) cell line is routinely used
in our laboratory between passage level 192 and 204. An additional RK-13 cell line, RK13 (KY), is also available in the laboratory and it is routinely used between passage level
397 and 409. The RK-13 (ATCC CCL-37) and RK-13 (KY) cell lines are
morphologically and karyotypically distinct. Hela cells were obtained from the American
Type Culture Collection (ATCC CCL-2) at passage level 95. Since it was found that Hela
cells had different susceptibilities to EAV strain VBS53 infection after extensive serial
passage, it was decided to categorize Hela cells from passage 95 to 115 as Hela ‘Low’
cells and these are not susceptible to EAV strain VBS53 infection. On the other hand,
Hela cells from passage 170 to 221 were referred to as Hela ‘High’ cells and these were
found to be partly susceptible to EAV strain VBS53 infection. All the cell lines were
grown in Eagle’s minimum essential medium (EMEM) with 10% ferritin supplemented
calf serum (FSCS), penicillin, streptomycin, fungizone, and sodium bicarbonate. The
RK-13, BHK-21, Hela, Hep-2, and L-M cell lines were grown at 37ºC in an aerobic
incubator. The C2C12 cell line was grown at 37ºC in the presence of 5% CO2. The RK13 cell lines were subcultured once weekly (1:5 split), whereas BHK-21, L-M, and Hep-2
cell lines were subcultured twice weekly (1:6 split), and the C2C12 and Hela cell lines
were subcultured once every 4 days (1:4 split) in accordance with routine procedures.
The origin, passage history and horse-pathogenicity of the virulent Bucyrus strain
(VBS53) of EAV are summarized in Fig 2.1. The original isolate of EAV in 1953 was
passaged 15 times in horses and the pleural fluid collected from the 15th inoculated horse
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was named as the VBS53 strain of EAV, which was highly virulent for horses. The EAV
strain VBS53 was propagated twice in BHK-21 cells to produce virus stocks which were
used in this study. Viral infectivity was determined by plaque assay on RK-13 (KY) cells
as previously described (McCollum et al. 1962).
Antibodies. The development and characterization of monoclonal antibodies to the
nucleocapsid protein (N; MAb 3E2) and the non-structural protein 1 (nsp1; MAb 12A4)
of EAV have been previously described (MacLachlan et al. 1998; Wagner et al. 2003).
Both MAbs 3E2 and 12A4 were kindly provided by Drs. Udeni Balasuriya and James
MacLachlan at University of California, Davis.
Growth of EAV in various cell lines. Growth of EAV strain VBS53 in RK-13,
BHK-21, C2C12, Hela, Hep-2, and L-M cell lines was compared. Subconfluent
monolayers of each cell line grown in T-25 flasks (approximately 2.2 × 106 cells/T-25
flask) were inoculated with EAV strain VBS53 at a multiplicity of infection (m.o.i.) of 3.
Flasks were incubated at 37°C for 1 h. The inoculum was aspirated, and cell sheets
washed three times with PBS to remove unbound virus and the sheets overlaid with 10 ml
of EMEM medium. This was designated time zero with respect to infection. Inoculated
cultures were incubated at 37°C. At 0, 12, 24, 36, 48, 60, and 72 h post infection (p.i.),
both supernatants and cells were harvested and sonicated three times (20V, 15 sec/time)
to fully disrupt the cells to release virus particles. Viral infectivity was determined by
plaque assay on RK-13 (KY) cells as previously described (McCollum et al. 1962).
Mock-infected cultures of each cell line were included in the experiment. Cell lines were
also grown in 8-chamber slides and infected with EAV strain VBS53. At 24 h and 72 h
post infection, cell sheets were examined by indirect immunofluorescence assay for
expression of the viral nucleocapsid (N) protein and non-structural protein 1 (NSP1). To
determine the effect of m.o.i. on the outcome of infection, RK-13 (KY), Hela, Hep-2, and
L-M cell lines were infected with EAV strain VBS53 at m.o.i. of 1, 3, 10, and 50. At 0 h
and 40 h after infection, extracellular virus (represented by culture supernatants) and cellassociated virus (represented by cell-lysates) were titrated separately by plaque assays.
Serial amplification of EAV in Hela ‘High’ and Hela ‘Low’ cell lines.
Subconfluent monolayers of Hela cells (low passage P109 and high passage P200) were
inoculated with EAV strain VBS53 at an m.o.i of 3 (using an inoculum of 0.3 ml). Mock-
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inoculated Hela cells (P109 and P200) were included. The same volume of EAV infective
inoculum was added to 10% EMEM medium without cells and included as an additional
control. After 1 h of incubation at 37ºC, without washing, 10 ml medium was added to
each culture. After 4 days of incubation at 37ºC, the supernatant (P1) (10 ml) was
harvested and centrifuged at 1900 rpm for 10 min to remove cell debris. The supernatant
was then filtered through a 0.45 µm membrane to ensure removal of cell debris. Filtered
supernatant (0.3 ml) from mock-inoculated Hela cells (P1 mock), EAV-inoculated Hela
cells (P1 EAV-Hela), and EAV-inoculated medium (P1 EAV-medium) were added to
uninfected Hela cell cultures (P110 or P201) or medium without cells, respectively, and
incubated at 37ºC for 1 h. A 10 ml volume of medium was added and the cultures
incubated for 4 days at 37ºC to provide ‘P2 mock’, 'P2 EAV-Hela', and 'P2 EAVmedium', respectively. The same procedure was followed in attempting to amplify the
virus up to P7.
Chromosomal analysis. Karyotypic analysis of low (P98) and high (P202) passage
Hela cells was performed using the conventional G-banding technique (ISCN 1985;
Yunis 1976) at Department of Cytogenetics, University of Kentucky. Twenty giemsabanded metaphase cells from passage 98 and passage 202 Hela cells were analyzed,
respectively.
In vitro transcription and transfection of cells with in vitro transcribed EAV
RNA. Viral RNA transcripts were in vitro-transcribed from the full-length infectious
EAV cDNA clone pEAV2421/211EB which was derived from EAV strain VBS53
(Balasuriya et al., unpublished). The in vitro transcription was carried out as previously
described (van Dinten et al. 1997) with minor modifications. Briefly, the plasmid DNA
was linearized with XhoI, digested with proteinase K, purified by phenol-chloroform
extraction, precipitated with ethanol, and dissolved in water. The in vitro transcription
was conducted in a reaction mixture of 50.0 µl: linear DNA 15.0 µl, rNTPs mix (10mM
each, Amersham) 5.0 µl, acetylated BSA (1 mg/ml, Promega) 5.0 µl, DTT (100 mM,
Promega) 2.5 µl, 5’ cap analog M7G(ppp)G (10 mM, New England Biolabs) 5.0 µl, RNA
guard RNase inhibitor (Pharmacia) 2.5 µl, T7 RNA polymerase (Promega) 2.5 µl, 5x T7
transcription buffer 10.0 µl, nuclease free water 2.5 µl. After 2 h of incubation at 37ºC,
the RNA quality and yield were assessed by agarose gel electrophoresis and
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spectrophotometry. RNA transcripts were introduced into BHK-21, Hela ‘High’, Hela
‘Low’, Hep-2, and L-M cell lines by means of electroporation following previously
described protocols (van Dinten et al. 1997) with minor modifications. Briefly, cells were
grown to subconfluence, trypsinized, washed with PBS, and resuspended in PBS at a
concentration of 1 x 107 cells per ml. A 15 µl aliquot of the transcripts mixture was added
to 500 µl of the cell suspension, which was then transferred into electroporation cuvettes
(0.4 cm electrode gap; Bio-Rad). Using a Gene Pulser II system (Bio-Rad), the cells were
pulsed twice at 850V and 25 µF, with the pulse controller set at ‘infinite’ ohms. The cells
were incubated at room temperature for a 10 min ‘recovery period’ after electroporation
and then resuspended in 15 ml of culture medium which was previously warmed to room
temperature. The cells were seeded into 8-chamber slides for immunofluorescence assays
or into a T-25 flask to monitor virus yield at 12, 24, 48, 72, and 96 h post transfection.
Indirect immunofluorescence assay (IFA). Mock-, EAV-infected, or EAV RNAtransfected cells grown in 8-chamber slides were fixed with cold acetone for 10 min, and
washed three times with PBS containing 10mM glycine. Slides were then incubated with
MAb 3E2 (ascitic fluid) specific for EAV nucleocapsid protein, or MAb 12A4 (ascitic
fluid) specific for EAV NSP1, followed by fluorescein-conjugated goat antimouse
immunoglobulin (Pierce). The cell sheets were counterstained with Evans blue. The
images were recorded using a LEICA confocal microscope.
Measurement of virus binding to and entry into cells. EAV binding to and etnry
into various cell lines were determined by modifying previously described asssays (de la
Torre et al. 1988a; Vlaycheva and Chambers 2002). Subconfluent monolayers of BHK21, Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines were trypsinized and
resuspended in culture medium at a concentration of 2 x 106 cells per ml, and cooled
down at 4ºC for at least 30 min. In the case of each cell line, 2 x 106 PFU of EAV strain
VBS53 (in 200 µl) was added to four replicates of 1 x 106 cells (500 µl) and held at 4ºC
for 1 h. The cells were then washed three times with cold PBS to remove unbound virus.
Two of the cell replicates were resuspended in 1 ml of cold culture medium. Cell
suspensions were subjected to three cycles of freezing and thawing to release attached
viruses, and then centrifuged for 10 min at 1900 rpm at 4ºC. Clarified supernatants were
titrated by plaque assay on RK-13 (KY) cells as previously described (McCollum et al.
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1962). The amount of virus attached to Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells
was calculated as a percentage of the virus attached to BHK-21 cells. The other duplicate
of the cells were resuspended in 1 ml of pre-warmed culture medium and incubated at
37ºC for 1 h with agitation. After incubation for 1 h at 37ºC, the cells were treated with
1.0 ml acid glycine (pH 3.0) to inactivate non-internalized virus. The cells were then
washed four times with PBS and resuspended in 1 ml of culture medium. The last wash
was saved for infectivity titration to confirm that no residual extracellular virus was
detectable in the cell suspensions. Serial decimal dilutions of the cell suspensions were
made in culture medium and then inoculated onto monolayers of RK-13 (KY) cells in 6well plates. Inoculated cultures were incubated at 37ºC for 1 h. Cell monolayers were
overlaid with culture medium containing 0.75% carboxymethyl cellulose and incubated
at 37ºC for 4 days. Infectious centers were counted after staining of plates with 10%
formalin buffered crystal violet. Efficiency of virus entry into Hela ‘High’, Hela ‘Low’,
Hep-2, and L-M cell lines was calculated as a ratio of infectious center counts in each cell
line being evaluated to infectious center counts in BHK-21 cell line.
Virus purification and biotinylation. Purification and biotinylation of EAV were
carried out according to previously described assay with minor modifications (Nauwynck
et al. 1999). The stocks of EAV strain VBS53 were pelleted by ultracentrifugation
through a 20% (wt/wt) sucrose cushion in TNE buffer (20 mM Tris-HCl (pH 7.6), 100
mM NaCl, 1 mM EDTA) for 5 h at 25,000 rpm (SW28 rotor) at 4°C. Virus pellets were
resuspended in TNE buffer and further purified by ultracentrifugation using a
discontinuous 20%-50% sucrose gradient for 16 h at 32,000 rpm (SW41 rotor) at 4ºC.
Visible virus bands were harvested and rinsed with bicarbonate buffer (pH 8.6) by
centrifugation for 5 h at 34,000 rpm (SW41 rotor) at 4ºC. In the final step, the purified
virus particles were resuspended in sodium bicarbonate buffer. The infectivity titer of the
resulting virus particles was approximately 5 × 109 pfu/ml, as determined by plaque assay
in RK13 (KY) cells. The protein concentration was 2.0 mg/ml, as determined by the
Bradford assay (Bio-Rad) with bovine serum albumin (BSA) as a standard. Purified EAV
particles in suspension were biotin labeled using a protein biotinylation kit (Amersham).
Briefly, virus particles were diluted to a concentration of 1 mg/ml in sodium bicarbonate
buffer and 40 µl of biotinylation reagents were added per mg of virus protein. The
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mixture was shaken for 1 h at 4°C. Biotinylated virus was collected after purification on a
Sephadex G25 column, aliquoted (0.5 ml/tube, 0.4 mg/ml), and stored at -70°C. The
infectivity titer of the biotinylated virus was 4 × 109 pfu/ml.
Analysis of biotinylated EAV attachment to cells by flow cytometry.
Attachment of biotinylated EAV to various cell lines were carried out by modifying
previously described procedures (Borrow and Oldstone 1992; Nauwynck et al. 1999).
Subconfluent monolayers of RK-13 (KY), RK-13 (ATCC), BHK-21, Hela ‘High’, Hela
‘Low’, Hep-2, and L-M cell lines were washed three times with cold PBS and then
treated with non-enzymatic cell dissociation solution (Sigma) for cell detachment.
Various amounts of biotinylated EAV [0, 2.5 µg (2.5 × 107 pfu), 5.0 µg (5.0 × 107 pfu),
7.5 µg (7.5 × 107 pfu), 10.0 µg (1.0 × 108 pfu), 12.5 µg (1.25 × 108 pfu)] were added to
aliquots of a suspension of each cell line containing 5 ×105 cells in a total volume of 500
µl of PBS containing 0.2% bovine serum albumin (PBSA) and incubated at 4ºC for 1 h.
The cells were washed three times with cold PBSA and incubated with 200 µl of a 1:100dilution of streptavidin-fluorescein conjugate in PBSA for 1 h at 4ºC. The cells were then
washed three times in PBS containing 2% fetal bovine serum (FBS), followed by
resuspension in 1.0 ml of PBS containing 2% FBS. Propidium iodide was added to the
cell suspensions (1 µg propidium iodide per ml of cell suspension) just before analysis by
flow cytometry. The relative fluorescence intensity of each sample was determined by
flow cytometry and 30,000 cells were counted in each sample. Dead cells labeled with
propidium iodide were excluded.
The specificity of the attachment of biotinylated EAV to cells was demonstrated by
two methods: (i) a competitive inhibition test with nonbiotinylated EAV; and (ii) binding
experiments with biotinylated BHK-21 cellular proteins. In the first case, 5 ×105 cells
were first incubated at 4ºC for 1 h with different amounts of nonbiotinylated EAV (0, 1 ×
108 pfu, 2.5 × 108 pfu, 5 × 108 pfu, 7.5 × 108 pfu) in a final volume of 300 µl of PBSA.
Then, 1 × 108 pfu of biotinylated EAV was added and the total volume was increased to
500 µl with PBSA. The cells were incubated at 4ºC for a further hour, and fluorescence
intensities were determined in accordance with previously described protocols. Inhibition
of attachment was calculated as follows: % inhibition = [Mean fluorescence intensity of
cells without nonbiotinylated EAV - Mean fluorescence intensity of cells with different
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amounts of nonbiotinylated EAV]/[Mean fluorescence intensity of cells without
nonbiotinylated EAV] × 100%. In the case of the second method used to confirm the
specificity of virus attachment, biotinylated BHK-21 cellular proteins (0, 2.5 µg, 5.0 µg,
7.5 µg, 10.0 µg, and 12.5 µg) were incubated with 5 ×105 cells of each cell line at 4ºC for
1 h, and the fluorescence intensities determined as already described.

RESULTS
Determination of the permissiveness of various cell lines to infection with the
VBS53 strain of EAV. In order to identify a cell line that lacks the receptor(s) for EAV
attachment and entry, a variety of cell lines of different species and tissue origin (Table
2.1) were tested for their permissiveness to infection with the VBS53 strain of EAV (Fig
2.1). The first approach used to achieve this objective was to determine whether each of
the selected cell lines supported efficient growth of the virus. In EAV-inoculated BHK21, RK-13 (ATCC), RK-13 (KY), and C2C12 cell lines, virus-specific cytopathic effects
(CPE) were first visualized from 24 h p.i. with all the cell monolayers destroyed by 48 h
p.i., confirming that EAV is very cytolytic in each of these cell lines. In contrast, virusspecific CPE were not observed in EAV-inoculated Hela, Hep-2, and L-M cell lines even
at 96 h after inoculation. Replication of EAV in BHK-21, RK-13 (ATCC), RK-13 (KY),
and C2C12 cells exhibted a typical growth kinetic curve, with 4-5 log10 increases in
infectivity titers within 24 h, followed by a gradual decline in titers after 48 h (Fig 2.2). In
contrast, virus infectivity titers in Hela (ATCC), Hep-2, and L-M cells did not increase
markedly (less than 2 log10 increase) during the entire observation period (Fig 2.2),
indicating that growth of this strain of EAV in these cell lines was restricted and not
efficient.
To determine whether virus antigens were synthesized during infection, indirect
immunofluorescence assays were performed. In EAV-infected BHK-21 (Fig 2.3A and B),
RK-13 (ATCC), RK-13 (KY), and C2C12 cells (data not shown), almost 100% cells were
positive for the structural protein N (Fig 2.3A) and for the non-structural protein nsp1
(Fig 2.3B) by 24 h post inoculation, confirming that EAV efficiently replicated in each of
these cell lines. However, in EAV-inoculated Hela (ATCC) and L-M cells, only a small
number of cells were fluorescent positive for N- (Fig 2.3C and K) or nsp1 protein (Fig
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2.3D and I) by 24 h after inoculation. The number of EAV fluorescent-positive cells in
Hela (ATCC) and L-M cell lines was less than 2% and 6%, respectively. Even by 72 h
post inoculation, the percentage of EAV-positive cells in Hela (ATCC) and L-M cell
lines had not increased (Fig 2.3E, F, M, and N), indicating that the spread of virus from
the initially infected cells to uninfected cells had not occurred. No EAV-positive cells
were observed in the EAV-inoculated Hep-2 cell line throughout the period of
observation (Fig 2.3O, P, Q, and R). Failure to detect expression of selected nonstructural and structural viral proteins in the majority of cells of the EAV-inoculated Hela
(ATCC), Hep-2, and L-M cell lines would suggest that EAV infection of these cell lines
might be restricted at steps that precede viral replication, e.g. viral attachment or entry
steps.
In order to determine whether increase of m.o.i. can result in productive infection of
EAV in Hela (ATCC), Hep-2, and L-M cells, various cell lines were inoculated with
VBS53 EAV at m.o.i. of 1, 3, 10, and 50, respectively. As shown in Table 2.2, with an
increase of m.o.i., there was a concomitant increase in residual virus in each cell line at 0
h post inoculation. However, with the increase in m.o.i., virus yields in RK-13 (KY) cells
had declined by 40 h post inoculation. In Hela (ATCC), Hep-2, and L-M cell lines, on the
other hand, an increase in m.o.i. resulted in increase in virus titer by 40 h post inoculation.
This increase probably reflected the increase amount of virus in the inoculum. Even at a
high m.o.i. (e.g. m.o.i. = 50), virus replication in Hela (ATCC), Hep-2, and L-M cell lines
was not as efficient as in the fully permissive RK-13 cell line. It should be pointed out
that in EAV-inoculated RK-13, Hep-2, and L-M cells, the percentage of extracellular
virus to the total virus present (the sum of extracellular virus and cell-associated virus)
was greater than 80%, while it was only around 50% in Hela (ATCC) cells (Table 2.2).
Taken collectively, these findings confirm that RK-13, BHK-21, and C2C12 cell
lines are fully susceptible to infection with the VBS53 strain of EAV, whereas Hela
(ATCC), Hep-2, and L-M cell lines only have limited susceptibility to infection with this
virus.
Enhancement of susceptibility of Hela cells to EAV infection after extended
serial passages. In the course of this study, it was found that the Hela cell line became
more susceptible to infection with EAV strain VBS53 after extended serial passage. Hela
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cells which were obtained from ATCC at passage level 95 were serially passed up to
passage 221 as described in Materials and Methods. As indicated in Fig 2.2, the virus
infectivity titer in EAV-inoculated Hela P176 cells was 1.5-2 log10s higher than that in
Hela P98 cells. Using the IFA test, it was found that at 24 h post inoculation, EAVpositive cells were approximately 12% in EAV-inoculated Hela P176 cells but less than
2% in Hela P98 cells (Fig 2.3C, D, G, and H). Moreover, spread of the virus from the
initially infected cells to uninfected cells was observed in Hela P176 cells as reflected by
the increase in percentage of EAV fluorescent-positive cells from 12% at 24 h post
inoculation to approximately 19% at 72 h post inoculation (Fig 2.3G, H, I, and J). This
was not observed in Hela P98 cells (Fig 2.3C, D, E, and F). Furthermore, it was shown
that Hela cells between passage level 170 and 221 have higher susceptibility to EAV
infection than Hela cells between passage level 95 and 115, which were found to be nonsusceptible to infection. Hela cells from passage 95 to 115 were referred to as Hela ‘Low’
cell line and Hela cells from passage 170 to 221 as Hela ‘High’ cell line. It should be
pointed out that the morphology and growth rate of the Hela ‘High’ cell line were
indistinguishable from those of the Hela ‘Low’ cell line. While Hela ‘High’ cell line was
more susceptible than Hela ‘Low’ cell line to infection with EAV strain VBS53,
susceptibility of Hela ‘High’ cell line to infection was remarkably less than that of RK-13,
BHK-21, and C2C12 cell lines (Fig 2.2 and Fig 2.3). Also, no apparent EAV-induced
CPE was observed during one-step growth curve experiment of EAV in the Hela ‘High’
cell line.
In order to further confirm that Hela ‘High’ cell line is more susceptible than Hela
‘Low’ cell line to EAV infection, serial passage of EAV strain VBS53 in low (P109) and
high (P200) passage Hela cells were carried out. As shown in Table 2.3, the VBS53 strain
of EAV was efficiently amplified in Hela ‘High’ cell line but not in Hela ‘Low’ cell line.
Furthermore, this strain of EAV was able to initiate persistent infection in Hela ‘High’
cell line but not in Hela ‘Low’ cell line (see Chapter 3), confirming that Hela cells
evolved and acquired some new characteristics during extended subculturing.
Chromosomal analysis of Hela ‘High’ and Hela ‘Low’ cell lines. To investigate
the possible changes between Hela ‘High’ and Hela ‘Low’ cell lines and also to rule out
the possibility that Hela ‘High’ cell line was contaminated by other cells during the serial
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subculturing of Hela ‘Low’ cell line, karyotypic analyses of low (P98) and high (P202)
passage Hela cells were performed using the conventional G-banding technique.
Analyses of 20 Giemsa-banded metaphase cells from passage 98 and passage 202 Hela
cells are presented in Table 2.4. It has been established that Hela cells have four typical
marker chromosomes: one copy of marker M1, one copy of marker M2, four to five
copies of marker M3, and two copies of marker M4. Marker M1 is the der(1;3)(q10;q10),
marker M2 is the der(3;5)(p10;q10), marker M3 is the i(5)(p10), and marker M4 consists
of

the

long

arm

of

chromosome

11

and

an

arm

of

chromosome

19

(http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum=CCL-2).
Both Hela ‘High’ and Hela ‘Low’ cell lines were observed to contain one copy of marker
M1, one copy of marker M2, and 3-5 copies of marker M3 (Table 2.4). Marker M4 may
be present, because a derivative chromosome consisting of the long arm of chromosome
11 and an arm of an unidentified chromosome was observed in both Hela ‘High’ and
Hela ‘Low’ cell lines. This unidentified chromosome resembles the long arm of
chromosome 20 more closely than either arm of chromosome 19 [?der(11;20)(q10;q10)]
(Table 2.4). The fact that Hela ‘High’ cells analyzed contained typical marker
chromosomes of Hela cells confirms that they had not been contaminated with other cells.
Karyotypic analyses also revealed some differences between Hela ‘High’ and Hela ‘Low’
cell lines at chromosomal level. Hela cells at passage level 202 are karyotypically more
heterogenous than those at passage level 98. Cells at both passage levels have a
hyperdiploid count with modal number of 81-82 chromosomes, but the hyperdiploid
count ranges from 78 to 94 chromosomes in passage 202 cells and from 81 to 82 in
passage 98 cells (Table 2.4). In comparing the cells at passage level 202 to those at
passage level 98, both gain and loss of chromosomal material appear to have occurred.
For example, cells at passage level 202 acquired the following materials: an
isochromosome for the short arm of chromosome 2, i(2)(p10); an isochromosome for the
long arm of chromosome 2, i(2)(q10); an additional copy of chromosome 6 (Table 2.4).
In contrast, a derivative chromosome der(15;15)(q10;q10) which exists in passage 98
cells was absent in passage 202 cells (Table 2.4). In summary, karyotypical analyses
revealed that cells at both passage level 98 and passage level 202 contain typical Hela
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marker chromosomes. However, chromosomal changes were demonstrated in Hela cells
between passage levels 98 and 202.
Transfection of cells with viral RNA in vitro transcribed from an infectious
EAV cDNA clone. As has been shown, RK-13, BHK-21, and C2C12 cell lines are fully
susceptible to infection with EAV strain VBS53, whereas Hela ‘High’, Hela ‘Low’, Hep2, and L-M cell lines are of limited susceptibility to infection. In order to determine
whether restriction of EAV infection is due to an intracellular block, viral RNA in vitro
transcribed from an infectious EAV cDNA clone pEAV2421/211EB which was derived
from EAV strain VBS53 (Balasuriya et al., unpublished) was transfected into BHK-21,
Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines. Cytopathic effects appeared and
progressed in BHK-21 cells 72 h after transfection. No CPE was observed in the
transfected Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines even at 96 h post
transfection. However, based on the results of virus titration and IFA testing, EAV in fact
replicated in all of the transfected cell lines (Fig 2.4 and Fig 2.5). At 24 h post
transfection, the percentage of EAV nsp1- and N-protein positive cells was
approximately 20% in all transfected cell lines (Fig 2.5A, C, E, G, I and data not shown).
Consistently, at 24 h post transfection, virus yields in transfected Hela ‘High’, Hela
‘Low’, Hep-2, and L-M cell lines were similar (approximately 1.4 × 105 pfu/ml); these
were even higher than the corresponding titer in transfected BHK-21 cells (approximately
2.4 × 104 pfu/ml) (Fig 2.4). This indicated that Hela ‘High’, Hela ‘Low’, Hep-2, and L-M
cell lines support EAV replication as efficiently as the permissive BHK-21 cell line once
the viral RNA is released into the cytoplasm. After 24 h post transfection, virus yields in
transfected BHK-21 cells increased to markedly higher levels than those in transfected
Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells (Fig 2.4). This probably reflects the
inefficiency of the released virus to initiate secondary rounds of infection in Hela, Hep-2,
and L-M cell lines. This was corroborated by the IFA results. In transfected BHK-21 cells,
efficient spread of the infection to nontransfected cells was observed by 48 h post
transfection (Fig 2.5A and B), followed by the development of CPE and cell death by 72
h post transfection. In transfected Hela ‘Low’, Hep-2, and L-M cell lines, however,
spread of the infection from transfected cells to nontransfected cells was not observed at
48 h (Fig 2.5C and D; G and H; I and J) or even up to 72 h (data not shown) post
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transfection. In transfected Hela ‘High’ cells, spread of infection from transfected cells to
nontransfected cells was not apparent (Fig 2.5E and F). Differences of virus yields in
transfected Hela ‘High’ and Hela ‘Low’ cell lines are not as marked as those in infected
Hela ‘High’ and Hela ‘Low’ cell lines (Fig 2.4 and Fig 2.2). Taken together, the
transfection experiments demonstrated that Hela ‘High’, Hela ‘Low’, Hep-2, and L-M
cell lines support EAV replication when the attachment and entry steps are bypassed,
suggesting the absence of an intracellular block later in the virus replication cycle. Thus,
EAV infection of these cell lines appears to be restricted at the attachment or entry steps.
Binding assays. In order to determine whether EAV infection of Hela ‘High’, Hela
‘Low’, Hep-2, and L-M cell lines is restricted at virus attachment step, virus binding to
these cell lines was carried out. The first approach used to study virus attachment was to
incubate cells with EAV strain VBS53 for 1 h at 4ºC and then the virus bound to cells
was titrated after unattached viruses were removed through extensive washing. As shown
in Fig 2.6, Hela ‘Low’, Hela ‘High’, and Hep-2 cell lines were able to bind EAV strain
VBS53 almost as efficiently as the fully susceptible BHK-21 cell line. The amount of
virus attached to L-M cell line was 25% greater than that attached to BHK-21 cell line
(Fig 2.6).
In order to confirm the attachment of EAV to these cell lines, another approach was
taken using flow cytometry to examine the binding of biotinylated EAV strain VBS53 to
each cell line. RK-13 (KY), RK-13 (ATCC), BHK-21, Hela ‘Low’, Hela ‘High’, Hep-2,
and L-M cell lines were incubated with various amounts (0, 2.5 µg, 5.0 µg, 7.5 µg, 10.0
µg, and 12.5 µg) of biotinylated EAV, respectively. The biotinylated EAV was found to
bind to all of the cell lines under study and the binding level (fluorescence intensity)
increased with the increase in the amount of biotinylated virus (Fig 2.7A, C, D, E, F, G
and H), suggesting that EAV binds to these cells in a dose-dependent manner. However,
using the same amount of virus, binding differences were observed between these cell
lines. RK-13 (Fig 2.7C), BHK-21 (Fig 2.7D), Hela ‘Low’ (Fig 2.7E), Hela ‘High’ (Fig
2.7F), and Hep-2 (Fig 2.7G) cells had similar levels of virus binding (fluorescence
intensities), while L-M cells had a significantly higher level of virus binding (Fig 2.7H).
Since EAV strain VBS53 was amplified in BHK-21 cells, the purified virus particles used
for biotinylation may still have contained some BHK-21 cellular proteins. In order to
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exclude the possibility that the binding observed was caused by BHK-21 cellular proteins,
mock-infected BHK-21 cell supernatants which underwent the same purification
procedure as used for EAV particles was biotinylated and various amounts of biotinylated
BHK-21 cellular proteins (0, 2.5 µg, 5.0 µg, 7.5 µg, 10.0 µg, and 12.5 µg) equivalent to
those of biotinylated EAV were used to perform binding assays. As shown in Fig 2.7, in
the case of each cell line, the fluorescence intensities resulting from biotinylated BHK-21
cellular proteins were significantly lower than those caused by biotinylated EAV.
Moreover, unlike biotinylated EAV, an increase in the amount of biotinylated BHK-21
cellular proteins did not remarkably increase the binding levels (fluorescence intensities).
This indicated that fluorescence intensities observed in binding experiments mainly
resulted from the biotinylated EAV rather than from biotinylated BHK-21 cellular
proteins. The specificity of biotinylated EAV attachment to cells was also confirmed by
the fact that the binding of biotinylated EAV to the various cell lines was competitively
inhibited by nonbiotinylated EAV (Fig 2.8).
These findings demonstrate that EAV strain VBS53 attaches to Hela ‘Low’, Hela
‘High’, Hep-2, and L-M cell lines as efficiently as it attaches to RK-13 and BHK-21 cell
lines, suggesting that virus attachment is not the major step in restricting EAV infection
in Hela, Hep-2, and L-M cell lines.
Entry assay. To determine whether infection of Hela ‘Low’, Hela ‘High’, Hep-2,
and L-M cell lines with EAV strain VBS53 is restricted at the entry step, the virus entry
into these cell lines was investigated. In attempting to use confocal microscopy to follow
the attachment and entry of biotinylated EAV into BHK-21, Hela, Hep-2, and L-M cell
lines, it was difficult to clearly distinguish attached virus from internalized virus (data not
shown). An alternative approach was taken using a modified conventional infectious
center assay to study EAV entry. A standardized amount of cells were incubated with a
standardized amount of EAV strain VBS53 for 1 h at 4ºC for virus attachment. After
extensive washing to remove unbound virus, cells were incubated at 37ºC for 1 h to allow
for virus entry. Then, cells were treated with acid glycine (pH 3.0) to inactivate noninternalized viruses. Subsequently, serial decimal dilutions of the cells were made and
respective dilutions were plated onto monolayers of RK-13 (KY) cells for quantitation of
infectious foci by plaque formation. Since it has been shown that Hela ‘High’, Hela
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‘Low’, Hep-2, and L-M cell lines support EAV replication as efficiently as BHK-21 cells
(Fig 2.4 and Fig 2.5) once viral RNA is introduced into the cell cytoplasm, it is
reasonable to propose that counts of infectious centers reflect the efficiency of EAV entry
into each cell line. As shown in Fig 2.9, the efficiency of VBS53 EAV entry into Hela
‘Low’, Hela ‘High’, Hep-2, and L-M cell lines was significantly lower than that of virus
entry into BHK-21 cells. In addition, it was observed that the efficiency of EAV entry
into Hela ‘High’ cell line was approximately five-fold higher than those of virus etnry
into Hela ‘Low’, Hep-2, and L-M cell lines (Fig 2.9). These findings indicate that
infection with EAV strain VBS53 is restricted at the entry step in Hela, Hep-2, and L-M
cell lines.

DISCUSSION
Neither viral molecules nor cellular factors involved in the early events (e.g.
attachment, penetration, uncoating) of the replication cycle of EAV have been elucidated.
One approach to studying host requirements for EAV infection is to identify cell lines
that are defective in their ability to support viral infection. In this study, we first
investigated the permissiveness of various cell lines to infection with EAV strain VBS53
and then attempted to establish the mechanism that restricts infection in non-permissive
cell lines. It had been previously demonstrated that RK-13, BHK-21, and Vero cell lines
are permissive to EAV infection and infection of these cell lines is highly cytocidal
(Snijder and Meulenberg 1998). In this study the cell line C2C12, derived from the
mouse muscle, was also found to be permissive to EAV infection with the development
of typical EAV-induced cytopathic effects. Furthermore, it was found that EAV infection
was restricted in Hela, Hep-2, and L-M cell lines in which no apparent CPE was observed
during one-step growth of EAV nor was efficient virus replication demonstrated. The
mechanism that restricts EAV infection in these cell lines was further investigated. When
attachment and entry steps are bypassed by transfection of Hela, Hep-2, and L-M cell
lines with viral RNA, these cell lines support EAV replication as efficiently as the
permissive BHK-21 cell line, suggesting the absence of an intracellular block later in the
virus replication cycle. Binding studies revealed that Hela, Hep-2, and L-M cell lines
were able to bind the VBS53 strain of EAV efficiently. Although it has been reported to
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use confocal microscopy to study the attachment and entry of biotinylated PRRSV into
alveolar macrophages (Nauwynck et al. 1999), it was difficult to clearly distinguish
attached virus from internalized virus when similar approach was used to study EAV
entry into BHK-21, Hela, Hep-2, and L-M cell lines (data not shown). Thus, a modified
infectious center assay was used in this study to investigate EAV entry into cells. After
one hour incubation of virus with cells at 4ºC for virus attachment, the temperature was
increased to 37ºC to allow for virus entry. Treatment of the cell suspensions with acid
glycine (pH 3.0) inactivates non-internalized virus and thus only the virus that has
successfully entered the cells can initiate subsequent replication. Since Hela, Hep-2, and
L-M cell lines support EAV replication as efficiently as BHK-21 cells, the plaque number
should reflect the efficiency of the virus entry into these cell lines. However, since no
apparent CPE was observed in EAV-inoculated Hela, Hep-2, and L-M cell lines, a plaque
assay cannot be directly performed in these cell lines. Therefore, after virus entry, the
serial decimal dilutions of suspensions of Hela, Hep-2, L-M, and BHK-21 cells are plated
onto monolayers of RK-13 (KY) cells which are overlaid with carboxymethyl cellulose.
With this assay, EAV infection of Hela, Hep-2, and L-M cell lines was shown to be
restricted at the entry step. However, there are shortcomings to this entry assay. It is
predicated on the fact that virus entering cells must first complete a single round of
infection in BHK-21, Hela, Hep-2, and L-M cells before infecting RK-13 cells and
forming infectious foci. Essentially, this assay does not establish virus entry directly
although it logically can reflect the entry efficiency. Furthermore, this assay cannot
distinguish defects at penetration step from those at the fusion/uncoating step. A more
direct virus entry assay will be performed to confirm these findings. For example, radiolabeled EAV particles can be used in a virus entry assay in which radioactivity of the cell
suspensions is measured to reflect entry efficiency after non-internalized viruses are
inactivated by acid glycine (pH 3.0) treatment.
In EAV-inoculated RK-13, Hep-2, and L-M cells, the percentage of extracellular
virus to the total virus present (the sum of extracellular virus and cell-associated virus)
was greater than 80%, while it was only around 50% in Hela cells. This would suggest
that virus release from Hela cells might be less efficient than that from RK-13, Hep-2,
and L-M cells.
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Another interesting finding from this study is that Hela cells become more
susceptible to EAV infection after extended serial passage. Hela ‘Low’ cells (P95 to P115)
are not susceptible to infection with EAV strain VBS53 whereas Hela ‘High’ cells (P170
to P221) are partly susceptible to infection. Increased susceptibility of Hela ‘High’ cells
to EAV infection appears to be a stable genetic trait since 51 subsequent serial passages
(from 170 to 221) did not result in any apparent alteration in the degree of susceptibility
of the cells to EAV (data not shown). This would suggest that in serially subculturing of
Hela cells up to passage 170, Hela cells acquire certain characteristics which would
appear stable. Furthermore, EAV strain VBS53 was able to initiate persistent infection in
Hela ‘High’ cell line but not in Hela ‘Low’ cell line (see Chapter 3), confirming that the
Hela cell line evolved during long-term serial passage. The results of karyotypic analysis
did not support the possibility that Hela ‘High’ cell line was contaminated by other cells.
The Hela ‘High’ cell line still contained the marker chromosomes characteristic of the
Hela cell line. Karyotypic analysis also revealed changes between Hela ‘Low’ and Hela
‘High’ cell lines at chromosomal level. However, the molecular changes that are
responsible for susceptibility differences of Hela ‘Low’ and Hela ‘High’ cell lines to
EAV infection are not yet determined. Based on the following i) virus yields in EAVinoculated Hela ‘High’ cell line are significantly lower than those in EAV-inoculated
BHK-21, RK-13, and C2C12 cell lines, ii) less than 100% of Hela ‘High’ cells are
infected with EAV, and iii) the efficiency of EAV entry into Hela ‘High’ cell line is only
about 10% of that with respect to BHK-21 cell line, it is postulated that Hela ‘High’ cell
line comprises a heterogenous population of cells of which only a certain percentage of
cells are fully permissive to EAV infection.
The evolution of cells and emergence of cell diversity is not an unusual event.
Normal tissues and cultured cells can exhibit a degree of heterogeneity (Ingram et al.
1985; Schafer et al. 1987). It has been reported that BHK(TK -) cells on subculture
spontaneously give rise to cells that are highly resistant to herpes simplex virus type-1
infection (Roller and Roizman 1994). Clonal selections of cell lines resistant to Theiler’s
murine encephalomyelitis virus or herpes simplex virus types 1 and 2 infections have
been reported as well (Hertzler et al. 2000; Roller and Herold 1997). The extent of
cellular heterogeneity is greatly increased in tumors and tumor cell heterogeneity appears
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to result from an enhanced genetic instability of transformed cells (Cifone and Fidler
1981; Crouch et al. 1987; Fidler et al. 1981; Lichtner et al. 1987; Nicolson 1987a, 1987b).
Hela cells were originally derived from a cervical adenocarcinoma and perhaps retain the
potential to evolve if they undergo extended serial passage. Cell evolution has also been
frequently observed in cell cultures persistently infected with a virus such as mouse L cell
evolution during persistent infection with reovirus (Ahmed et al. 1981), BHK-21 cell
evolution during persistent infection with foot-and-mouth disease virus (de la Torre et al.
1988a; 1989), and Hela cell and human neuroblastoma cell evolution during persistent
infection with poliovirus (Kaplan et al. 1989; Pavio et al. 2000).
In recent years it has become evident that viral attachment to and entry into the cell
are frequently more complex than previously thought. A number of viruses have been
shown to enter cells via receptor complexes rather than by an individual cell surface
molecule. For example, human immunodeficiency virus attaches to CD4 molecule
(Maddon et al. 1986) but requires the presence of chemokine receptors as its coreceptor
for virus entry (Choe et al. 1996; Deng et al. 1996; Doranz et al. 1996; Dragic et al. 1996;
Feng et al. 1996). Adenovirus subgroups A, C, D, E, and F bind to molecule CAR
(coxsackievirus and adenovirus receptor) (Roelvink et al. 1998) and adenovirus types 2
and 5 bind to heparan sulfate glycosaminoglycans (Dechecchi et al. 2001), however,
these binding molecules are insufficient for adenovirus entry which needs the
involvement of coreceptor αv–integrins (Wickham et al. 1993). Coxsackievirus A21
(CAV21) has been shown to bind to both decay-accelerating factor (DAF) and
intercellular adhesion molecule 1 (ICAM-1) (Shafren et al. 1997). However, DAF just
functions as a low-affinity attachment receptor and does not initiate a productive
infection; high-affinity binding molecule ICAM-1 is required for virus entry into cells
(Shafren et al. 1997). Similarly, PRRSV, another arterivirus, has been shown to attach to
heparan sulfate and porcine sialoadhesin on porcine macrophages (Delputte et al. 2002;
Vanderheijden et al. 2003). Heparan sulfate alone is sufficient to mediate PRRSV
attachment but not entry, whereas sialoadhesin alone is sufficient for both virus
attachment and virus entry (Delputte et al. 2005).
Cell receptors mediating EAV attachment and entry have not been identified. One
previous study suggested that a heparin-like molecule on the surface of RK-13 cells
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might serve as cell receptor for EAV (Asagoe et al. 1997). However, heparinase
treatment of RK-13 cells could not completely block EAV infection (Asagoe et al. 1997),
implying that other molecules on the cell might serve as EAV receptors as well. Data
from this study indicate that Hela, Hep-2, and L-M cell lines are able to bind EAV strain
VBS53 efficiently but cannot provide mechanism for virus entry. This would suggest that
cell receptor(s) for attachment of EAV strain VBS53 are present on the surface of these
cell lines, but these attachment receptor(s) are not sufficient to enable efficient virus entry.
Additional cellular factor(s) are therefore likely to be required for entry of EAV strain
VBS53 and these cellular factor(s) are probably absent or expressed at very low levels on
Hela ‘Low’, Hep-2, and L-M cell lines. Compared to Hela ‘Low’ cell line, Hela ‘High’
cell line is more susceptible to infection with EAV strain VBS53, and this increased
susceptibility appears to be due to increased virus entry efficiency. It would appear that
some Hela ‘High’ cells probably have acquired the ability to express the cellular factor(s)
which are necessary for EAV entry. RK-13, BHK-21, and C2C12 cell lines being fully
susceptible to EAV infection presumably constitutively express the cellular factor(s)
essential for both EAV attachment and entry. The availability of cell lines with varying
susceptibility to EAV infection should be useful for studying post-attachment events
involved in EAV entry.
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Table 2.1 Source and passage level of cell lines used in study
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Cell line

Species Tissue

Morphology

Source

BHK-21 (ATCC CCL-10)

Hamster Kidney

Fibroblast

Dr. George Allen, University of Kentucky

RK-13 (ATCC CCL-37)
(passage 192-204)

Rabbit

Kidney

Epithelial

Dr. William McCollum, University of Kentucky

RK-13 (KY)
(passage 397-409)

Rabbit

Kidney

Epithelial

Dr. William McCollum, University of Kentucky

C2C12 (ATCC CRL-1772)

Mouse

Muscle, myoblast

Fibroblast

Dr. Carole Moncman, University of Kentucky

Hela ‘Low’ (ATCC CCL-2)
(passage 95-115)

Human Cervical Carcinoma

Epithelial

American Type Culture Collection

Hela ‘High’
(passage 170-221)

Human Cervical Carcinoma

Epithelial

Derived from Hela ‘Low’ cell line by the author

Hep-2 (ATCC CCL-23)

Human

Epidermoid Laryngal
Carcinoma

Epithelial

Dr. William McCollum, University of Kentucky

L-M (ATCC CCL-1.2)

Mouse

Connective tissue

Fibroblast

Dr. George Allen, University of Kentucky

Table 2.2 Effect of multiplicity of infection on outcome of infection of selected cell
lines with EAV strain VBS53

cells and
m.o.ia

Virus Titer (pfu/ml)
(0 h p.i.)
cell-associated
extracellular
b
virus
virus

Virus Titer (pfu/ml)
(40 h p.i.)
cell-associated
extracellular
virus
virus

RK-13 (KY)
P406
m.o.i. = 1

1.3×101

1.1×102

1.5×106

6.1×107 (97.6)c

m.o.i. = 3

5.0×101

3.0×102

2.1×106

4.5×107 (95.5)

m.o.i. = 10

1.4×102

1.6×103

5.2×105

3.0×107 (98.3)

m.o.i. = 50

1.8×103

5.0×104

4.4×105

1.7×107 (97.5)

Hela P100
m.o.i. = 1

3.2×101

1.6×102

1.4×103

1.7×103 (54.8)

m.o.i. = 3

8.0×101

6.1×102

6.3×103

7.6×103 (54.7)

m.o.i. = 10

5.2×102

3.1×103

2.4×104

2.3×104 (48.9)

m.o.i. = 50

2.2×103

3.8×104

6.5×104

7.8×104 (54.5)

Hep-2 P454
m.o.i. = 1

6.7×101

1.8×102

1.6×102

6.6×102 (80.5)

m.o.i. = 3

1.4×102

3.3×102

8.6×102

3.2×103 (78.8)

m.o.i. = 10

8.7×102

1.7×104

2.3×103

1.1×104 (82.7)

m.o.i. = 50

3.5×103

6.7×104

8.0×103

3.9×104 (83.0)

L-M P305
m.o.i. = 1

7.0×100

2.7×102

6.9×101

3.6×103 (98.1)

m.o.i. = 3

2.7×101

1.9×102

3.8×102

1.7×104 (97.8)

m.o.i. = 10

1.4×102

1.2×103

1.8×103

8.3×104 (97.9)

m.o.i. = 50

2.2×103

4.3×104

3.6×103

3.6×105 (99.0)

a

Various cells were inoculated with EAV strain VBS53 at an m.o.i. of 1, 3, 10, 50 at 37ºC for
1 h. The inoculum was removed and the cells were washed three times with PBS. The cells
were supplemented with 10 ml culture medium and incubated at 37ºC. This was designated
time zero of infection. At 0 h and 40 h after infection, the extracellular virus (the supernatants)
and cell-associated virus (the cell lysate) were harvested and titrated on RK-13 (KY) cells.
b
For harvesting cell-associated viruses, the cells were resuspended in 10 ml culture medium,
sonicated three times (20V, 15 sec/time), and centrifuged at 1900 rpm for 10 min to remove
cell debris.
c
The numbers in parentheses represent percentage of extracellular virus titer to the total virus
titer. (total virus = extracellular virus + cell-associated virus)
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Table 2.3 The outcome of serial passaging of EAV strain VBS53
in Hela ‘Low’ and Hela ‘High’ cell lines*
Hela ‘Low’
P109
1 h p.i.
P1
P2
P3
P4
P5
P6
P7
Hela ‘High’
P200
1 h p.i.
P1
P2
P3
P4
P5
P6
P7

EAV titer (pfu/ml)
Mock-Hela
0
0
0
0
0
0
0
0
Mock-Hela
0
0
0
0
0
0
0
0

EAV-Hela

EAV-medium

5

1.55 × 10
1.12 ×105
9.4 × 102
0
0.5
0
0
0
0
0
0
0
0
0
0
0
EAV titer (pfu/ml)
EAV-Hela
EAV-medium
5
1.14 × 10
1.12 × 105
5
2.05 × 10
0
1.65 × 104
0
4
1.70 × 10
0
3.5 × 105
0
6
1.5 × 10
0
7.2 × 106
0
2.1 × 107
0

* Hela ‘Low’ (P109) and Hela ‘High’ (P200) cell lines were inoculated with EAV strain
VBS53 at an m.o.i of 3 (using an inoculum of 0.3 ml). Mock-inoculated Hela cells were
included. The same volume of EAV infective inoculum was added to 10% EMEM
medium without cells and included as an additional control. After 1 h of incubation at
37ºC, no washing, 10 ml medium was added to each culture. After 4 days of incubation at
37ºC, the supernatant (P1) (10 ml) was harvested, centrifuged at 1900 rpm for 10 min to
remove cell debris. The clarified supernatant was then filtered through a 0.45 µm
membrane to ensure removal of cell debris. Filtered supernatant (0.3 ml) from mockinoculated Hela cells (P1 mock-Hela), EAV-inoculated Hela cells (P1 EAV-Hela), and
EAV-inoculated medium (P1 EAV-medium) were added to uninfected Hela cell cultures
(P110 or P201) or medium without cells, respectively, and incubated at 37ºC for 1 h. A
10 ml volume of medium was added and the cultures incubated for 4 days at 37ºC to
provide ‘P2 mock-Hela’, 'P2 EAV-Hela', and 'P2 EAV-medium', respectively. The same
procedure was followed in attempting to amplify the virus up to P7.
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Table 2.4 The results of karyotypic analyses of Hela ‘Low’ (P98) and Hela ‘High’ (P202)
cell lines using G-banding technique

Hela ‘Low’ (P98)

Hela ‘High’ (P202)

81-82, XXX, +der(1;3)(q10;q10), der(1;9)(p10;q10),
add(2)(q37), add(3)(q12)×1-2, +der(3;5)(p10;q10),
add(5)(p10), +i(5)(p10)×3-5, +add(7)(p11.2), +9, +i(9)(p10),
+10, der(10)t(10;?)(p13;?), ?der(11;20)(q10;q10),
+der(12)t(3;12)(q21;q21.2), -13, +der(15;15)(q10;q10), +17,
add(19)(p13.1), +20, add(22)(q13.3), +1-4mar[cp]
chromosome pattern.
78-94, XXX, +der(1;3)(q10;q10), der(1;9)(p10;q10),
add(2)(q37), i(2)(p10), i(2)(q10), add(3)(q12)×1-2,
+der(3;5)(p10;q10), add(5)(p10), +i(5)(p10)×3-5, +6,
+add(7)(p11.2), +9, +i(9)(p10), +10,
der(10)t(10;?)(p13;?), ?der(11;20)(q10;q10),
+der(12)t(3;12)(q21;q21.2), +17, add(19)(p13.1), +20,
add(22)(q13.3), +1-14mar, 0-4dmin[cp] chromosome
pattern.
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ORIGINAL
ISOLATE (1953)
Bucyrus strain of EAV
from the lung of an
aborted fetus in Ohio,
1953

MLV VACCINE
HISTORY
Passaged in horses 9 times
(H9). Highly virulent in
horses.
[The EAV strain isolated in
1953 was passaged in horses 8
times (H8). H8 EAV was used
to inoculate a pregnant mare

The EAV from aborted fetal
lung tissue

Passaged in Horse Kidney
(HK) cells 131 times and in
Rabbit Kidney (RK-13)
cells 111 times

Passaged in Equine
Dermis (ED) cells 24
times

EAV ATCC STRAIN
HISOTRY
Passaged in horses 15 times
(H15). Highly virulent in horses.
[The EAV isolated from the
pregnant mare (H9 EAV) was
further passaged in horses for 6
times. Totally 15 times in
horses.]

Pleural fluid of 15 th horse. Also
called Pleural Fluid of Virulent
Bucyrus Strain (VBS53)

Submitted to ATCC and ATCC
made its stock by passaging in
RK-13 cells for unknown times

Virulent EAV ATCC strain
(ATCC VR-796)

ARVAC® MLV vaccine
266 serial passages in
cell culture (HK 131/RK
111/ED 24)

Fig 2.1 Passage history of the original Bucyrus virus to produce the ATCC and MLV
vaccine strains of EAV. The EAV strain VBS53 that was used in this study is highlighted.
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Virus titer (LogPFU/ml)

9
8

RK-13 (KY)
P404

7

RK-13 (ATCC)
P199
BHK-21 P114

6

C2C12 P8

5

Hela 'Low'
P98

4

Hep-2 P452

3

L-M P303

2

Hela 'High'
P176

1
0
0

12

24

36

48

60

72

Hours post infection (h p.i.)

Fig 2.2 Growth of the VBS53 strain of EAV in eight cell lines. Subconfluent monolayers
of BHK-21, RK-13 (ATCC), RK-13 (KY), Hela ‘High’, Hela ‘Low’, Hep-2, and L-M
cell lines were inoculated with EAV strain VBS53 at an m.o.i. of 3 at 37°C for 1 h and
then washed three times with PBS to remove unbound virus. The cultures were then
supplemented with 10 ml EMEM medium and incubated at 37°C to allow virus growth.
This was designated time zero with respect to infection. At 0, 12, 24, 36, 48, 60, and 72 h
p.i., both the supernatants and cells were harvested and sonicated three times (20V, 15
sec/time) to fully disrupt the cells and release virus particles. Virus (supernatants and
cells together) was titrated by plaque assay on RK-13 (KY) cells as previously described
(McCollum et al. 1962). These results were confirmed in three separate experiments.
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BHK-21

Hela ‘Low’

Hela ‘High’

L-M

Hep-2

A

C

G

K

O

B

D

H

L

P

E

I

M

Q

F

J

N

R

VBS53
24 h p.i.
aN

VBS53
24 h p.i.
aNSP1

VBS53
72 h p.i.
aN

VBS53
72 h p.i.
aNSP1

Fig 2.3 Indirect immunofluorescence assays on cells infected with the VBS53 strain of
EAV. At 24 and 72 h post infection, EAV-infected cells grown in 8-chamber slides were
fixed with cold acetone for 10 min, and then washed three times with PBS plus 10mM
glycine. Slides were incubated with MAb 3E2 against EAV nucleocapsid protein (A, C,
G, K, O for 24 h p.i., and E, I, M, Q for 72 h p.i.) or MAb 12A4 against EAV NSP1 (B, D,
H, L, P for 24 h p.i., and F, J, N, R for 72 h p.i.) followed by FITC-conjugated goat
antimouse immunoglobulin. The cells were counterstained by Evans blue. The images
were recorded with a LEICA confocal microscope.

79

8
7

Virus Titer (LogPFU/ml)

6
5
4
3
BHK21
Hela 'Low'

2

Hela 'High'
L-M

1

Hep-2

0
12

24
48
72
Hours Post Transfection (h p.t.)

96

Fig 2.4 Virus yield in cells transfected with viral RNA in vitro transcribed from an
infectious EAV cDNA clone pEAV2421/211EB. BHK-21, Hela ‘Low’, Hela ‘High’,
Hep-2, and L-M cell lines were transfected with in vitro-transcribed viral RNA by means
of electroporation (see Materials and Methods). At 12, 24, 48, 72, and 96 h post
transfection, the supernatants were harvested and titrated by plaque assay on RK-13 (KY)
cells.
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BHK-21
A

Hela ‘Low’
C

Hela ‘High’

L-M

Hep-2

E

G

I

F

H

J

24 h
aNSP1

B

D

81

48 h
aNSP1

Fig 2.5 Indirect immunofluorescence assays on cells transfected with in vitro-transcribed viral RNA. At 24 and 48 h post transfection,
viral RNA-transfected cells grown in 8-chamber slides were fixed with cold acetone for 10 min, and then washed three times with
PBS plus 10mM glycine. Slides were incubated with MAb 12A4 against EAV NSP1 (A-J) or MAb 3E2 against EAV nucleocapsid
protein (data not shown) followed by FITC-conjugated goat antimouse immunoglobulin. The cells were counterstained by Evans blue.
The images were recorded with a LEICA confocal microscope.

% of binding relative to BHK-21 cells

140%
120%
100%
80%
60%
40%
20%
0%
BHK-21

Hela 'Low' Hela 'High'

L-M

Hep-2

Fig 2.6 Binding of the VBS53 strain of EAV to various cell lines. Subconfluent
monolayers of BHK-21, Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines were
trypsinized and resuspended in culture medium at a concentration of 2 x 106 cells per ml,
and cooled down at 4ºC for at least 30 min. For each cell line, 2 x 106 PFU of EAV (in
200 µl) were added to duplicates of 1 x 106 cells (500 µl) and maintained at 4ºC for 1 h.
The cells were washed three times with cold PBS to remove unbound virus and then
resuspended in 1 ml of cold culture medium. The cell suspensions were subjected to three
cycles of freezing and thawing to release attached viruses, and centrifuged for 10 min at
1900 rpm at 4ºC. The clarified supernatants were titrated by plaque assay on RK-13 (KY)
cells. The amount of virus attached to Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells
was calculated as percentage of the virus attached to BHK-21 cells. Mean ± Standard
Deviation is shown.
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Fig 2.7 Binding of biotinylated EAV strain VBS53 to various cell lines as determined by
flow cytometry. Suspensions of RK-13 (KY), RK-13 (ATCC), BHK-21, Hela ‘High’,
Hela ‘Low’, Hep-2, and L-M cells were inoculated with different amounts (0, 2.5 µg, 5.0
µg, 7.5 µg, 10.0 µg, and 12.5 µg) of biotinylated EAV or biotinylated BHK-21 cellular
proteins (control). Following 1 h of adsorption at 4ºC, cells were washed with PBSA and
incubated with streptavidin-fluorescein conjugate for 1 h at 4ºC. The cells were washed
and fluorescence intensity of each sample was analyzed by flow cytometry. In the case of
each sample, 30,000 cells were counted and dead cells were excluded through propidium
iodide staining. Binding of biotinylated EAV or biotinylated BHK-21 cellular proteins to
RK-13 (KY) cells were shown in (A) and (B), respectively. The binding of biotinylated
EAV or biotinylated BHK-21 cellular proteins to other cell lines were converted to
another format as shown in (C-H): RK-13 (ATCC) (C), BHK-21 (D), Hela ‘Low’ (E),
Hela ‘High’ (F), Hep-2 (G), and L-M (H). In (C-H), Mean ± Standard Deviation is shown.
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Fig 2.8 Binding of biotinylated EAV strain VBS53 to various cell lines was competitively
inhibited by nonbiotinylated EAV. Suspensions of RK-13 (KY), Hela ‘High’, Hela ‘Low’,
Hep-2, and L-M cells were first incubated at 4ºC for 1 h with different amounts of
nonbiotinylated EAV (0, 1 × 108 pfu, 2.5 × 108 pfu, 5 × 108 pfu, 7.5 × 108 pfu) and then
incubated with 1 × 108 pfu biotinylated EAV for another 1 h at 4ºC. The amount of
biotinylated virus attached to cells was determined by flow cytometry as described above.
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Fig 2.9 Entry of EAV strain VBS53 into various cell lines. Subconfluent monolayers of
BHK-21, Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cells were trypsinized and
resuspended in culture medium at a concentration of 2 x 106 cells per ml, and cooled
down at 4ºC for at least 30 min. For each cell line, 2 x 106 PFU of EAV (in 200 µl) were
added to duplicates of 1 x 106 cells (500 µl) and maintained at 4ºC for 1 h to allow for
virus attachment. The cells were washed three times with cold PBS to remove unbound
virus and then resuspended in 1 ml of pre-warmed culture medium and incubated at 37ºC
for 1 h with agitation to allow for virus entry. After 1 h of incubation at 37ºC, the cells
were treated with 1.0 ml acid glycine (pH 3.0) to inactivate non-internalized virus. Then
cells were washed four times with PBS and resuspended in 1 ml of culture medium. The
last wash was saved for titration. Serial decimal dilutions of the cell suspensions were
made in culture medium and plated onto monolayers of RK-13 (KY) cells. Inoculated
cultures were incubated at 37ºC for 1 h. Cell monolayers were overlaid with culture
medium containing 0.75% carboxymethyl cellulose and incubated at 37ºC for 4 days.
Infectious centers were counted after staining of plates with 10% formalin buffered
crystal violet. Efficiency of virus entry into Hela ‘High’, Hela ‘Low’, Hep-2, and L-M
cells was calculated as a ratio of infectious center counts in each cell line being evaluated
to infectious center counts in BHK-21 cells. Mean ± Standard Deviation is shown.
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Chapter Three
Establishment and Characterization of Persistent Equine Arteritis
Virus Infection in Hela Cells

ABSTRACT
It has been previously demonstrated that BHK-21, RK-13, and C2C12 cell lines are
fully susceptible, Hela ‘High’ cell line (P170-221) is partly susceptible, and Hep-2, L-M,
and Hela ‘Low’ (P95-115) cell lines are non-susceptible, to infection with the VBS53
strain of EAV (Chapter 2). Furthermore, it was shown that the VBS53 strain of EAV was
able to establish persistent infection in Hela ‘High’ cell line, but unable to establish
persistent infection in either BHK-21, RK-13, or C2C12 cell lines in which EAV
infection was highly cytolytic, with all the cells dead by 48 h post infection. Persistent
infection also could not be established in Hep-2, L-M, or Hela ‘Low’ cell lines in which
virus could no longer be detected after two passages. Similarly, transfection with in vitrotranscribed viral RNA was capable of initiating persistent infection only in the Hela
‘High’ cell line but not in BHK-21, Hep-2, L-M, or the Hela ‘Low’ cell lines. Persistently
infected Hela ‘High’ cell line had the following characteristics: i) The persistently
infected cells had been subcultured and maintained for over 3 years. ii) Persistently
infected cell monolayers underwent recurrent episodes of partial destruction and
subsequent recovery over the period under study. iii) Over the course of the study, the
percentage of EAV fluorescent-positive cells in the persistently infected monolayers
varied from 1% to 37%. In most passage levels, the percentage of virus-positive cells
ranged between 15% and 25%. iv) Infectious virus was continuously produced
throughout the course of persistent infection. Virus infectivity titers varied from 102 to
106 plaque forming units (pfu) per ml but in most passage levels tested, the titer ranged
from 104 to 106 pfu per ml. In all cases, the yield of cell-associated virus was comparable
to that of extracellular virus. v) After cryopreservation for 3 years in liquid nitrogen,
revived cultures still could produce infectious virus. Virus infectivity titers were similar
before and after freezing of the cell line. vi) An attempt to clone a single cell that could
continuously produce infectious virus was unsuccessful. vii) Addition of EAV
neutralizing antibody-positive equine serum to the medium in which the persistently
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infected cell line was cultivated resulted in the elimination of the persistent infection. The
viruses recovered from the 35th passage (Hela-EAVP35) and the 80th passage (HelaEAVP80) of the persistently infected Hela ‘High’ cell line grew more efficiently than the
VBS53 strain of EAV in Hela ‘Low’ and Hela ‘High’ cells. EAV strains VBS53, HelaEAVP35, and Hela-EAVP80 grew with the similar efficiency in BHK-21 cells. No
significant differences were observed in the growth of EAV strains VBS53, HelaEAVP35, and Hela-EAVP80 in Hep-2 and L-M cell lines, respectively. Notwithstanding
the fact that the VBS53 strain of EAV can only establish persistent infection in the Hela
‘High’ cell line but not in the Hela ‘Low’ cell line, Hela-EAVP35 and Hela-EAVP80
virus strains were able to establish persistent infection in both Hela ‘High’ and Hela
‘Low’ cell lines. Neither of these strains, however, was able to establish persistent
infection in BHK-21, Hep-2, and L-M cell lines. Entire genome sequencing of EAV
strains VBS53, Hela-EAVP35, and Hela-EAVP80 revealed nucleotide and deduced
amino acid changes during the course of persistent infection. The entire genome of each
of these three EAV strains was 12,704 nucleotide (nt) in length. The nucleotide
differences between EAV strains VBS53 and Hela-EAVP35, VBS53 and Hela-EAVP80,
Hela-EAVP35 and Hela-EAVP80 totaled 26 nt, 34 nt, and 16 nt, respectively. The
replicase polyprotein and the structural proteins had 15 aa, 17 aa, and 6 aa differences,
respectively, between EAV strains VBS53 and Hela-EAVP35, VBS53 and HelaEAVP80, and Hela-EAVP35 and Hela-EAVP80. The majority of deduced amino acid
changes involved EAV structural proteins E, GP2b, GP3-5 encoded by ORFs2a, 2b, and
3-5, respectively. In conclusion, an in vitro model of EAV persistence in cell culture was
established for the first time. Properties of the model system were characterized. The
strain of EAV that evolved during establishment and maintenance of persistent infection
in Hela cells was phenotypically and genetically analyzed.
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INTRODUCTION
Equine arteritis virus (EAV) is the prototype member of the family Arteriviridae in
the order Nidovirales (Cavanagh 1997). The genome of equine arteritis virus is a singlestranded, positive-sense RNA molecule of 12.7 kb, which includes nine functional open
reading frames (ORFs) (Snijder and Meulenberg 1998; Snijder et al. 1999). The first two
ORFs (1a and 1b) are located at the 5’-terminal three-quarters of the genome and encode
viral replicases; the other seven ORFs (2a, 2b, and 3-7) are located at the 3’ one-quarter
of the genome and encode structural proteins E, GP2b (Gs), GP3, GP4, GP5 (GL), M, and
N, respectively (den Boon et al. 1991; Snijder et al. 1999). The ORF1a and ORF1b are
translated from the genomic RNA into two replicase polyproteins which are
proteolytically processed into 12 nonstructural proteins (nsp1-12) and multiple
processing intermediates required for viral replication and transcription (den Boon et al.
1991; Snijder and Meulenberg 1998; Ziebuhr et al. 2000). The structural proteins are
expressed from 5’- and 3’-coterminal nested set of six subgenomic mRNAs (de Vries et
al. 1990).
EAV is the causative agent of equine viral arteritis (EVA), a globally distributed
infectious disease of equids. Most EAV infections are subclinical in nature; occasionally
infection results in respiratory or systemic illness, abortion/stillbirths in pregnant mares,
and interstitial pneumonia, enteritis, or pneumonoenteritis in young foals (Glaser et al.
1997; Timoney and McCollum 1993; 1996). After natural infection with EAV, up to 30%
to 70% of stallions can subsequently become carriers and these constantly shed the virus
in their semen (Timoney and McCollum 1993). Persistently infected stallions are the
principal reservoir of EAV and are responsible for perpetuation and dissemination of
EAV in equine populations (Balasuriya and MacLachlan 2004c; Timoney and McCollum
1993). Carrier stallions are also thought to be a significant natural source of genetic and
phenotypic diversity of EAV (Balasuriya et al. 1999a; 2004a; Hedges et al. 1999a). There
is convincing evidence that establishment and maintenance of the carrier state in the
stallion is testosterone-dependent with the detailed mechanism as yet unknown (Little et
al. 1991; McCollum et al. 1994). What host factor(s) (except testosterone) or viral
factor(s) contribute to the establishment and maintenance of persistent EAV infection in
stallions remain to be determined. Geographically and temporally distinct EAV isolates
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can vary markedly in the incidence and severity of the clinical disease they induce and in
their abortigenic potentials (Balasuriya et al. 1998; 1999b; Balasuriya and MacLachlan
2004c; McCollum and Timoney 1999; Timoney and McCollum 1993). The genetic
determinants of virulence have not yet been defined for EAV.
The ability of many viruses to establish persistent infection in cell culture has been
documented. Such infections have been used to study virus-host cell interactions. Also,
they are a useful tool for investigating virus and cell evolution (Ahmed et al. 1981;
Colbere-Garapin et al. 1989; de la Torre et al. 1988a; 1989; Kaplan et al. 1989).
Persistent infection in cell culture could possibly serve as a model system for elucidating
mechanisms of viral persistence in vivo. In fact, genetic and phenotypic characterizations
of virus mutants and host cell mutants during persistent infection have already greatly
helped in the study of virus-receptor interactions (Borzakian et al. 1993; Calvez et al.
1993; Colbere-Garapin et al. 1989; de la Torre et al. 1989; Duncan et al. 1998; Gosselin
et al. 2003; Pavio et al. 1996; 2000; Pelletier et al. 1991; 1998a). Such studies have also
served to define virus virulence gene (Couderc et al. 1993; 1994; Diez et al. 1990a;
1990b), and to identify viral and host cell determinants involved in persistent viral
infection (Benton et al. 1996; Borzakian et al. 1993; Calvez et al. 1993; Chen et al. 1996;
Desforges et al. 2001; Dryga et al. 1997; Duncan et al. 1998; Okada et al. 1987; Pelletier
et al. 1998a).
EAV infection is usually highly cytolytic in cell culture, e.g. BHK-21, RK-13, and
C2C12 (Snijder and Meulenberg 1998 and Chapter 2). Recently, it has been found that a
Hela ‘High’ cell line (P170-221) is partly susceptible to infection with the VBS53 strain
of EAV, whereas Hep-2, L-M, and Hela ‘Low’ (P95-115) cell lines are non-susceptible to
this virus strain (Chapter 2). The present study further demonstrated that the VBS53
strain of EAV was able to establish persistent infection in Hela ‘High’ cell line but not in
Hela ‘Low’, Hep-2, or L-M cell lines. Properties of the persistent EAV infection in Hela
‘High’ cell line were characterized. Genetic and phenotypic variations in the virus during
the course of persistent infection were investigated. The mechanism and significance of
persistent EAV infection in Hela cells are discussed.
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MATERIALS AND METHODS
Cells and viruses. The origin and conditions for the cultivation of BHK-21, RK-13,
C2C12, Hep-2, L-M, Hela ‘Low’, and Hela ‘High’ cell lines have been described in
Chapter 2. The origin and passage history of the VBS53 strain of EAV have been
described in Chapter 2. The VBS53 strain of EAV was propagated twice in BHK-21 cells
to produce virus stocks which were used in an attempt to establish persistent infection in
vitro. Hela-EAVP35 and Hela-EAVP80 are the virus strains obtained from the 35th and
80th passage of the persistently infected Hela ‘High’ cell line, respectively.
Antibodies. The development and characterization of monoclonal antibodies to the
nucleocapsid protein (N; MAb 3E2) and the non-structural protein 1 (nsp1; MAb 12A4)
of EAV have been previously described (MacLachlan et al. 1998; Wagner et al. 2003).
Both MAbs 3E2 and 12A4 were kindly provided by Drs. Udeni Balasuriya and James
MacLachlan at University of California, Davis.
Cell counting and cell viability. Before serially passaging cells, cell culture
supernatants containing detached cells were transferred to a tube. Cells were trypsinized
and the detached cells pooled together to provide a cell suspension. A 100 µl volume of
cell suspension was mixed with 100 µl of 0.4% trypan blue and loaded onto a
hemocytometer. Dead cells are stained by trypan blue. Cells were counted and cell
viability was calculated.
Attempt to establish persistent EAV infection. Subconfluent monolayers of
BHK-21, RK-13 (KY), C2C12, Hela ‘High’ (P171), Hela ‘Low’ (P98), Hep-2, and L-M
cell lines grown in T-25 flasks were inoculated with the VBS53 strain of EAV at an m.o.i.
of 3. Following one-hour absorption at 37ºC, the cells were washed three times with PBS
and 10 ml of fresh culture medium was added. Inoculated cultures were incubated at 37ºC.
Cultures were microscopically monitored daily for the development of cytopathic effect
and subcultured once every four days (1:4 split) if any cells survived. Extracellular and
cell-associated viruses were harvested separately, and titrated by routine plaque assay in
the RK-13 (KY) cell line. Expression of the viral nucleocapsid (N) protein and nonstructural protein 1 (NSP1) was examined using an indirect immunofluorescence assay.
Attempts to establish persistent infection in Hela ‘Low’ (P98), Hep-2, and L-M cell lines
with EAV strain VBS53 was repeated once. The attempt to establish persistent infection
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in the Hela ‘High’ (P196) cell line was repeated twice. Attempts to establish persistent
infection in BHK-21, Hela ‘Low’ (P98), Hela ‘High’ (P196), Hep-2, and L-M cell lines
with Hela-EAVP35 or Hela-EAVP80 viruses were performed in accordance with
protocols described above.
RT-PCR detection of viral RNA. The aim of the study was to establish persistent
infection in the Hela ‘High’ (P171) and Hela ‘Low’ (P98) cell lines with EAV strain
VBS53. At selected cell culture passages, supernatants and cells were harvested and
sonicated three times (20V, 15 sec/time) to fully disrupt the cells and release virus
particles. Cell debris was removed by centrifugation and 140 µl of clarified supernatants
were used for viral RNA extraction using the QIAamp viral RNA mini kit (Qiagen). The
primers used for one-step RT-PCR were based on amplification of a conserved region of
ORF1b (Gilbert et al. 1997): forward primer 9299P (nt position 9299-9318:
5’CCTGAGACACTGAGTCGCGT3’) and reverse primer 9464N (nt position 9483-9464:
5’CCTGATGCCACATGGAATGA3’). A 10 µl volume of extracted RNA was used for
the one-step RT-PCR in a total volume of 50 µl following the instructions of the one-step
RT-PCR kit (Qiagen). The reaction mixtures were incubated at 50ºC for 30 min and at
95ºC for 15 min and then were cycled for 40 times as follows: 94ºC for 30 sec, 53ºC for
30 sec, and 72ºC for 1 min. The reaction was terminated by a single extension step at
72ºC for 10 min. A 10 µl volume of the one-step RT-PCR products were analyzed on a
1.8% agarose gel. The predicted PCR products are 185 bp long. After addition of antiEAV equine serum to the medium of persistently infected cells, RT-PCR analysis of viral
RNA at each cell passage level was carried out in accordance with the protocols
previously described.
Transfection of cells with in vitro transcribed EAV RNA. In vitro transcription
of viral RNA from the full-length infectious EAV cDNA clone pEAV2421/211EB and
transfection of BHK-21, Hela ‘High’ (P200), Hela ‘Low’ (P102), Hep-2, and L-M cell
lines with viral RNA have been described previously (Chapter 2). After transfection, the
cultures were microscopically monitored daily for the development of cytopathic effect
and subcultured once every four days (1:4 split) if any cells survived. Extracellular
viruses were harvested and titrated by routine plaque assay in RK-13 (KY) cells.
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Expression of the viral nucleocapsid (N) protein and non-structural protein 1 (NSP1)
were determined using an indirect immunofluorescence assay.
Cloning of cells. Subconfluent monolayers of the 26th passage of the persistently
infected Hela ‘High’ cell line initiated with the VBS53 strain of EAV were washed,
trypisinized, and resuspended in fresh culture medium. After counting, the cells were
diluted to a concentration of 10 cells per ml and then distributed into two 96-well plates
in the amount of 0.1 ml per well. Plates were incubated at 37ºC in the presence of 5%
CO2. Individual wells were inspected and culture medium was supplemented until the
cell monolayer reached confluence. Supernatants from those wells which initially
contained a single cell were titrated by plaque assay in RK-13 (KY) cells.
Effect of anti-EAV equine serum on persistent EAV infection. EAV neutralizing
Ab-positive equine serum used in the study was the O.I.E affirmed ‘medium positive
reference serum standard (BL394080, produced in 1993)’. On multiple repeat testing, the
reference serum standard had a neutralizing antibody titer of 1:32 when titrated against
the attenuated vaccine strain of equine arteritis virus (ARVAC®, FDAH). The 81st serial
passage of the persistently infected Hela ‘High’ cell line initiated with the VBS53 strain
of EAV was subcultured (1:4 split ratio) and grown in Eagle’s minimum essential
medium (EMEM) with 10% ferritin supplemented calf serum (FSCS), and EMEM with
10%

EAV-neutralizing

antibody-positive

equine

serum,

respectively.

Serial

subcultivation of the persistently infected Hela cells grown in each medium was carried
out once every four days (1:4 split ratio). From the 88th passage, EAV Ab-positive equine
serum was removed from the medium of one replicate of the culture which was further
serially passed up to the 94th passage. The other replicate of the cell culture continued to
be passed in the presence of EAV Ab-positive equine serum up to the 94th passage. At
each passage level, extracellular and cell-associated virus containing materials were
harvested and titrated by plaque assay. Expression of the viral nucleocapsid (N) protein
was investigated using an indirect immunofluorescence assay. Also, RT-PCR analysis of
viral RNA was also carried out at each passage level.
Indirect immunofluorescence assay (IFA). The indirect immunofluorescence
assay was performed as previously described (Chapter 2).
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Growth of different EAV strains in various cells. Growth of EAV strains VBS53,
Hela-EAVP35, and Hela-EAVP80 in BHK-21, Hela ‘High’ (P198), Hela ‘Low’ (P100),
Hep-2, and L-M cell lines was compared. Subconfluent monolayers of each cell line
grown in T-25 flasks were inoculated with the respective viruses at an m.o.i. of 3. Flasks
were incubated at 37°C for 1 h. The inoculum was aspirated off, and cell sheets washed
three times with PBS to remove unbound virus and the sheets then overlaid with 10 ml of
EMEM medium. This was designated time zero with respect to infection. Inoculated
cultures were incubated at 37°C. At 0, 24, 48, 72, and 96 h post infection (p.i.),
supernatants were harvested and viral infectivity was determined by plaque assay on
cultures of the RK-13 (KY) cell line as previously described (McCollum et al. 1962).
Isolation of viral RNA, RT-PCR amplification and sequencing. Viral RNA was
directly isolated from EAV strains VBS53, Hela-EAVP35, and Hela-EAVP80 using the
QIAamp viral RNA mini kit (Qiagen). The complete genomes of these three viruses were
amplified in nine overlapping fragments (Appendix 1). Viral RNA was first reverse
transcribed with Superscript II (Invitrogen) into cDNA following the manufacture’s
instructions. Then, PCR amplification was performed with high-fidelity proof-reading
PfuTurbo DNA polymerase (Stratagene) following optimized thermocycling protocols
(Appendix 2). The PCR products were gel-purified using QIAquick gel extraction kit
(QIAGEN). Both sense and anti-sense strands were sequenced with a total of 76 primers
(Appendix 3) using BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems)
and Half-Dye Mix (Bioline) following the optimized cycle sequencing protocols
(Appendix 4). After cycle sequencing, extension products were purified using the
ethanol/EDTA precipitation method and then resuspended in template suppression
reagent (TSR). The samples were then loaded onto ABI PRISM 310 Genetic Analyzer.
Sequence data were analyzed with Vector NTI Suite V.7 software and summarized in
Appendices 5 to 13.

RESULTS
The VBS53 strain of EAV is capable of establishing persistent infection in Hela
‘High’ cell line but not in BHK-21, RK-13, C2C12, Hela ‘Low’, Hep-2 and L-M cell
lines. It has been previously demonstrated that BHK-21, RK-13, and C2C12 cell lines are
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fully susceptible, the Hela ‘High’ cell line (P170-221) is partly susceptible, and Hep-2, LM, and Hela ‘Low’ (P95-115) cell lines are non-susceptible, to infection with the VBS53
strain of EAV (Chapter 2). EAV infection of BHK-21, RK-13, and C2C12 cell lines is
highly cytolytic leading to the death of all cells by 48 h post infection. However,
inoculation of Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines with the VBS53 strain
of EAV did not result in any apparent cytopathic effects (CPE) throughout the course of a
one-step growth curve up to 96 h post infection (Chapter 2). In the case of each cell line,
inoculated cells appeared to be morphologically indistinguishable from mock-inoculated
cells. Surprisingly, it was possible to initiate persistent infection with the VBS53 strain of
EAV in Hela ‘High’ (P171) cells and these continuously produced infectious virus even
after 94 serial passages (Fig 3.1). The ability of EAV strain VBS53 to establish persistent
infection in the Hela ‘High’ cell line was confirmed in two further experiments in Hela
P196 cells (data not shown). In contrast, after two serial passages, no infectious virus
could be detected in Hela ‘Low’ (P98), Hep-2, and L-M cell lines inoculated with EAV
strain VBS53 (Table 3.1), indicating that persistent infection was not established in these
cell lines. In order to determine whether any noninfectious virus was present, the Hela
‘Low’ (P98) cell line inoculated with EAV strain VBS53 and subsequent passages
derived from it were examined for the presence of viral proteins and viral RNA. On IFA,
few cells were positive for the nucleocapsid protein (Fig 3.2) and non-structural protein 1
(nsp1) (data not shown) at the 1st passage level of EAV-inoculated Hela ‘Low’ cell line.
No viral specific fluorescence was detected from the 2nd to 20th passage of EAVinoculated Hela ‘Low’ cell line. In contrast, expression of viral proteins was detected by
IFA throughout the course of persistent infection in the Hela ‘High’ cell line (Fig 3.2),
although the percentage of EAV fluorescent-positive cells fluctuated. On RT-PCR
analysis for viral RNA, EAV RNA was detected throughout the course of persistent
infection in the Hela ‘High’ cell line (Fig 3.3A), whereas viral RNA was only detected at
the 1st and 2nd passages, and not from the 3rd to 20th passages, of the EAV-inoculated
Hela ‘Low’ cell line (Fig 3.3B). Collectively, these findings confirm that the VBS53
strain of EAV is able to establish persistent infection in the Hela ‘High’ cell line, but
unable to do so either in BHK-21, RK-13, C2C12 cell lines in which all the cells
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eventually die due to the cytolytic effects of the virus, or in the Hela ‘Low’, Hep-2, and
L-M cell lines in which cells survive without continuous production of virus.
Transfection with viral RNA is capable of initiating persistent infection in the
Hela ‘High’ cell line but not in BHK-21, Hep-2, L-M, and Hela ‘Low’ cell lines. In
order to determine whether failure to establish persistent EAV infection in Hela ‘Low’,
Hep-2, and L-M cell lines was due to the fact that the virus cannot achieve cell entry,
various cell lines were transfected with viral RNA in vitro-transcribed from an infectious
EAV cDNA clone pEAV2421/211EB (Balasuriya et al., unpublished). In the case of
transfected BHK-21 cells, cytopathic effects appeared and progressed from 72 h post
transfection with all the cells had died by 96 h after transfection. In contrast, no CPE was
observed in transfected Hela ‘High’, Hela ‘Low’, Hep-2, and L-M cell lines up to 96 h
post transfection, although infectious virus production was detected in these transfected
cells as shown in Table 3.2. Serial passaging of these transfected cell lines resulted in two
distinct outcomes. Serial subculture of transfected Hela ‘High’ cells led to establishment
of persistent infection in which infectious virus was produced throughout the observation
period (from passage 1 to passage 10) (Table 3.2). Whereas no apparent CPE was
observed from passage 1 to passage 5 in this line, cell destruction of limited extent was
observed from passage 6 to passage 10. On the other hand, one or two more
subcultivations of transfected Hep-2, L-M, and Hela ‘Low’ cells resulted in loss of
infectious virus production (Table 3.2), indicating that persistent infection was not
established in these cell lines. No cell destruction was observed in transfected Hep-2, LM, and Hela ‘Low’ cell lines throughout the observation period (from passage 1 to
passage 10).
Characterization of persistently infected Hela ‘High’ cells. Persistently infected
Hela ‘High’ cells initiated with the VBS53 strain of EAV were characterized by the
following properties. i) The persistently infected cells had been subcultured and
maintained for over 3 years. ii) Persistently infected cultures underwent recurrent
episodes of partial destruction and subsequent recovery (Table 3.3). For example, in
passages 1 and 2, no apparent cell destruction was observed; from passage 3 to passage 5,
a degree of cell destruction was observed; from passage 6 to passage 9, cells gradually
recovered and the extent of cell destruction decreased compared to that observed in
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passages 4 and 5; some cell destruction was observed again from passage 10 to passage
14; cells again gradually recovered from passage 15 to passage 18; such recurrences of
partial destruction and subsequent recovery of cells continued throughout the observation
period. The percentage of dead cells (as determined by trypan blue staining) during
periods of cell destruction was higher than that during periods of cell recovery. iii)
During the course of persistent infection, the percentage of EAV fluorescent-positive
cells varied from 1% to 37%. But in most passages of the persistently infected culture,
the percentage of virus-positive cells ranged between 15% and 25% (Table 3.3). IFA
images of persistently infected Hela ‘High’ cells at randomly selected passages are shown
in Fig 3.2. It should be pointed out that cell death and EAV fluorescent-positive cells
were determined randomly for some passages but not every passage of the persistently
infected Hela ‘High’ cell line. iv) Infectious virus was continuously produced throughout
the course of persistent infection with virus infectivity titers varying from 102 to 106 pfu
per ml. The virus infectivity titers ranged from 104 to 106 pfu per ml in most passages of
the persistently infected culture (Table 3.3; Fig 3.1). The yield of cell-associated virus
was comparable (at the same log level) to that of extracellular virus at every passage level
tested (Table 3.4). The ratio of extracellular virus to cell-associated virus fluctuated from
30:70 to 55:45 (Table 3.4). v) After storage for 3 years in liquid nitrogen, the revived cell
culture was still able to produce infectious virus with the virus titer similar to what it was
prior to freezing. vi) An attempt to clone a single cell that could continuously produce
infectious virus was unsuccessful. Cells were cloned from the 26th passage of the
persistently infected Hela ‘High’ cell line by distributing an appropriately diluted cell
suspension into 96-well plates. Wells were visually examined and only those wells that
received a single cell were used. Eventually, 46 clones were obtained. However, none of
them were found to produce infectious virus. vii) The effect of EAV neutralizing
antibody-positive equine serum on persistently infected cells is shown in Table 3.5. The
persistently infected Hela ‘High’ cells were treated with EAV neutralizing antibodypositive equine serum from the 82nd passage. Before treatment with antiserum, the
extracellular and cell-associated virus in the persistently infected Hela ‘High’ cell line
was 5.7 × 105 pfu/ml and 9.5 × 105 pfu/ml, respectively. After two serial passages in the
presence of antiserum, no infectious virus was detectable in either the supernatants or the
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lysates of the culture. The cell culture treated with antiserum was maintained up to the
94th passage during which no infectious virus could be detected. Interestingly, in the case
of antiserum-treated cell cultures, expression of viral nucelocapsid protein was
undetectable by the IFA test from the 83rd to the 94th cell culture passage, although viral
RNA was still detectable by the RT-PCR from the 83rd to the 85th cell culture passage.
This indicated that viral RNA could be present for several additional passages even when
infectious virus and viral protein expression were no longer detectable. Following
removal of the antiserum from the culture medium at the 88th serial passage, no renewed
virus replication, viral antigen expression, or EAV RNA production was detected upon 7
additional passages of Hela ‘High’ cells. This is evidence that persistently infected Hela
‘High’ cells could be cured of EAV infection by culturing the cells in the presence of
EAV neutralizing antibody-positive equine serum. In contrast, infectious virus, viral
protein expression, and viral RNA were consistently detected in the mock-treated cell
culture throughout the observation period.
Growth kinetics of persistent viruses in various cell cultures. To determine
whether the growth properties of the challenge strain of EAV had changed during the
course of persistent infection, growth kinetics of the parental EAV strain VBS53 and
viruses recovered from the 35th (Hela-EAVP35) and the 80th (Hela-EAVP80) passage of
the persistently infected Hela ‘High’ cell line were compared in BHK-21, Hela ‘High’
(P198), Hela ‘Low’ (P100), Hep-2, and L-M cell lines. In BHK-21 cells (Fig 3.4A), EAV
strains VBS53, Hela-EAVP35, and Hela-EAVP80 all caused a cytolytic infection.
Replication of each virus strain followed a similar growth kinetic curve, with 3-4 log10
increase in infectivity titers within 24-48 h, followed by a gradual decline in titers after
48 h. This indicated that these three EAV strains can cause productive infections and
grow with similar efficiency in BHK-21 cells. In both Hep-2 (Fig 3.4B) and L-M (Fig
3.4C) cell lines, the growth of EAV strains VBS53, Hela-EAVP35, and Hela-EAVP80
was not efficient, having similar growth kinetics for all three strains. On the other hand,
in both Hela ‘High’ (Fig 3.4D) and Hela ‘Low’ (Fig 3.4E) cell lines, Hela-EAVP35 and
Hela-EAVP80 strains grew better and replicated more efficiently than the VBS53 strain
of EAV. Hela-EAVP35 and Hela-EAVP80 strains had almost the same replication
efficiency in either Hela ‘High’ (Fig 3.4D) or Hela ‘Low’ (Fig 3.4E) cells.
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Ability of Hela-EAVP35 and Hela-EAVP80 to establish persistent infection in
both Hela ‘Low’ and Hela ‘High’ cell lines but not in BHK-21, Hep-2, and L-M cell
lines. To determine whether virus recovered from persistently infected cells has acquired
any new features in establishing persistent infection, an attempt was made to establish
persistent infection in BHK-21, Hela ‘Low’, Hela ‘High’, Hep-2, and L-M cell lines with
Hela-EAVP35 and Hela-EAVP80, respectively. As was the experience with the VBS53
strain of EAV, Hela-EAVP35 and Hela-EAVP80 caused cytolytic infection in BHK-21
cells with all the cells dead by 48 h post inoculation without the establishment of
persistent infection. Similar to EAV strains VBS53, Hela-EAVP35 and Hela-EAVP80
were not able to establish persistent infection in Hep-2 and L-M cell lines in which three
serial passages led to the loss of virus production (Fig 3.5A). In contrast to the VBS53
strain of EAV, which can only establish persistent infection in the Hela ‘High’ but not in
the Hela ‘Low’ cell line, Hela-EAVP35 and Hela-EAVP80 were able to establish
persistent infections in both Hela ‘High’ and Hela ‘Low’ cell lines (Fig 3.5 B and C).
This was confirmed by IFA studies (Fig 3.6). In the persistently infected Hela ‘High’ cell
line in which infection was initiated with Hela-EAVP35 or Hela-EAVP80, the virus
infectivity titer on 1st passage reached 2 × 106 pfu/ml (Fig 3.5B and C). In contrast, when
infection in persistently infected Hela ‘High’ cell line was initiated with EAV strain
VBS53, the virus infectivity titer on 1st passage was less, only reaching 104 pfu/ml. It
took two or three serial passages for the virus titer to reach 106 pfu/ml (Fig 3.1). This
confirmed that Hela-EAVP35 and Hela-EAVP80 viruses grow better than EAV strain
VBS53 in the Hela ‘High’ cell line in the course of the initial few passages in cell culture.
In Hela ‘High’ cells persistently infected with Hela-EAVP35 or Hela-EAVP80, apparent
cell destruction was observed from the initial passage, whereas cell destruction was not
observed until the 6th serial passage in persistently infected Hela ‘Low’ cells. During the
initial number of passages (1st to 5th), virus yields in Hela ‘Low’ cells were consistently
lower than those in Hela ‘High’ cells persistently infected with the same virus strains (Fig
3.5B and C). Virus strains Hela-EAVP35 and Hela-EAVP80 evidently grow better in
Hela ‘High’ cells than in Hela ‘Low’ cells over the course of the initial several passages
of infection. However, from the 6th and subsequent passages, the level of cell destruction
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and virus yields in persistently infected Hela ‘Low’ cells approximated to those in Hela
‘High’ cells (Fig 3.5B and C).
Comparative nucleotide and amino acid sequence analysis of the viruses
capable of establishing persistent infection in Hela cells. To investigate genetic
variation of EAV during persistent infection of Hela cells, the entire genomes of EAV
strains VBS53, Hela-EAVP35, and Hela-EAVP80 were sequenced. Sequences were
determined by direct sequencing of RT-PCR fragments and could thus be assumed to
reflect the consensus sequence of the virus population at the time of RNA extraction. The
full-length nucleotide sequences and the deduced amino acid sequences of EAV strains
VBS53, Hela-EAVP35, and Hela-EAVP80 were compared and the findings summarized
in Table 3.6. The entire genomes of EAV strains VBS53, Hela-EAVP35, and HelaEAVP80 were all 12,704 nt in length, namely the same length as the published sequence
of EAV030. The complete nucleotide (nt) differences between EAV strains VBS53 and
Hela-EAVP35, VBS53 and Hela-EAVP80, Hela-EAVP35 and Hela-EAVP80 were 26 nt,
34 nt, and 16 nt, respectively. All of these nucleotide changes occurred at ORFs1a, 1b, 2a,
2b, and 3-5; no nucleotide changes were observed at the 5’ non-translated region (NTR 1224 including 5’ leader 1-211), nor in ORFs 6-7 and the 3’ NTR (12646-12704). The
total number of amino acid differences in the replicase polyprotein and structural proteins
between EAV strains VBS53 and Hela-EAVP35, VBS53 and Hela-EAVP80, HelaEAVP35 and Hela-EAVP80 were 15 aa, 17 aa, and 6 aa, respectively. There were 14 nt,
20 nt, and 10 nt differences in the replicase gene, most of which were silent mutations
which only resulted in 3 aa, 4 aa, and 1 aa changes, between EAV strains VBS53 and
Hela-EAVP35,

VBS53

and

Hela-EAVP80,

Hela-EAVP35 and Hela-EAVP80,

respectively. There were 12 nt, 14 nt, and 6 nt differences in the structural protein genes
(ORFs2a, 2b, and 3-5), respectively. Most of these were non-synonymous mutations
which resulted in 12 aa, 13 aa, and 5 aa changes between EAV strains VBS53 and HelaEAVP35, VBS53 and Hela-EAVP80, Hela-EAVP35 and Hela-EAVP80, respectively.
The majority of deduced amino acid changes involved EAV structural proteins E, GP2b,
GP3-5 which are encoded by ORFs2a, 2b, and 3-5, respectively.
The catalytic dyad (Cys-164 and His-230) of the nsp1 protease, the critical residues
(Cys-270, His-332, Cys-319, Cys-349, Cys-354, Cys-344, and Cys-356) of the nsp2
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protease, the catalytic triad (His-1103, Asp-1129 and Ser-1184) of the nsp4 protease, the
putative substrate-binding region (Thr-1179 and His-1198) of the nsp4 protease, and 11
cleavage sites on the replicase polyprotein 1ab were all conserved in three EAV strains
VBS53, Hela-EAVP35, and Hela-EAVP80 (Table 3.6; Snijder and Meulenberg 1998;
Ziebuhr et al. 2000). No potential N-glycosylation site changes were observed with
respect to the structural proteins of these three EAV strains.
Five ambiguous nucleotides were observed in EAV strain VBS53: 3707Y, 7021R,
8260Y, 8290Y, and 10722Y (Y is T or C; R is A or G). Because of the existence of
degenerate codons, however, the ambiguity of nucleotide at 3707, 7021, 8260, and 8290
did not cause any change to the respective amino acids encoded by them. The ambiguity
of nucleotide T or C at 10722 resulted in the ambiguity of amino acid Leu or Ser at
position 8 of the GP4 protein. No ambiguous nucleotides were observed in either HelaEAVP35 or Hela-EAVP80. The degree of homology between Hela-EAVP35 and HelaEAVP80 (6 aa differences) was higher than that between either of these strains and the
VBS53 strain of EAV (15 aa differences between VBS53 and Hela-EAVP35; 17 aa
differences between VBS53 and Hela-EAVP80). This would indicate that EAV evolved
during the course of persistent infection in the Hela ‘High’ cell line. Most of the
mutations would appear stable. However, reversion of mutations was occasionally
observed. For example, the amino acid at position 88 of the GP2b protein of EAV strains
VBS53, Hela-EAVP35, and Hela-EAVP80 was Met, Val, and Met, respectively; the
amino acid at position 246 of the GP5 protein was Arg, Lys, and Arg, respectively.

DISCUSSION
Equine arteritis virus infection is usually highly cytolytic in cultured cells, e.g.
BHK-21, RK-13, and C2C12 ((Snijder and Meulenberg 1998 and Chapter 2). It has
recently been found, however, that Hela ‘High’ cell line (P170-221) is partly susceptible
to infection with the VBS53 strain of EAV, whereas Hep-2, L-M, and Hela ‘Low’ (P95115) cell lines are non-susceptible to this virus strain (Chapter 2). In this study the
VBS53 strain of EAV was shown to be able to establish persistent infection in a Hela
‘High’ cell line. To the authors’ knowledge, it is the first report of establishment of
persistent EAV infection in cell culture.
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Characterization of persistent viral infection in cell culture. Persistently infected
cell cultures may or may not exhibit virus-specific cytopathic effects despite the fact that
they continuously produce infectious virus (Frisk et al. 1999; Gercel et al. 1985; Kaplan
et al. 1989; Moscona and Galinski 1990). In this study, it was shown that persistently
infected Hela ‘High’ cells in which infection was initiated with EAV strain VBS53,
underwent multiple episodes of partial destruction and subsequent recovery. During the
course of persistent infection in the Hela ‘High’ cell line, the percentage of EAV
fluorescent-positive cells varied from 1% to 37% but with the range falling between 15%
and 25% in most passages. The observation that the percentage of virus-positive cells can
show cyclic variation has also been reported for other persistent systems. For instance, in
BHK-21 cells persistently infected with rabies virus, the percentage of cells exhibiting
positive immunofluorescence varied from 5% to 100% in cycles of 6-8 subcultures
(Wiktor and Clark 1972); in Hela cells persistently infected with human rhinovirus-2, the
percentage of cells producing infectious centers varied from 0.03% to 23% (Gercel et al.
1985). In contrast to persistent poliovirus infection in Hela cells in which freezing down
of cells in liquid nitrogen resulted in the cells losing the ability to produce infectious
virus (Kaplan et al. 1989), Hela cells persistently infected with EAV were still able to
produce infectious virus after being frozen down in liquid nitrogen for 3 years, with the
virus titer similar to what it had been prior to freezing (data not shown).
Addition of virus-specific antibodies or anti-viral compounds to the media of
persistently infected cells may or may not result in elimination of the persistent infection.
It has been shown that cloning or subculture of measles virus/Hela cells in the presence
of anti-measles serum in the culture medium led to a state in which no infectious virus
was released, whereas the vast majority of these cells were still immunofluorescence
positive (Rustigian 1966b), indicating the existence of viral antigen. When human
influenza C virus/MDCK cells (Goshima and Maeno 1989) or poliovirus/human
erythroblastoid K562 cells (Lloyd and Bovee 1993) were subcultured for several serial
passages with growth medium containing homologous virus-neutralizing antibodies,
extracellular virus became undetectable. However, upon further passage in the absence of
antiserum there was a return of infectious virus yield. In contrast, it was observed that
three serial subcultivations of human rhinovirus-2/Hela cells in the presence of antiserum
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resulted in a cure (no extracellular virus or infectious centers or viral antigens could be
detected) (Gercel et al. 1985). In addition, after removal of antiserum, no renewed virus
production or viral antigen expression could be detected upon 12 further passages (Gercel
et al. 1985), indicating that the formerly persistently infected cells were permanently
cleared of infection. It was also found that the anti-viral compound ribavirin was able to
eliminate foot-and-mouth disease virus (FMDV) from persistently infected BHK-21 cells
(de la Torre et al. 1987). Addition of EAV neutralizing antibody-positive equine serum to
the medium of persistently infected Hela ‘High’ cells resulted in the elimination of
persistent infection. No renewed virus production or viral antigen expression or EAV
RNA replication occurred upon 7 further passages in the absence of anti-EAV serum.
Characteristically, persistently infected cells are resistant to superinfection with
homologous viruses but are still susceptible to infection with heterologous viruses. For
example, Hela cells persistently infected with human rhinovirus-2 (HRV-2) were
resistant to superinfection with homologous viruses (HRV-2, HRV-2 TS-1 mutant, and
HRV-4) but were susceptible to poliovirus type 2 and vesicular stomatitis virus (VSV)
infection (Gercel et al. 1985). The virus yields in HRV-2/Hela cells superinfected with
HRV-2, TS-1 mutant, or HRV-4 were similar to those produced in HRV-2/Hela cells
alone (mock-superinfected) but were less than those produced in normal Hela cells
infected with the respective virus. In contrast, virus yields in HRV-2/Hela cells
superinfected with poliovirus type 2 or VSV were comparable to those obtained in
normal Hela cells infected with the respective virus (Gercel et al. 1985). The question
whether Hela ‘High’ cells persistently infected with EAV are resistant to superinfection
with EAV was investigated in this study (Table 3.7). Virus yields in persistently infected
Hela ‘High’ cell line which was superinfected with EAV strain VBS53 were comparable
to those obtained in persistently infected Hela ‘High’ cells which were mocksuperinfected, but were not less than those produced in normal Hela ‘High’ cells which
were infected with EAV strain VBS53. On the basis of this observation, it was not certain
whether persistently infected Hela ‘High’ cells were resistant to superinfection with EAV.
The difference between HRV-2/Hela cells and EAV/Hela ‘High’ cells is probably caused
by the fact that normal Hela cells are fully susceptible to HRV-2 infection, whereas
normal Hela ‘High’ cells are only partly susceptible to infection with EAV strain VBS53.
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Virus and cell evolution during persistent infection of cell culture. Equine
arteritis virus evolution during persistent infection of the Hela ‘High’ cell line was
observed in this study. Hela-EAVP35 and Hela-EAVP80, isolated from the 35th and 80th
passage of persistently infected Hela ‘High’ cell line, respectively, grew more efficiently
than the parental EAV strain VBS53 in Hela ‘Low’ and Hela ‘High’ cell lines. HelaEAVP35 and Hela-EAVP80 were able to establish persistent infections in Hela ‘Low’
cells, whereas the parental EAV strain VBS53 was unable to do so (Table 3.8).
Furthermore, compared to the parental EAV strain VBS53, Hela-EAVP35 and HelaEAVP80 had different neutralization phenotypes (Chapter 4) and exhibited potential
changes in pathogenicity (Chapter 5). Besides these phenotypic changes, direct
sequencing of the entire genomes of EAV strains VBS53, Hela-EAVP35, and HelaEAVP80 provides clearcut evidence of viral genetic evolution during persistent infection
of Hela ‘High’ cells. It should be pointed out that the entire genome sequences of these
three viruses are actually the predominant sequences within the viral quasispecies. In the
replicase, amino acid mutations were only observed in nsp1, nsp2, nsp7, and nsp9. In the
structural proteins, amino acid changes were found in E, GP2b, GP3, GP4, and GP5
proteins but not in either M or N proteins.
Further studies are needed to determine which amino acid(s) mutations are
responsible for the corresponding phenotypic changes. Special attention should be paid to
nsp2 Asp-577? Gly, nsp9 Pro-1933? Ser, E Ser-53? Cys, GP2b Leu-15? Ser, GP2b
Trp-31? Arg, GP3 Leu-135? Pro, and GP5 Pro-98? Leu.
It is interesting that, compared to the VBS53 strain of EAV, neither Hela-EAVP35
nor Hela-EAVP80 exhibited apparent phenotypic differences (e.g. growth kinetics and
the ability to establish persistent infection) in BHK-21, Hep-2, or L-M cell lines (Fig 3.4
and Table 3.8).
The virus-encoded RNA-dependent RNA polymerases (RdRp) are low fidelity
enzymes with mutation rates as high as the order of 10-3 to 10-5 errors per nucleotide per
replication cycle (Domingo and Holland 1997; Drake 1993). In addition, RNA viruses
have very short replication times and generate very large populations during replication.
Therefore, RNA viruses exist not as a single genotype but rather as a heterogeneous
mixture of related genomes known as a viral quasi-species (Holland et al. 1992). The
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quasi-species nature of RNA viruses allows viruses to adapt to environmental changes
more rapidly and facilitates the emergence of viral variants (Castro et al. 2005).
Therefore, it is not surprising that EAV has evolved after long-term persistence in Hela
cells. In fact, EAV may also evolve after many passages of cytolytic infection in cell
cultures. For example, the parent EAV strain isolated from horses did not infect primary
hamster kidney cells; however, when the same parent EAV strain underwent 82 passages
of cytolytic infection in horse kidney cells, the obtained virus could be able to infect
primary hamster kidney cells (Wilson et al. 1962). Also, after many passages of cytolytic
EAV infection in cell cultures, the virus had been observed to get attenuated (McCollum
1969).
Cell evolution during persistent EAV infection of Hela cells was not investigated in
this study. Previously, it has been demonstrated that the Hela cell line becomes more
susceptible to infection with EAV strain VBS53 after extended serial passage (Chapter 2).
It is reasonable to postulate that cells would evolve during persistent infection of the Hela
‘Low’ cell line initiated with Hela-EAVP35 or Hela-EAVP80. The question whether
Hela cells cured of persistent infection with anti-EAV serum have different susceptibility
from the corresponding passage level of normal Hela cells to EAV infection also needs to
be investigated.
Virus and cell evolution have also been observed in other persistent viral infection
systems. Genetic and antigenic changes have been demonstrated in hepatitis A virus
(HAV) variants arising during persistent infection of BS-C-1 cells (Lemon et al. 1991).
Foot-and-mouth disease virus isolated from persistently infected BHK-21 cells was more
cytolytic than parental FMDV for BHK-21 cells (de la Torre et al. 1988a). Further studies
revealed amino acid substitutions of the viral capsid protein and antigenicity alteration of
FMDV during persistence (Diez et al. 1990a). Moreover, FMDV became progressively
less virulent for mice and cattle during the course of persistence in BHK-21 cells (Diez et
al. 1990b). The poliovirus mutants selected from human neuroblastoma IMR-32 cells
persistently infected with the Sabin strains could reach 1-3 log10 units higher titer in IMR32 cells than that in non-neural Hep-2 cells, while parental viruses had similar titers in
both cell lines (Colbere-Garapin et al. 1989). Correlated with this modified cell tropism,
the poliovirus mutants recovered from carrier culture could establish secondary persistent
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infection in non-neural Hep-2 cells (Pelletier et al. 1991). Cell evolution has been
documented in mouse L cells persistently infected with reovirus (Ahmed et al. 1981),
BHK-21 cells persistently infected with FMDV (de la Torre et al. 1988a; 1989; Martin
Hernandez et al. 1994), and Hela cells (Kaplan et al. 1989; Kaplan and Racaniello 1991),
human neuroblastoma cells (Pavio et al. 2000), and Hep-2 cells (Borzakian et al. 1992)
persistently infected with poliovirus.
Mechanisms of persistent viral infection in cell culture. A number of studies
have shown that various viral and host cell factors could be involved in the establishment
and maintenance of persistent infection in cell cultures. For example, temperaturesensitive viral mutants (Preble and Youngner 1972, 1973a, 1973b; Youngner et al. 1976),
defective interfering viral particles (Ahmed et al. 1981; Calain et al. 1999; Holland and
Villarreal 1974; Holland et al. 1976; Kaplan et al. 1989; Weiss et al. 1980), alteration of
viral RNA or protein synthesis (Chen et al. 1996; Desforges et al. 2001; Dryga et al.
1997), and specific amino acid substitutions (Borzakian et al. 1993; Calvez et al. 1993;
Duncan et al. 1998; Matloubian et al. 1990; Pelletier et al. 1991; 1998a; 1998b) have
been shown to be involved in different persistent infection systems. Various host factors
such as host cell type (Hecht and Summers 1974; Poste et al. 1972; Zhang and Racaniello
1997), host cell mutants (Kaplan et al. 1989; Kaplan and Racaniello 1991), host cell
differentiation stage (Benton et al. 1995; 1996; Okada et al. 1987) and so on may also be
involved in the establishment and maintenance of persistent viral infection. However, the
detailed molecular mechanisms of persistent viral infection in cell cultures are not yet
well understood and furthermore, the mechanisms may be unique in each system.
The VBS53 strain of EAV is able to establish persistent infection in the Hela ‘High’
but not Hela ‘Low’ cell line, suggesting that some unidentified host cell factors are
involved in persistent EAV infection. On the other hand, Hela-EAVP35 and HelaEAVP80 are able to establish persistent infection in the Hela ‘Low’ cell line, whereas
EAV strain VBS53 is unable to do so. This suggests that unidentified viral factors are
also involved in the establishment of persistent EAV infection. The fact that EAV strain
VBS53 is able to establish persistent infection in the Hela ‘High’ cell line but not in Hela
‘Low’ cell line is consistent with the observation that Hela ‘High’ cells are more
susceptible than Hela ‘Low’ cells to the virus infection (Chapter 2). Correlated with the
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observation that Hela-EAVP35 and Hela-EAVP80 are able to, whereas EAV strain
VBS53 is unable to, establish persistent infection in the Hela ‘Low’ cell line, is the fact
that Hela-EAVP35 and Hela-EAVP80 grow more efficiently than EAV strain VBS53 in
the Hela ‘Low’ cell line. Based on these findings, it is speculated that establishment and
maintenance of persistent EAV infection in Hela cells is related to the susceptibility of
the cells to EAV infection. It has been previously suggested that higher susceptibility of
the Hela ‘High’ cell line than the Hela ‘Low’ cell line to infection with the VBS53 strain
of EAV is because of higher efficiency of virus entry into Hela ‘High’ cells than into
Hela ‘Low’ cells (Chapter 2). It would be interesting to investigate whether growth
efficiencies of Hela-EAVP35 and Hela-EAVP80 in Hela ‘High’ and Hela ‘Low’ cell
lines can be correlated with corresponding virus attachment and entry levels. Should this
prove to be true, it would suggest that Hela-EAVP35 and Hela-EAVP80 recognize some
new cell receptors on Hela cells. It may, thus, be postulated that establishment and
maintenance of persistent EAV infection in Hela cells would be predicated on virus-cell
receptor interactions. In fact, it has been suggested that interactions between poliovirus
and its receptor may be involved in establishment and maintenance of persistent
poliovirus infection in host cells (Borzakian et al. 1993; Calvez et al. 1993; ColbereGarapin et al. 1989; Duncan et al. 1998; Pavio et al. 1996; 2000; Pelletier et al. 1991;
1998a).
In above proposed model, cell heterogeneity is another key factor. If all of the cells
in a cell line, such as BHK-21, RK-13, and C2C12, are susceptible to EAV infection,
virus infection kills all of the cells and persistent infection cannot be established. If too
few cells in a cell line, such as Hep-2 and L-M, are susceptible to EAV infection, the
virus is not able to initiate and maintain a persistent infection. Failure to establish
persistent infection in the Hela ‘Low’ cell line with EAV strain VBS53 may be such a
case. However, in the case of the Hela ‘High’ cell line, a certain percentage but not 100%
of the cells are susceptible to infection with EAV strain VBS53 or Hela-EAVP35 or
Hela-EAVP80; infection of the Hela ‘High’ cell line with these viruses is not able to kill
all of the cells, instead, a persistent infection may be initiated and maintained.
Establishment of persistent infection in the Hela ‘Low’ cell line with either HelaEAVP35 or Hela-EAVP80 may be due to the same reason. The finding that persistently
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infected Hela cells can be cured by treatment with anti-EAV serum would suggest that
the persistent EAV infection is maintained by horizontal transmission of the virus
released from infected cells to uninfected susceptible cells. It would appear that virus
spread from cell to cell through cell fusion or virus spread from parent cells to daughter
cells through cell division is not very likely. Failure to establish persistent infection in
Hela ‘Low’, Hep-2, and L-M cell lines upon transfection with EAV RNA (Table 3.2) and
failure to obtain a single clone that can continuously produce infectious EAV would
support this hypothesis. It has been demonstrated that more than 103 cells derived from
persistently infected BHK-21 cells are needed to reinitiate a stable, FMDV-producing
carrier culture (de la Torre and Domingo 1988b), which would suggest that the persistent
infection of cell culture is the result of complex interactions acting at the population level.
In either a one-step growth curve of EAV in Hela cells (Chapter 2) or in persistently
infected Hela cells, the percentage of extracellular virus to the total virus present (the sum
of extracellular virus and cell-associated virus) was around or below 50%, whereas it was
greater than 80% in a one-step growth curve of EAV in BHK-21, Hep-2, or L-M cells.
Whether this factor is implicated to the establishment and maintenance of persistent EAV
infection in Hela cells remains to be determined.
Whether defective interfering particles of equine arteritis virus are involved in
establishment and maintenance of persistent EAV infection in Hela cells also remains to
be determined. Whether EAV infection induces production of interferon in Hela cells,
and if yes, whether interferon plays a role in the establishment and maintenance of
persistent EAV infection in Hela cells is unclear.
Significance of persistent viral infection in cell culture. Persistent viral
infections of cell culture have been used to study virus-host cell interactions. They have
also been shown to be a useful tool for investigating virus and cell evolutions (Ahmed et
al. 1981; Colbere-Garapin et al. 1989; de la Torre et al. 1988a; Kaplan et al. 1989).
Persistent EAV infection of Hela cells provides a model system to study viral and host
cell factors involved in viral persistence. It also provides a tool for elucidating virus-host
cell interactions, e.g. EAV-cell receptor interactions. Furthermore, such a system can be
used to investigate virus evolution and to study phenotypic (such as neutralization and
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virulence) changes. Persistent EAV infection in cell culture may also assist in elucidating
the mechanisms of EAV persistence in the carrier stallions.
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Table 3.1 The outcome of serial passaging Hela ‘Low’ (P98), Hep-2, and L-M cell lines inoculated with EAV strain VBS53*
Hela ‘Low’ cells (P98)
Passage No.
1 h p.i.
P1
P2
P3
P4
P5 – P20
*

Extracellular virus
(pfu/ml)
3.0 × 102
5.7 × 102
5.0
0
0
0

Cell-associated virus
(pfu/ml)
5.0 × 101
2.3 × 102
2.0
0
0
0

L-M cells (P302)
Extracellular virus
(pfu/ml)

Hep-2 cells (P460)
Extracellular virus
(pfu/ml)

5.4 × 102
2.9 × 103
1.2 × 101
0
0
0

4.7 × 102
5.5 × 102
8.0
0
0
0
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Selected cell lines were inoculated with the VBS53 strain of EAV at an m.o.i. of 3. Inoculated cultures were incubated at
37ºC and subcultured once every four days (1:4 split). Extracellular and cell-associated virus was harvested and titrated by
plaque assay on RK-13 (KY) cells. These results were confirmed in two separate experiments.

Table 3.2 Transfection with viral RNA established persistent infection in the Hela ‘High’ cell line
but not in Hela ‘Low’, Hep-2, and L-M cell lines*

Passage No.
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P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
*

Hela ‘Low’ cells (P102) Hela ‘High’ cells (P200)
Extracellular virus
Extracellular virus
(pfu/ml)
(pfu/ml)
5.2 × 104
1.3 × 103
1.0 × 101
0
0
0
0
0
0
0

2.1 × 105
6.6 × 103
4.0 × 103
4.4 × 104
1.2 × 105
3.9 × 105
1.3 × 106
3.6 × 106
8.6 × 105
2.6 × 105

L-M cells (P306)
Extracellular virus
(pfu/ml)

Hep-2 cells (P455)
Extracellular virus
(pfu/ml)

6.4 × 104
2.3 × 102
0
0
0
0
0
0
0
0

1.4 × 104
1.1 × 102
0
0
0
0
0
0
0
0

Selected cell lines were transfected with viral RNA in vitro-transcribed from a full-length infectious EAV cDNA
clone. Transfected cells were incubated at 37ºC and subcultured once every four days (1:4 split). Extracellular virus
was harvested and titrated by plaque assay on RK-13 (KY) cells.

Table 3.3 Some properties of persistently infected Hela ‘High’ cell line1 initiated with the VBS53 strain of EAV
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Passage
level

Extracellular
virus titer
(pfu/ml)

Cell destruction

1 h p.i.
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
P13
P14
P15
P16
P17
P18
P19
P20
P21
P22
P23
P24
P25
P26

4.7×102
6.0×104
6.3×104
2.90×10 5
1.79×10 6
6.00×10 5
1.95×10 5
1.0×105
4.5×105
5.7×105
1.5×106
6.8×105
1.4×106
9.1×105
9.9×105
2.9×105
3.0×105
1.8×105
1.5×105
1.0×106
6.3×105
4.4×105
1.2×106
2.1×104
3.9×105
1.1×106
1.4×106

no
no
no
partial destuction
cell destuction
cell destuction
partial recovery
partial recovery
recovery
recovery
partial destuction
partial destuction
cell destuction
cell destuction
cell destuction
partial recovery
recovery
recovery
recovery
partial destuction
partial destuction
cell destuction
cell destuction
recovery
recovery
partial destuction
cell destuction

cell
death2
(%)
12.5
13.2
16.4
35.3
31.2
17.8
16.2
15.8

IFA
aN3
positive
7.8%

22.2%

IFA
aNSP14
positive
8.2%

24.7%

18.1
11.6%

11.0%

12.3
17.5%

20.7%

Passage

Extracellular
virus titer
(pfu/ml)

Cell destruction

P27
P28
P29
P30
P31
P32
P33
P34
P35
P36
P37
P38
P39
P40
P41
P42
P43
P44
P45
P46
P47
P48
P49
P50
P51
P52
P53

1.2×106
8.2×105
2.0×106
9.6×105
2.1×104
2.4×105
1.5×106
2.4×106
4.0×106
7.9×105
7.7×105
9.0×104
1.3×105
6.5×105
1.2×106
4.5×105
6.2×105
1.8×105
1.7×105
5.1×105
1.1×106
1.1×104
1.2×104
6.8×105
3.1×106
4.4×104
2.1×104

cell destuction
cell destuction
cell destuction
partial recovery
recovery
recovery
partial destuction
cell destuction
cell destuction
partial recovery
recovery
recovery
recovery
partial destuction
cell destuction
partial recovery
partial recovery
recovery
recovery
recovery
cell destuction
partial recovery
partial recovery
partial recovery
cell destuction
partial recovery
partial recovery

cell
death2
(%)

IFA
aN3
positive

IFA
aNSP14
positive

17.8%

17.2%

35.8%

37.4%

1.4%

2.7%

15.4

29.3

37.8

5.2%

2.7%

38.4%

37.1%

(Table 3.3 continued)
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Passage

Extracellular
virus titer
(pfu/ml)

Cell destruction

P54
P55
P56
P57
P58
P59
P60
P61
P62
P63
P64
P65
P66
P67
P68
P69
P70
P71
P72
P73
P74

9.3×103
2.6×102
5.1×102
3.0×104
1.1×106
2.8×106
2.9×104
1.4×105
4.4×105
4.9×105
6.2×105
6.0×105
7.5×105
3.5×105
2.7×105
1.8×105
3.1×105
1.9×105
1.4×105
3.1×105
5.5×105

partial recovery
partial recovery
partial recovery
recovery
partial destuction
cell destuction
partial recovery
recovery
recovery
partial destuction
cell destuction
cell destuction
cell destuction
partial recovery
partial recovery
partial recovery
partial recovery
partial recovery
recovery
partial destuction
partial destuction

cell
death2
(%)

IFA
aN3
positive
0.4%

IFA
aNSP14
positive
0.9%

Passage

Extracellular
virus titer
(pfu/ml)

Cell destruction

P75
P76
P77
P78
P79
P80
P81
P82
P83
P84
P85
P86
P87
P88
P89
P90
P91
P92
P93
P94

5.7×105
3.8×105
9.7×104
5.0×105
6.9×105
2.4×105
5.7 ×105
5.5 × 10 5
1.4 × 10 5
1.6 × 10 5
2.9 × 10 5
1.7 × 10 5
3.7 × 10 5
5.2 × 10 5
2.8 × 10 5
1.1 × 10 5
1.1 × 10 5
1.8 × 10 5
7.3 × 10 4
1.9 × 10 5

partial destuction
recovery
recovery
recovery
recovery
recovery
partial destuction
partial destuction
recovery
recovery
recovery
recovery
recovery
partial destuction
recovery
recovery
recovery
recovery
recovery
recovery

Note: 1 Persistent infection was initiated in Hela ‘High’ (P171) cell line with the VBS53 strain of EAV.
2
Cell death was determined by trypan blue staining as described in Materials and Methods.
3
aN - monoclonal antibody 3E2 against EAV nucleocapsid protein.
4
aNSP1 – monoclonal antibody 12A4 against EAV non-structural protein 1.

cell
death2
(%)

IFA
aN3
positive

IFA
aNSP14
positive

12.5%

15.6%

16.8%

Table 3.4 Ratio of extracellular to cell-associated virus at selected passage levels of the persistently infected
Hela ‘High’ cell line initiated with the VBS53 strain of EAV
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Passage number of
persistently infected
Hela ‘High’ cells
P1
P24
P50
P51
P68
P74
P80
P81
P82
P83
P86
P88
*

Virus titer (pfu/ml)
Extracellular virus

Cell-associated virus

Ratio of extracellular to cellassociated virus*

6.0 × 104
3.9 × 105
6.8 × 105
3.1 × 106
2.7 × 105
5.5 × 105
2.4 × 105
5.7 × 105
5.5 × 105
1.4 × 105
1.7 × 105
5.2 × 105

5.0 × 104
7.3 × 105
9.6 × 105
4.2 × 106
5.3 × 105
8.1 × 105
5.2 × 105
9.0 × 105
7.6 × 105
2.4 × 105
2.3 × 105
7.1 × 105

54.5 : 45.5
34.8 : 65.2
41.5 : 58.5
42.5 : 57.5
33.8 : 66.2
40.4 : 59.6
31.6 : 68.4
38.8 : 61.2
42.0 : 58.0
36.8 : 63.2
42.5 : 57.5
42.3 : 57.7

Determined 4 days after cells were subcultured.

Table 3.5 Effect of EAV neutralizing antibody-positive equine serum on the persistently infected
Hela ‘High’ cell line initiated with the VBS53 strain of EAV*
In EMEM with 10% EAV Ab-positive
equine serum

In EMEM with 10% FSCS

Extracellular
Virus
(pfu/ml)

Cellassociated
Virus
(pfu/ml)

+

5.7 × 10 5

9.0 × 10 5

+

+

NA†

NA

NA

NA

+

0

1.2 × 10

3

+

+

NA

NA

NA

NA

0

2.5 × 10

0

-

+

NA

NA

NA

NA

+

0

0

-

+

NA

NA

NA

NA

+

0

0

-

+

NA

NA

NA

NA

ND

+

0

0

ND

-

NA

NA

NA

NA

+

+

0

0

-

-

NA

NA

NA

NA

+

+

0

0

-

-

0

0

-

-

ND

+

0

0

ND

-

0

0

-

-

+

+

0

0

-

-

0

0

-

-

ND

+

0

0

ND

-

0

0

-

-

+

+

0

0

-

-

0

0

-

-

ND

+

0

0

ND

-

0

0

-

-

Cellassociated
Virus
(pfu/ml)

PI 81

5.7 × 10 5

9.0 × 10 5

PI 82

5.5 × 10

5

7.6 × 10

5

1.4 × 10

5

2.4 × 10

5

+

+

1.6 × 10

5

5.6 × 10

5

+

2.9 × 10

5

6.9 × 10

5

+

1.7 × 10

5

2.3 × 10

5

3.7 × 10

5

1.2 × 10

6

5.2 × 10

5

7.1 × 10

5

2.8 × 10

5

7.6 × 10

5

1.1 × 10

5

2.5 × 10

5

1.1 × 10

5

2.3 × 10

5

1.8 × 10

5

3.4 × 10

5

7.3 × 10

4

2.8 × 10

5

PI 83
PI 84
PI 85
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RTPCR
result

Extracellular
Virus
(pfu/ml)

Passage
number

PI 86
PI 87
PI 88
PI 89
PI 90
PI 91
PI 92
PI 93

5

5

In EMEM with 10% FSCS (previously in
EMEM with 10% EAV Ab-positive
equine serum)
CellRTExtracellular
associated IFA
PCR
Virus
Virus
result
(pfu/ml)
(pfu/ml)

IFA

+
+

‡

4.0 × 10

IFA

RTPCR
result

PI 94
1.9 × 10
6.5 × 10
+
+
0
0
0
0
The 81st passage of persistently infected Hela ‘High’ cells were subcultured and grown in EMEM with 10% ferritin supplemented calf serum (FSCS), and
EMEM with 10% EAV-neutralizing Ab-positive equine serum, respectively. Serial subcultivation of the cultures grown in each kind of medium was carried
out once every four days (1:4 split ratio). From the 88th passage, EAV Ab-positive equine serum was removed from the medium of one replicate of the culture
which was further passed up to the 94th passage. The other replicate of the culture was passed still in the presence of EAV Ab-positive equine serum up to the
94th passage. At each passage, extracellular and cell-associated virus was harvested and titrated by plaque assay. Expression of the viral nucleocapsid (N)
protein was examined using IFA. RT-PCR detection of viral RNA at each passage was also carried out.
†
NA—Not applicable. ‡ ND—Not done.

*

Table 3.6. Comparison of nucleotide and amino acid sequences of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80
Leader or ORF
5' NTR (1-224)
5' Leader (1-211)
ORF1ab (225-9751)

Protein (aa length)
N/A3
N/A
Nonstructural proteins (nsp)
1ab polyprotein (3175)
nsp1: Met1-Gly260 (260)
nsp2: Gly261-Gly831 (571)
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nsp3: Gly832-Glu1064 (233)
nsp4: Gly1065-Glu1268 (204)
nsp5: Ser1269-Glu1430 (162)
nsp6: Gly1431-Glu1452 (22)
nsp7: Ser1453-Glu1677 (225)
nsp8/9: Gly1678-Asn1727
(50)/Glu2370(693)

nsp10: Ser2371-Gln2837 (467)

nsp11: Ser2838-Glu3056 (219)
nsp12: Gly3057-Val3175 (119)

Position
-4
-

Nucleotide1
VBS53
HelaEAV
EAVP35
-

HelaEAVP80
-

658
695
1280
1889
1954
1979
2057
2483
2898
3011
3707
3797
4349
4900
4913

C
C
C
T
A
C
C
A
C
G
Y5
T
G
A
T

T
C
C
C
G
T
T
A
C
G
C
T
A
G
C

T
T
T
C
G
T
T
T
T
A
C
C
A
G
T

6020

C

C

T

6752
7021
8260
8290
8398
9727

T
R5
Y
Y
T
T

C
A
C
C
T
C

C
A
C
C
C
T

Position

Modified Amino Acid2
VBS53
HelaHelaEAV
EAVP35
EAVP80

145

Ala

Val

Val

577

Asp

Gly

Gly

1559

Lys

Arg

Arg

1933

Pro

Pro

Ser

-

-

-

-

(Table 3.6 continued)
Leader or ORF

ORF2a (9751-9954)

ORF2b (9824-10507)

Protein (aa length)
Structure proteins
E (67)

GP2b (227)

GP3 (163)

ORF4 10700-11158)

GP4 (152)

ORF5 (11146-11913)

GP5 (255)

ORF6 (11901-12389)
ORF7 (12313-12645)

M (162)
N (110)
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ORF3 (10306-10797)

Position
9867
9907
9914
9867
9907
9914
10082
10085
10157
10189
10648
10709
10722
10709
10722
11024
11171
11438
11475
11704
11882
-

Nucleotide1
VBS53
HelaEAV
EAVP35
T
A
T
T
A
T
G
A
G
T
A
T
Y
T
Y
A
T
C
T
T
G
-

C
A
C
C
A
C
G
G
A
C
G
C
T
C
T
A
C
T
T
C
A
-

HelaEAVP80
C
T
C
C
T
C
C
A
A
C
G
C
T
C
T
T
C
T
C
C
G
-

Position

Modified Amino Acid2
VBS53
HelaEAV
EAVP35

HelaEAVP80

53
55
15

Ser
Val
Leu

Ser
Ala
Ser

Cys
Ala
Ser

31
87
88
112

Trp
Val
Met
Ala

Arg
Val
Val
Thr

Arg
Leu
Met
Thr

115
135

Ser
Leu

Gly
Pro

Gly
Pro

4
8
109
9
98

Tyr
Leu/Ser6
Ile
Phe
Pro

His
Leu
Ile
Ser
Leu

His
Leu
Phe
Ser
Leu

246
-

Arg
-

Lys
-

Arg
-

3' NTR (12646-12704)
N/A
Note: 1 Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et. al., 1997).
2
Only missense mutations are shown and silent mutations are not shown. Amino acids of non-structural proteins are numbered according to their location
in ORF1ab polyprotein. Amino acids of structural proteins are numbered according to their locations in individual structural protein.
3
N/A: Not Applicable. 4 - No nucleotide and amino acid changes occurred. 5 Y = T or C; R = A or G. 6 Leu/Ser means leucine or serine.

Table 3.7 Superinfection experiments with the persistently infected Hela ‘High’ (P171)
cell line initiated with the VBS53 strain of EAV
EAV Titer (pfu/ml) *
1 h p.i.
48 h p.i.
96 h p.i.

Cell Line

Infection

Hela P243

Mock-infection

0

0

0

Hela P243

Infection with EAV strain
VBS53 (moi = 3)

4.5 × 103

2.35 × 104

6.4 × 104

PI 73

Mock-superinfection

4.65 × 103

3.55 × 105

1.65 × 105

PI 73

Superinfection with EAV
strain VBS53 (moi = 3)

1.6 × 104

4.45 × 105

1.4 × 105

*

Equine arteritis virus titer was determined by plaque assay on RK-13 (KY) cells.
pfu/ml – plaque forming unit per ml.

Table 3.8 Summary of the ability of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80 to
establish persistent infection in various cell lines
Cell Lines
Hela ‘High’

VBS53
EAV
+

Hela-EAV
P35
+

Hela-EAV
P80
+

Hela ‘Low’

-

+

+

Hep-2

-

-

-

L-M

-

-

-

BHK-21

-

-

-

Note: + Able to establish persistent infection
- Unable to establish persistent infection

118

Extracellular virus titer (LogPFU/ml)

7

6

5

4

3

P90

P85

P80

P75

P70

P65

P60

P55

P50

P45

P40

P35

P30

P25

P20

P15

P10

P5

1 h p.i.

2

Passage number of persistently infected Hela cells

Fig 3.1 Extracellular virus produced in the persistently infected Hela ‘High’ cell line
initiated with the VBS53 strain of EAV. Subconfluent monolayers of Hela ‘High’ (P171)
cells grown in T-25 flasks were inoculated with EAV strain VBS53 at an m.o.i. of 3.
Following one-hour absorption at 37ºC, the cells were washed three times with PBS and
10 ml fresh culture medium was added. Inoculated cultures were incubated at 37ºC and
subcultured once every four days (1:4 split ratio). Extracellular virus was harvested
before subculturing each cell passage. Virus infectivity was titrated by plaque assay on
RK-13 (KY) cells. Establishment of persistent infection in Hela ‘High’ cells with the
VBS53 strain of EAV was confirmed in three separate experiments.
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Passage 1

Passage 2

Hela ‘Low’
VBS53 EAV
aN

PI 29

PI 44

Hela High
VBS53 EAV
aN

PI 25

PI 48

Hela High
VBS53 EAV
aNSP1

Fig 3.2 Indirect immunofluorescence assay on VBS53 EAV-inoculated Hela ‘Low’ and
persistently infected Hela ‘High’ cell lines. At indicated passages, cells were fixed with
cold acetone for 10 min, and then washed three times with PBS containing 10mM glycine.
Slides were incubated with MAb 3E2 against EAV nucleocapsid protein or MAb 12A4
against EAV NSP1 followed by FITC-conjugated goat antimouse immunoglobulin. The
cells were counterstained by Evans blue. The images were recorded with a LEICA
confocal microscope. The VBS53 strain of EAV failed to establish persistent infection in
Hela ‘Low’ (P98) cells. Passage 1 and passage 2 were shown. The VBS53 strain of EAV
initiated persistent infection in Hela ‘High’ (P171) cells. The persistently infected cells at
the 25th (PI 25), 29th (PI 29), 44th (PI 44) and 48th (PI 48) passage were shown.
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A

1

2

3

1

2

3

4

5

6

7

8

9

10

11

12

225 bp
175 bp

B

4

5

6

7

8

9

10

11

225 bp
175 bp

Fig 3.3 RT-PCR detection of viral RNA in persistently infected Hela ‘High’ cells (A) and
VBS53 EAV-inoculated Hela ‘Low’ cells (B). In (A), the VBS53 strain of EAV
established persistent infection in Hela ‘High’ (P171) cells. Lanes 1-9 correspond to the
1st, 10th, 20th, 30th, 40th, 50th, 60th, 70th, and 80th passage of persistently infected Hela
‘High’ cells, respectively. In (B), Hela ‘Low’ (P98) cells inoculated with the VBS53
strain of EAV underwent serial subculturing. Lanes 1-8 correspond to the 1st, 2nd, 3rd, 4th,
5th, 10th, 15th, and 20th passage, respectively. Lane 10 in (A) and lane 9 in (B) are the
positive controls with RT-PCR amplification of the parental virus VBS53 EAV. Lane 11
in (A) and lane 10 in (B) are the negative controls of mock-infected Hela ‘High’ and Hela
‘Low’ cells. Lane 12 in (A) and lane 11 in (B) are negative controls with water as the
template for RT-PCR.
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0

24
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Hela High + VBS53 EAV
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72

96
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L-M + Hela-EAV P35

6.0

L-M + Hela-EAV P80

5.0
4.0
3.0
2.0
1.0

4.0
Hela Low + VBS53 EAV

2.0

Hela Low + Hela-EAV P35

1.0

Hela Low + Hela-EAV P80
0

24

48

72

Hours Post Infection (h p.i.)

24

48

72

96

Fig 3.4 Growth kinetics of VBS53 EAV,
Hela-EAVP35, and Hela-EAVP80 in
BHK-21, Hela ‘Low’ (P100), Hela High
(P198), Hep-2, and L-M cell lines. Each
cell line was inoculated with respective
virus at an m.o.i. of 3. At indicated time
points, virus infectivity in the culture
supernatant was titrated by plaque assay
in RK-13 (KY) cells.
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E
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Passage number of EAV-inoculated cells

B
Hela-EAVP35

7

Virus titer (LogPFU/ml)

6
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4
Extracellular virus in Hela P98
Cell-associated virus in Hela P98
3
Extracellular virus in Hela P196
Cell-associated virus in Hela P196
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P2
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Passage number of persistently infected Hela cells
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P18

P20

C

Hela-EAVP80

Extracellular Virus Titer (LogPFU/ml)

7

6

5

4
Hela P196
3

Hela P98

2
'1 h
p.i.

P1

P2
P3
P4
P5
P6
P7
P8
P9
Passage number of persistently infected Hela cells

P10

Fig 3.5 Attempts to establish persistent infection in Hela ‘Low’ (P98), Hela ‘High’
(P196), Hep-2, and L-M cell lines with Hela-EAVP35 and Hela-EAVP80. In (A), attempt
to establish persistent infection in Hep-2 and L-M cells with Hela-EAVP35 and HelaEAVP80 was performed. In (B), attempt to establish persistent infection in Hela ‘Low’
and Hela ‘High’ cells with Hela-EAVP35 was carried out. The infectivity titers of both
extracellular and cell-associated viruses at each passage were shown. In (C), attempt to
establish persistent infection in Hela ‘Low’ and Hela ‘High’ cells with Hela-EAVP80
was conducted.
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PI 1

PI 18

PI 20

Hela ‘Low’
Hela-EAVP35
aNSP1

PI 1

PI 8

PI 10

Hela High
Hela-EAVP35
aNSP1

Fig 3.6 Indirect immunofluorescence assay on persistently infected Hela ‘Low’ and Hela
‘High’ cell lines initiated with Hela-EAVP35. At indicated passages, cells were fixed
with cold acetone for 10 min, and then washed three times with PBS containing 10mM
glycine. Slides were incubated with MAb 12A4 against EAV NSP1 followed by FITCconjugated goat antimouse immunoglobulin. The cells were counterstained by Evans blue.
The images were recorded with a LEICA confocal microscope.
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Chapter Four
Genetic Characterization of Equine Arteritis Virus during Persistent Infection of
Hela Cells and Identification of a New Neutralization Determinant

ABSTRACT
Persistent EAV infection in Hela cells has been recently established (Chapter 3). It
has also been shown that EAV evolves during persistent infection with respect to its
growth properties and its ability to initiate secondary persistent infection (Chapter 3). In
this study, the viruses recovered from the persistently infected Hela cells were
characterized for their neutralization phenotypes using EAV-specific monoclonal
antibodies and EAV strain-specific polyclonal equine antisera. Neutralization phenotypic
differences were observed between these viruses, indicating that viral variants with novel
neutralization phenotypes have emerged during persistent infection in Hela cells.
Sequencing of the entire structural protein genes (ORFs2a, 2b, and 3-7) revealed
nucleotide and deduced amino acid changes among these viruses. In the case of EAV,
four neutralization determinant sites have been previously identified within the
ectodomain of the GP5 protein (site A: aa 49; site B: aa 61; site C: aa 67-90; and site D:
aa 99-106). All of these previously identified neutralization determinants were conserved
among the viruses recovered from persistently infected Hela cells, in spite of the fact that
neutralization phenotypic differences were found between these viruses. This suggested
that some as yet unidentified neutralization determinant(s) exists. An infectious EAV
cDNA clone and reverse genetics technology were used to identify additional potential
neutralization epitope(s). Five chimeric viruses were generated each of which contained
the corresponding ORF5 (which encodes GP5) of the aforementioned viruses recovered
from persistently infected Hela cells. The neutralization phenotype of each chimeric virus
was compared to that of its parental virus from which the substituted ORF5 was derived.
The replacement of ORF5 correlated with the neutralization phenotypic differences
determined by most of the EAV-specific monoclonal antibodies, suggesting that the
unidentified neutralization determinant(s) recognized by these monoclonal antibodies is
located on the EAV GP5 protein. Site-directed mutagenesis further identified that amino
acid 98 in the EAV GP5 protein was critical for virus neutralization. Amino acid 98 in

126

the EAV GP5 protein is a previously unrecognized and undescribed neutralization
determinant. It is suggested that amino acid 98 be classified in neutralization site D which
is redefined to cover amino acids 98-106.

INTRODUCTION
Equine arteritis virus (EAV) is the prototype virus in the family Arteriviridae, genus
Arterivirus in the order Nidovirales (Cavanagh 1997). The family Arteriviridae also
contains porcine respiratory and reproductive syndrome virus (PRRSV), lactate
dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV)
(Snijder and Meulenberg 1998). The EAV genome is a single-stranded, positive-sense
RNA molecule of 12.7 kb, which includes nine functional open reading frames (ORFs)
(Snijder and Meulenberg 1998; Snijder et al. 1999). The two ORFs most proximal to the
5’ end of the virus (1a and 1b) are approximately 9.5 kb in length and encode two
replicase polyproteins (1a and 1ab) (de Vries et al. 1997; Snijder and Meulenberg 1998).
The remaining seven ORFs (2a, 2b, and 3-7) located at the 3’ end of the genome are
approximately 2.9 kb in length and encode structural proteins E, GP2b, GP3, GP4, GP5,
M, and N, respectively (den Boon et al. 1991; Snijder and Meulenberg 1998; Snijder et al.
1999).
There is only one serotype of EAV (Fukunaga and McCollum 1977; Golnik et al.
1986), and all strains evaluated thus far are neutralized by polyclonal equine sera raised
against the virulent Bucyrus strain of EAV (Balasuriya and MacLachlan 2004c).
However, EAV strains frequently exhibit neutralization phenotypic differences; e.g.,
different EAV strains are neutralized to various degrees with different polyclonal antisera
and monoclonal antibodies (Balasuriya et al. 1997; 2004a; 2004b; Hedges et al. 1999a).
The EAV GP5 protein has been shown to express neutralization determinants of the virus
(Balasuriya et al. 1993; 1995b; 1997; 2004b; Chirnside et al. 1995; Deregt et al. 1994;
Glaser et al. 1995). The hydropathy profile of the GP5 protein predicts that amino acid
residues 1-18 constitute the putative signal sequence, 19-116 constitute the hydrophilic
ectodomain of the protein, while the C-terminal half consists of three membranespanning domains followed by an endodomain of about 64 amino acids (de Vries et al.
1992; Snijder et al. 2003). Chirnside et al. (1995) has shown that horses developed
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EAV-neutralizing antibodies after they were inoculated with either a fusion protein
including GP5 aa 55-98 or a synthetic peptide corresponding to GP5 aa 75-97. It was
further demonstrated that an E. coli-expressed recombinant protein comprising the entire
ectodomain (aa 18-122) of EAV GP5 protein induced high neutralizing antibodies in
ponies (Castillo-Olivares et al. 2001). These data support the hypothesis that the
ectodomain (aa 19-116) of EAV GP5 protein is immunodominant. By comparing the
sequences of neutralization-sensitive EAV and neutralization-resistant viruses (escape
mutants, EM), Glaser et al. (1995) identified that amino acid residues at 99 and 100 are
critical for virus neutralization. After extensive comparison of GP5 amino acid sequences
and neutralization phenotypes of a large number of field and laboratory EAV strains
using both neutralizing monoclonal antibodies and EAV strain-specific polyclonal equine
antisera, Balasuriya et al. (1993; 1995b; 1997) identified four distinct neutralization sites.
These sites include amino acids 49 (site A), 61 (site B), 67-90 (site C), and 99-106 (site D)
in the GP5 protein. In a recent study, the ORF5 of an infectious EAV clone was replaced
with that of different laboratory, field, and vaccine strains of EAV, thus generating
various chimeric viruses (Balasuriya et al. 2004b). The comparative characterization of
the neutralization phenotypes of chimeric viruses and parental viruses has further
confirmed the importance of the aforementioned four neutralization sites in the GP5
protein. Taken together, these studies demonstrated that the ectodomain of the GP5
protein contains EAV neutralization determinants. Site D includes several overlapping
linear epitopes. The four neutralization sites (A-D) are conformationally interactive
(Balasuriya et al. 1997; 2004b).
An in vitro model of viral persistence involving Hela cell cultures infected with
EAV has been recently developed (Chapter 3). In this study, it was shown that viral
variants with novel neutralization phenotypes emerged during persistent infection of Hela
cells. Sequencing of the entire structural protein genes (ORFs2a, 2b, and 3-7) revealed
nucleotide and deduced amino acid changes among these viruses. However, all of the
previously identified neutralization determinants (sites A to D) were conserved among
the viruses recovered from persistently infected Hela cells, in spite of the fact that
neutralization phenotypic differences were found between these viruses. This suggested
that some as yet unidentified neutralization determinant(s) exists. An infectious EAV

128

cDNA clone and reverse genetics technology were used to identify additional potential
neutralization epitope(s).

MATERIALS AND METHODS
Cells and viruses. Rabbit kidney (RK-13, KY) and baby hamster kidney (BHK-21)
cells were maintained in Eagle’s medium (EMEM) with 10% ferritin supplemented calf
serum (FSCS), penicillin, streptomycin, fungizone, and sodium bicarbonate. The VBS53
strain of EAV was propagated twice in BHK-21 cells to produce virus stocks which were
used to establish persistent infection in the Hela ‘High’ cell line. Hela-EAVP10, HelaEAVP35, Hela-EAVP60, and Hela-EAVP80 are the viruses isolated from the 10th, 35th,
60th, and 80th passage levels of the persistently infected Hela ‘High’ cell line, respectively.
Monoclonal antibodies and polyclonal anti-sera. The development and
characterization of a panel of 12 neutralizing monoclonal antibodies to GP5 (MAbs 5G11,
6D10, 7E5, 9F2, 10F11, 10H4, 1H7, 1H9, 5E8, 6A2, 7D4, and 10B4) and nonneutralizing monoclonal antibodies to the nucleocapsid protein (N; MAb 3E2) and
nonstructural protein 1 (nsp1; MAb 12A4) of EAV have been previously described
(Table 4.1; Balasuriya et al. 1993; 1995b; 1997; 2004b; MacLachlan et al. 1998; Wagner
et al. 2003). The source of EAV strain-specific polyclonal equine antisera (anti-GP5/M,
anti-KY53, anti-KY84, anti-KY53+KY84, anti-CA95, anti-ARVAC, anti-NVSL, and
anti-EAV030H) and negative control sera (control sera NVSL and OAT PB) have also
been previously described (Table 4.1; Balasuriya et al. 2002; 2004b; MacLachlan et al.
1998; Wagner et al. 2003).
Sequencing of structural protein genes of Hela-EAVP10 and Hela-EAVP60.
The entire genomes of EAV strain VBS53, Hela-EAVP35, and Hela-EAVP80 have been
sequenced (Chapter 3). The structural protein genes (ORFs2a, 2b, and 3-7) of HelaEAVP10 and Hela-EAVP60 were sequenced following the procedures described for
sequencing Hela-EAVP35 and Hela-EAVP80 (Chapter 2). The sequence data and
alignments results are summarized in Appendices 5, and 7 to 13.
Construction of chimeric full-length EAV cDNA clones containing ORF5 from
EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and HelaEAVP80. EAV infectious cDNA clone pA45 (de Vries et al. 2000; Dobbe et al. 2001)
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served as the backbone for all chimeric constructs used in this study. In the construct
pA45, the naturally overlapping ORFs 4 and 5 were separated by a newly introduced 24nucleotide sequence containing a unique AflII restriction site (Fig 4.1B). The separation
did not change the amino acids encoded by ORFs 4 and 5, and did not interfere with virus
replication. The progeny viruses stably maintained the mutations that were introduced (de
Vries et al. 2000). A shuttle vector (pS45) containing a BglII (10704)- XhoI (12869)
fragment of the pA45 plasmid was used for cloning of ORF5 from individual EAV
strains. To facilitate cloning, a NotI restriction site was inserted downstream of the AflII
site in the sequence separating ORFs 4 and 5 (Fig 4.1A; Dobbe et al. 2001). Both the
infectious cDNA clone pA45 and the shuttle vector pS45 were kindly provided by Dr.
Eric Snijder, Leiden University, the Netherlands.
The ORF5 sequences were RT-PCR-amplified from EAV strains VBS53, HelaEAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 using a forward primer
11152SD which contains a NotI site upstream of the ORF5 translation initiation codon
and a reverse primer 11960N which contains a natural XbaI site just downstream of the
ORF5 sequence (Table 4.5). The PCR products were digested with restriction enzymes
(NotI and XbaI), and ligated into the pS45 shuttle vector which had been digested with
the same restriction enzymes (Fig 4.1). The ligation mixture was transformed into Ecoli
DH5a cells. The colonies were digested with restriction enzymes for screening positive
clones. The RT-PCR-derived insert was sequenced to confirm that recombinant shuttles
(pS45VBS53,

pS45Hela-EAVP10,

pS45Hela-EAVP35,

pS45Hela-EAVP60,

and

pS45Hela-EAVP80) contained the correct insert sequences. The BglII-XhoI fragments
corresponding to ORFs 4-7 and the genomic 3’ end were subcloned from recombinant
shuttle vectors into the pA45 plasmid to obtain full-length chimeric EAV cDNA clones
containing ORF5 from individual EAV strains (Fig 4.1). The authenticity of the ORF5
inserts in full-length chimeric EAV cDNA clones (5rVBS53, 5rHela-EAVP10, 5rHelaEAVP35, 5rHela-EAVP60, and 5rHela-EAVP80 clones) was confirmed by sequencing.
Site-directed mutagenesis. The site-specific nucleotide substitution of ORF5
11438C? T (which results in GP5 98Pro? Leu) in EAV strain VBS53 was carried out at
the PCR step (Fig 4.2). The first-step PCR was performed with positive primer
C211156P and negative mutagenic primer 11443N (Table 4.5) using the recombinant
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shuttle pS45VBS53 as template. The second-step PCR was performed using the mixture
of the 1st mutagenesis PCR product and the template pS45VBS53 together with negative
primer 11515N in which the 1st mutagenesis PCR product acted as the positive primer.
The 2nd mutagenesis PCR product was the desired fragment containing the site-specific
nucleotide substitution (Fig 4.2). The thermacycling conditions for site-directed
mutagenesis PCR reactions are shown in Appendix 14. The 2nd mutagenesis PCR
products were digested with restriction enzymes (NotI and EcoRI) and cloned into the
shuttle pS45VBS53 to obtain site-mutated shuttle pS45VBS53P98L from which the
BglII-XhoI fragment was subcloned into the plasmid pA45, thus generating the sitemutated chimeric EAV cDNA clone 5rVBS53P98L. On completion of each cloning step,
authenticity of the inserts was confirmed by sequencing.
In vitro transcription and generation of chimeric viruses. Viral RNA transcripts
were generated in vitro from each chimeric/mutant infectious cDNA clone as previously
described (Chapter 2; van Dinten et al. 1997). Full-length RNA transcripts were
transfected into BHK-21 cells by electroporation in accordance with previously described
protocols (Chapter 2; Balasuriya et al. 2004b; van Dinten et al. 1997). The cells were
incubated at room temperature for a 10 min ‘recovery period’ after electroporation and
then resuspended in 15 ml of culture medium which was previously warmed to room
temperature. The cells were seeded into T-25 flasks and incubated at 37ºC until
cytopathic effects were evident. Meanwhile, an aliquot of electroporated cells was seeded
into 8-chamber slides, incubated at 37ºC for 24 h, and then examined by indirect
immunofluorescence assay (IFA). Monoclonal antibodies 12A4 and 3E2 specific for
EAV nonstructural protein 1 and the nucleocapsid protein (N), respectively, were used to
detect virus replication and protein expression according to previously described
protocols (Chapter 2). When cytopathic effects were evident (usually 72 h post
transfection), tissue culture fluids were harvested from T-25 flasks and centrifuged at
1900 rpm for 10 min at 4ºC. Infectivity titers of chimeric/mutant viruses (5rVBS53,
5rVBS53P98L, 5rHela-EAVP10, 5rHela-EAVP35, 5rHela-EAVP60, and 5rHelaEAVP80) were determined as tissue culture infectious doses (TCID50) using RK-13 (KY)
cells as the indicator cells. The infectivity titers of these viruses ranged from 104.5 to 105
TCID50 units per 50 µl. The authenticity of the ORF5 insert in each chimeric/mutant virus
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was confirmed by RT-PCR amplification and sequencing as previously described
(Chapter 3).
Microneutralization assay. Neutralization titers of various monoclonal antibodies
and polyclonal antisera (Table 4.1) against each virus strain were determined by
microneutralization assay as previously described (Balasuriya et al. 1995b; 1997; 2004b).
Briefly, two-fold dilutions of heat-inactivated monoclonal antibodies and polyclonal
equine antisera were made in EMEM, with the lowest dilution of 1:32 and 1:8,
respectively. Serially diluted monoclonal antibodies (from 1:32 to 1:4096) and polyclonal
antisera (from 1:8 to 1:1024) were added to 96-well plates in duplicate for each antibody.
Then approximately 200 TCID50 of each virus strain was added and mixed with
monoclonal antibodies or polyclonal antisera. The plates were incubated at 37ºC for 30
min. A suspension of RK-13 (KY) cells was then added, and cultures were incubated at
37ºC for 60-72 h until cytopathic effect had fully developed in the control wells.
Neutralization titers of each antibody against each virus were recorded as the reciprocal
of the highest final dilution that provided at least 50% protection of the RK-13 (KY) cell
monolayers.

RESULTS AND DISCUSSION
Emergence of viral variants with novel neutralization phenotypes during
persistent EAV infection of Hela cells. Persistent EAV infection in Hela cells has been
recently established (Chapter 3). It has been shown that EAV evolves during persistent
infection of cultured cells with respect to its growth properties and its ability to initiate
secondary persistent infection (Chapter 3). In order to determine whether EAV had
undergone neutralization phenotypic changes during persistent infection of Hela cells, the
parental EAV strain VBS53 and the viruses recovered from the 10th (Hela-EAVP10), 35th
(Hela-EAVP35), 60th (Hela-EAVP60), and 80th (Hela-EAVP80) passage levels of the
persistently infected Hela ‘High’ cell line were characterized in term of their
neutralization phenotypes using EAV-specific monoclonal antibodies and EAV strainspecific polyclonal equine antisera (Table 4.1). Neutralization phenotypic differences
were observed in these viruses. For example, EAV strains VBS53 and Hela-EAVP10
were neutralized by monoclonal antibodies (MAbs) 5G11, 6D10, 7E5, 9F2, 10F11, 10H4,
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and 6A2, whereas Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 were not
neutralized by any of these MAbs (Table 4.2). On the other hand, EAV strains VBS53
and Hela-EAVP10 were resistant to neutralization by MAb 1H7, whereas Hela-EAVP35,
Hela-EAVP60, and Hela-EAVP80 were neutralized by this MAb (Table 4.2). Similarly,
some of the EAV strain-specific polyclonal equine antisera (e.g. anti-GP5/M and antiEAV030H) neutralized Hela-EAVP80 to a significantly higher titer than EAV strain
VBS53 (Table 4.3). These findings indicate that viral variants with novel neutralization
phenotypes emerged during persistent EAV infection in Hela cells. In vivo, it has also
been repeatedly demonstrated that viruses of different neutralization phenotypes emerge
during persistent EAV infection of stallions (Balasuriya et al. 1999a; 2001; 2004a;
Hedges et al. 1999a).
Comparison of the structural protein genes of EAV strains VBS53, HelaEAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80. In order to further
characterize the relationship between EAV structural protein sequences and
neutralization phenotypes, EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, HelaEAVP60, and Hela-EAVP80 were compared for their nucleotide and deduced amino acid
sequences of the structural protein genes (ORFs 2a, 2b, and 3-7). The entire genomes of
EAV strains VBS53, Hela-EAVP35, and Hela-EAVP80 have been sequenced previously
(Chapter 3). In this study, the structural protein genes (ORFs 2a, 2b, and 3-7) of HelaEAVP10 and Hela-EAVP60 were sequenced. As shown in Table 4.4, nucleotide and
amino acid changes were observed in the structural proteins E, GP2b, GP3, GP4, and
GP5, but not in M and N proteins. The amino acid sequences of structural proteins were
100% identical between EAV strains VBS53 and Hela-EAVP10 except that the amino
acid at position 8 of the GP4 protein was Leucine or Serine for VBS53 while Leucine for
Hela-EAVP10 (Table 4.4). The degree of amino acid identity among Hela-EAVP35,
Hela-EAVP60, and Hela-EAVP80 was higher than that between any of these strains and
VBS53 or Hela-EAVP10 (Table 4.4).
The EAV GP5 protein has been shown to express neutralization determinants of the
virus (Balasuriya et al. 1993; 1995b; 1997; 2004b; Chirnside et al. 1995; Deregt et al.
1994; Glaser et al. 1995). To date, four neutralization sites have been identified for EAV
and all of them are located within the N-terminal ectodomain of the GP5 protein (site A:
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amino acid 49; site B: amino acid 61; site C: amino acids 67-90; and site D: amino acids
99-106) (Balasuriya et al. 1993; 1995b; 1997; 2004b). All of these four neutralization
sites were conserved among EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, HelaEAVP60, and Hela-EAVP80 (Table 4.4), although neutralization phenotypic differences
were observed among these viruses (Table 4.2). This suggested that some as yet
unidentified neutralization determinant(s) exists. Since all of the EAV-neutralizing
monoclonal antibodies that have been characterized thus far recognize the GP5 protein as
shown by Western blot and/or immunoprecipitation assays (Balasuriya et al. 1993; 1995b;
1997; Deregt et al. 1994; Glaser et al. 1995), it is suspected that the potential
neutralization determinant(s) responsible for the neutralization phenotypic differences
among EAV strains VBS53, Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and HelaEAVP80 is also located on the GP5 protein.
Generation of GP5 chimeric viruses and neutralization phenotypes of these
chimeric viruses. To confirm that the potential neutralization determinant(s) responsible
for the neutralization phenotypic differences among viruses recovered from persistently
infected Hela cells is located on the GP5 protein, the ORF5 of the infectious EAV cDNA
clone pA45 was replaced with the respective ORF5 of EAV strains VBS53, HelaEAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 (Fig 4.2). The neutralization
phenotypes of chimeric viruses (5rVBS53, 5rHela-EAVP10, 5rHela-EAVP35, 5rHelaEAVP60, and 5rHela-EAVP80) were determined with EAV-specific MAbs and EAVstrain specific polyclonal equine antisera, and compared to those of the parental viruses
from which the substituted ORF5 was derived (Table 4.2 and 4.3). As shown in Table 4.2,
chimeric viruses 5rVBS53 and 5rHela-EAVP10 were neutralized by MAbs 5G11, 6D10,
7E5, 9F2, 10F11, 10H4, and 6A2, whereas none of 5rHela-EAVP35, 5rHela-EAVP60,
and 5rHela-EAVP80 viruses was neutralized by any of these MAbs. This is consistent
with the neutralization results of their respective parental viruses with the same MAbs
(Table 4.2). All of the chimeric viruses 5rVBS53, 5rHela-EAVP10, 5rHela-EAVP35,
5rHela-EAVP60, and 5rHela-EAVP80 shared the same backbone as the pA45 virus and
the only differences among them were ORF5 sequences. This would suggest that the
neutralization phenotypic differences among chimeric viruses detected by above MAbs
result from differences in the GP5 proteins. The potential neutralization determinant(s)
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recognized by MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, and 6A2 are located on the
EAV GP5 proteins. On the other hand, it was observed that chimeric viruses 5rHelaEAVP35, 5rHela-EAVP60, and 5rHela-EAVP80 were resistant to neutralization by MAb
1H7, whereas their parental viruses Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
were neutralized by this MAb (Table 4.2). These three chimeric viruses have the same
ORF5 sequences as their respective parental viruses. This would suggest that
neutralization of Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 by MAb 1H7 may
involve some other structural proteins. Since the M and N proteins of these viruses did
not show any sequence differences (Table 4.4), it is probable that one or some of
structural proteins E, GP2b, GP3, and GP4 are involved in neutralization by MAb 1H7. It
has been previously demonstrated that MAb 1H7 recognizes amino acid 49 of EAV GP5
protein (Balasuriya et al. 1997; 2004b). Furthermore, individual neutralization sites (A-D)
interact with one another to form conformation-dependent epitopes (Balasuriya et al.
1995b; 1997; 2004b). Therefore, it would appear that the neutralization sites are
conformationally dependent and they not only interact with each other but also may
interact with other structural proteins.
Generation of mutant virus with site-specific substitution in the GP5 protein
and its neutralization phenotype. As has been shown, the potential neutralization
determinant(s) recognized by MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, and 6A2 are
located on the EAV GP5 proteins. Comparison of the GP5 protein sequences revealed
that there were four amino acid changes (amino acids 9, 98, 202, and 246) among these
viruses (Fig 4.3). At position 202, only Hela-EAVP60 and 5rHela-EAVP60 were
different from the other viruses; at position 246, only Hela-EAVP35 and 5rHela-EAVP35
were different from the other viruses. Based on the fact that EAV strains VBS53, HelaEAVP10 and their respective GP5 chimeric viruses were neutralized by MAbs 5G11,
6D10, 7E5, 9F2, 10F11, 10H4, and 6A2, whereas Hela-EAVP35, Hela-EAVP60, HelaEAVP80 and their respective GP5 chimeric viruses were not neutralized by these MAbs,
amino acids 202 and 246 do not appear to be the potential neutralization determinant(s)
responsible for neutralization phenotypic differences detected by these MAbs. In contrast,
amino acids 9 and 98 would appear to be the possible potential neutralization
determinant(s). Since amino acids 1-18 of the GP5 protein are the putative signal
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sequence which is cleaved off during transport through the endoplasmic reticulum (de
Vries et al. 1992; Snijder et al. 2003), amino acid 9 is unlikely to be the potential
neutralization determinant(s). By exclusion, therefore, amino acid 98 would appear to be
the potential neutralization determinant. To unequivocally demonstrate this, amino acid
98 on the GP5 protein of the virus 5rVBS53 was site-specifically mutated from Proline to
Leucine (Fig 4.2). The neutralization phenotypes of the mutant virus 5rVBS53P98L were
determined and compared to those of the other viruses (Table 4.2 and 4.3). It was shown
that 5rVBS53 EAV was neutralized by MAbs 5G11, 6D10, 7E5, 9F2, 10F11, 10H4, and
6A2, whereas the mutant virus 5rVBS53P98L was resistant to neutralization by these
MAbs (Table 4.2). This clearly demonstrated that the neutralization phenotypic
differences were caused by the exchange of Proline to Leucine in amino acid 98. The
neutralization phenotypes of parental EAV strains and chimeric viruses and their
respective amino acids at 98 of the GP5 protein are consistent with this finding (Table 4.2
and Fig 4.3). It has been previously demonstrated that MAb 6A2 recognizes amino acid
69 of the EAV GP5 protein (Balasuriya et al. 1997; 2004b). This study showed that MAb
6A2 may also recognize amino acid 98 of the EAV GP5 protein, confirming that
neutralization epitopes may interact with each other and are conformationally dependent.
On the other hand, exchange of Proline to Leucine in amino acid 98 did not result in
VBS53 EAV becoming susceptible to neutralization by MAb 1H7, confirming that the
neutralization phenotypic differences detected by MAb 1H7 among EAV strains VBS53,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80 were not caused by
this site-specific substitution.
In summary, this study demonstrated that viral variants with novel neutralization
phenotypes emerged during persistent EAV infection in Hela cells. Previously identified
four neutralization sites (A-D) were all conserved among viruses recovered from
persistently infected Hela cells, suggesting the existence of some as yet unidentified
neutralization determinant(s). Using an infectious EAV cDNA clone and reverse genetics
technology, it was identified that amino acid 98 on the EAV GP5 protein is a new
neutralization determinant. It is suggested that amino acid 98 be classified in
neutralization site D which covers amino acids 98-106.
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Table 4.1 Monoclonal antibodies and polyclonal antisera to equine arteritis virus
Antibody
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Monoclonal antibodies
5G11
6D10
7E5
9F2
10F11
10H4
1H7
1H9
5E8
6A2
7D4
10B4
3E2
12A4

Antibody specificity/epitope location (amino acid position and [site])
recognized by the antibody
GP5/99 and 102; [D]
GP5/99 and 102; [D]
GP5/99 and 102; [D]
GP5/99 and 102; [D]
GP5/99 and 102; [D]
GP5/99, 102, and 103; [D]
GP5/49; [A]
GP5/69; [C]
GP5/61; [B]
GP5/69; [C]
GP5/69; [C]
GP5/99, 102, and 103; [D]
N
nsp1

polyclonal equine antisera
anti-GP5/M
GP5 and M proteins
anti-KY53
polyclonal
anti-KY84
polyclonal
anti-KY53+KY84
polyclonal
anti-CA95
polyclonal
anti-ARVAC
polyclonal
anti-NVSL
polyclonal
anti-EAV030H

polyclonal

control serum NVSL

Not applicable

control serum
OAT PB

Not applicable

Reference
Balasuriya et al. 1993; 1995b
Balasuriya et al. 1993; 1995b
Balasuriya et al. 1993; 1995b
Balasuriya et al. 1993; 1995b
Balasuriya et al. 1993; 1995b
Balasuriya et al. 1993; 1995b
Balasuriya et al. 1997
Balasuriya et al. 1997
Balasuriya et al. 1997
Balasuriya et al. 1997
Balasuriya et al. 1997
Balasuriya et al. 1997
MacLachlan et al. 1998
Wagner et al. 2003

Balasuriya et al. 2002
MacLachlan et al. 1998
MacLachlan et al. 1998

MacLachlan et al. 1998
Wagner et al. 2003
Commercial serum from National
Veterinary Services Laboratory
Commercial serum from National
Veterinary Services Laboratory

Table 4.2 Neutralization titers a of monoclonal antibodies against parental and chimeric equine arteritis viruses
Monoclonal antibodies
Virus strain
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5G11
6D10
7E5
9F2
10F11
10H4
1H7
1H9
5E8
6A2 7D4
10B4 3E2c
12A4 d
VBS53 EAV
4096
>4096
1024
512
>4096
>4096
<32
<32
<32
64
<32
<32
<32
<32
5rVBS53 EAV
>4096
>4096
>4096
>4096
>4096
>4096
32
<32
<32
128
<32
<32
<32
<32
5rVBS53P98L
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
Hela-EAVP10
4096
>4096
2048
1024
>4096
>4096
<32
<32
<32
512
<32
<32
<32
<32
5rHela-EAVP10
4096
>4096
2048
2048
>4096
>4096
<32
<32
<32
512
<32
<32
<32
<32
Hela-EAVP35
<32
<32
<32
<32
<32
<32
2048
<32
<32
<32
<32
<32
<32
<32
5rHela-EAVP35
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
Hela-EAVP60b
<32
<32
<32
<32
<32
<32
2048
<32
<32
<32
<32
<32
<32
<32
5rHela-EAVP60b
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
Hela-EAVP80
<32
<32
<32
<32
<32
<32
>4096 <32
<32
<32
<32
<32
<32
<32
5rHela-EAVP80
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
<32
a
Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 200 TCID 50 of virus
b
Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 100 TCID 50 of virus
c
control MAb to N protein of EAV
d
control Mab to nsp1 of EAV

Table 4.3 Neutralization titers a of polyclonal equine antisera against parental and chimeric equine arteritis viruses
Polyclonal equine antisera
Virus strain
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VBS53 EAV
5rVBS53 EAV
5rVBS53P98L
Hela-EAVP10
5rHela-EAVP10
Hela-EAVP35
5rHela-EAVP35
Hela-EAVP60b
5rHela-EAVP60b
Hela-EAVP80
5rHela-EAVP80
a

AntiGP5/M

AntiKY53+KY84

AntiKY84

AntiCA95

AntiARVAC

AntiEAVNVSL

AntiEAV030H

AntiKY53

NVSL
NEGc

OAT PBd

8
64
128
16
128
64
256
128
256
1024
128

>1024
>1024
>1024
>1024
>1024
>1024
>1024
>1024
>1024
>1024
>1024

256
1024
>1024
256
1024
512
1024
512
>1024
>1024
>1024

512
>1024
>1024
512
1024
1024
1024
1024
>1024
>1024
>1024

8
32
32
<8
64
16
16
16
32
32
32

64
256
256
128
128
256
512
512
256
512
128

64
512
1024
256
256
128
256
256
512
1024
1024

256
>1024
>1024
1024
1024
512
1024
512
>1024
1024
1024

<8
<8
<8
<8
<8
<8
<8
<8
<8
<8
<8

<8
<8
<8
<8
<8
<8
<8
<8
<8
<8
<8

Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 200 TCID 50 of virus
Neutralization titers are expressed as the inverse of the antibody dilution providing 50% protection of RK-13 (KY) cell monolayers against 100 TCID 50 of virus
c,d
Negative control equine serum
b

Table 4.4 Comparison of structural protein genes of EAV strains VBS53, Hela-EAVP10, -P35, -P60, and -P80
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Nucleotide
location1
9867
9907
9914

Amino acid
location2
39
53
55

T (Val)3
A (Ser)
T (Val)

HelaEAVP10
C (Val)
A (Ser)
T (Val)

HelaEAVP35
C (Val)
A (Ser)
C (Ala)

HelaEAVP60
C (Val)
T (Cys)
C (Ala)

HelaEAVP80
C(Val)
T (Cys)
C (Ala)

GP2b (227)

9867
9907
9914
10082
10085
10157
10189
10267

15
28
31
87
88
112
122
148

T (Leu)
A (Ala)
T (Trp)
G (Val)
A (Met)
G (Ala)
T (Ile)
T (Tyr)

T (Leu)
A (Ala)
T (Trp)
G (Val)
A (Met)
G (Ala)
C (Ile)
T (Tyr)

C (Ser)
A (Ala)
C (Arg)
G (Val)
G (Val)
A (Thr)
C (Ile)
T (Tyr)

C (Ser)
T (Ala)
C (Arg)
C (Leu)
A (Met)
A (Thr)
C (Ile)
C (Tyr)

C (Ser)
T (Ala)
C (Arg)
C (Leu)
A (Met)
A (Thr)
C (Ile)
T (Tyr)

ORF3 (10306-10797)

GP3 (163)

10648
10709
10722

115
135
139

A (Ser)
T (Leu)
Y (Ile)

A (Ser)
T (Leu)
T (Ile)

G (Gly)
C (Pro)
T (Ile)

G (Gly)
C (Pro)
T (Ile)

G (Gly)
C (Pro)
T (Ile)

ORF4 (10700-11158)

GP4 (152)

10709
10722
11024

4
8
109

T (Tyr)
Y (Leu/Ser) 4
A (Ile)

T (Tyr)
T (Leu)
A (Ile)

C (His)
T (Leu)
A (Ile)

C (His)
T (Leu)
T (Phe)

C (His)
T (Leu)
T (Phe)

ORF5 (11146-11913)

GP5 (255)

11171
11438
11475
11704
11749
11882

9
98
110
187
202
246

T (Phe)
C (Pro)
T (Ile)
T (Leu)
A (Ile)
G (Arg)

T (Phe)
C (Pro)
T (Ile)
T (Leu)
A (Ile)
G (Arg)

C (Ser)
T (Leu)
T (Ile)
C (Leu)
A (Ile)
A (Lys)

C (Ser)
T (Leu)
C (Ile)
C (Leu)
G (Val)
G (Arg)

C (Ser)
T (Leu)
C (Ile)
C (Leu)
A (Ile)
G (Arg)

ORF6 (11901-12389)
ORF7 (12313-12645)

M (162)
N (110)

-5
-

-

-

-

-

-

-

Leader or ORF

Protein (aa length)

ORF2a (9751-9954)

E (67)

ORF2b (9824-10507)

VBS53 EAV

Notes to Table 4.4:
1
Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et al. 1997).
2
Amino acids of structural proteins are numbered according to their locations in individual structural protein.
3
Nucleotide and amino acid changes are shown. Amino acid is shown by three-letter symbols in parenthesis. Missense mutations are shown in bold.
4
Leu/Ser means leucine or serine.
5
- No nucleotide and amino acid changes occurred.

Table 4.5 Oligonucleotide primers used for RT-PCR amplification
Primer ID

Polarity

Sequence (5'-3')

Position (nt)

Primers for cloning entire ORF5 from EAV strains VBS53, Hela-EAVP10, -P35, -P60, and -P80
into the shuttle vector pS45
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11152SD

Positive

TCT GTG AAC TTA AGG CGG CCG CAG CAT GTT ATC TAT GAT TG

11152-11176 a/11146-11161 b

11960N

Negative

AAA GTA ATC TAG ATA CTC ACC TAA AAT CCC GTC ACC ACA AAA TGA ATC TA

11960-11911 b

Primers for site-directed mutagenesis
C211156P

Positive

GGC TCA ACG CTG TTA TCT GTG AAC

11137-11160 a

11443Nc

Negative

TGT ACA GTC CAT GCG CCT GTT CCA

11443-11420 b
(nt change at positive sense
strand: 11438 C? T; aa
change GP5 98 Pro? Leu);
mutagenesis of ORF5 from
VBS53 EAV

11515N

Negative

ACA CAT CCA ACA CAA CTA TGC C

11515-11494 b

a

Nucleotide sequence from the plasmid pS45 and numbered accordingly.
EAV sequence numbered according to the pEAV030 sequence and the NotI site in the primer 11152SD is underlined; natural XbaI site in the primer 11960N
is underlined and italicized.
c
Mutagenesis primer and the mutated nucleotide is underlined and in bold.
b

A

pS45 shuttle vector
containing BglII – XhoI fragment

XbaI
ORF6

5’

ORF4

ORF5

AAAAAn 3’

ORF7

CGCTGTTATCTGTGAacttaaggcggccgcagcatgctgtccatgaTT
AflII NotI
▲

▲
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BglII
(10704)

B

ORF5 start codon

ORF4 stop codon

XhoI
(12869)
BglII
(10704)

pA45 plasmid
5’

1a

2a
1b

3
2b

6
4

5

CGCTGTTATCTGTGAacttaagcaacatgctgtccatgaTT
AflII
▲
▲
ORF4 stop codon

ORF5 start codon

7

AAAAAn 3’

XhoI
(12869)

C

EAV RNA

XhoI

XhoI

RT-PCR
XbaI

PvuI

ORF5

pS45

XbaI

pA45

EcoRI
NotI

XbaI

EcoRI

NotI
BglII

NotI

XhoI

BglII
XbaI

PvuI

rpS45

XhoI
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EcoRI
Neutralization
assay

XbaI

NotI

rpA45

BglII

Chimeric
Virus

Transfection of
BHK21 cells using
electroporation

EcoRI
RNA
transcript

Linearization
with Xho I

NotI

In vitro transcription

BglII

Fig 4.1 Flow diagram outlining construction of the full-length chimeric clone which contains ORF5 from different strains of EAV
using the backbone of the infectious cDNA clone pA45 (de Vries et al. 2000; Dobbe et al. 2001) and generation of chimeric viruses.
In A and B, the nucleotides that were inserted to separate ORFs 4 and 5 are shown in lowercase. See Materials and Methods for details.

Negative
mutagenic primer
11443N
NotI
5’

Step 1

3’

3’

5’
EcoRI

Positive primer
C2 11156P
5’

3’

3’ 1st mutagenesis
5’ PCR product

Negative primer
11515N

NotI

5’
3’

Step 2

NotI

5’
3’

1st mutagenesis
PCR product

Template
pS45VBS53

3’
5’
3’
EcoRI
5’

NotI

EcoRI

5’
3’

Template
pS45VBS53

2nd mutagenesis

3’ PCR product
5’

Fig 4.2 Flow diagram outlining the site-directed mutagenesis of EAV ORF5 11438C? T
in plasmid pS45VBS53. In step 1, the mutation was introduced to the DNA by
performing PCR with positive primer C211156P and negative mutagenic primer 11443N
using the template pS45VBS53. In step 2, the 1st mutagenesis PCR product was mixed
with the template pS45VBS53 and PCR was performed with positive primer (the 1st
mutagenesis PCR product acting as positive primer) and negative primer 11515N. The
2nd mutagenesis PCR product is the desired fragment containing site-specific nucleotide
substitution.
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VBS53EAV
5rVBS53
5rVBS53P98L
Hela-EAVP10
5rHela-EAVP10
Hela-EAVP35
5rHela-EAVP35
Hela-EAVP60
5rHela-EAVP60
Hela-EAVP80
5rHela-EAVP80

1
50
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........S........................................................................................L..
........S........................................................................................L..

VBS53EAV
5rVBS53
5rVBS53P98L
Hela-EAVP10
5rHela-EAVP10
Hela-EAVP35
5rHela-EAVP35
Hela-EAVP60
5rHela-EAVP60
Hela-EAVP80
5rHela-EAVP80

101
150
200
VLFDDMPPFIYYGREFGIVVLDVFMFYPVLVLFFLSVLPYATLILEMCVSILFIIYGIYSGAYLAMGIFAATLAIHSIVVLRQLLWLCLAWRYRCTLHAS
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....................................................................................................
....................................................................................................
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....................................................................................................
....................................................................................................

VBS53EAV
5rVBS53
5rVBS53P98L
Hela-EAVP10
5rHela-EAVP10
Hela-EAVP35
5rHela-EAVP35
Hela-EAVP60
5rHela-EAVP60
Hela-EAVP80
5rHelaEAVP80

201
250
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Fig 4.3 Aligned deduced amino acid sequence of the GP5 proteins of parental and chimeric equine arteritis viruses.

Chapter Five
Potential Changes in Pathogenicity of Equine Arteritis Virus
During Persistent Infection of Hela Cells

ABSTRACT
A previously described in vitro assay has shown that the growth characteristics of
different EAV strains in equine endothelial cells can generally be related to the
pathogenicity of individual strains of the virus for horses [Moore et al. (2002) Virology
298, 39-44; Moore et al. (2003) Am J Vet Res 64, 779-84]. Virulent strains of EAV
usually replicated more quickly, caused larger plaques, and gave rise to more rapid cell
lysis in equine endothelial cells than did avirulent strains of the virus. In the present study,
this in vitro assay was used to investigate whether virus recovered from Hela cells
persistently infected with EAV differed in characteristics from the original strain of EAV
used to initiate infection. It was found that viruses recovered from persistently infected
Hela cells over time progressively caused smaller and smaller plaques in equine
endothelial cells, suggesting that EAV probably became less virulent during the course of
persistent infection in Hela cells. Since the actual virulence of different EAV strains can
only be definitely determined in horses, the potential changes in pathogenicity of EAV
during persistent infection of Hela cells need to be verified by challenge studies in horses.

INTRODUCTION
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), a
globally distributed infectious disease of equids (Timoney and McCollum 1993). EAV is
a single-stranded, positive sense RNA virus and the prototype member of the family
Arteriviridae in the order Nidovirales (Cavanagh 1997). Only one serotype of EAV has
been recognized (Fukunaga and McCollum 1977; Golnik et al. 1986), and all strains
evaluated thus far are neutralized by polyclonal equine sera raised against the virulent
Bucyrus strain of EAV (Balasuriya and MacLachlan 2004c). However, geographically
and temporally distinct EAV isolates vary not only antigenically but also in the severity
of the clinical disease they induce and in their abortigenic potential (Balasuriya et al.
1998; 1999b; Balasuriya and MacLachlan 2004c; McCollum and Timoney 1999;
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Timoney and McCollum 1993). While the majority of field strains of EAV cause
subclinical infection in horses, some strains can cause the clinical manifestations of EVA.
For example, the virulence of certain EAV strains for horses has been defined: highly
virulent (VBS53 and ATCC EAV), moderately virulent (KY84, CAN86, AZ87, and
IL93), mildly virulent (SWZ64, AUT68, IL94, and CA97), and putatively avirulent
(KY63, PA76, KY77, CA95G, and ARVAC vaccine) strains of EAV (MacLachlan et al.
1996; McCollum 1981; McCollum and Timoney 1984; McCollum et al. 1995; McCollum
and Timoney 1999; Moore et al. 2003b; Patton et al. 1999; Timoney and McCollum
1993).
EAV has a particular tropism for macrophages and vascular endothelium in infected
horses, and the clinical manifestations of EVA reflect endothelial injury (Crawford and
Henson 1973; Del Piero 2000; Estes and Cheville 1970; MacLachlan et al. 1996;
McCollum 1981). An in vitro assay has recently been developed (Moore et al. 2002;
2003b) which has been used to investigate the virulence of various strains of EAV in
horses. Comparison of growth characteristics in equine endothelial cells (EECs) of
various EAV strains whose virulence had been previously determined in horses revealed
that virulent strains of EAV generally replicated more quickly, caused larger plaques, and
led to more rapid cell lysis in cultured EECs than the avirulent strains did. However,
there was one notable exception. The highly attenuated modified live vaccine strain of
EAV caused larger plaques in equine endothelial cells than known virulent strains of the
virus (Moore et al. 2003b). Based on the findings of the studies, it was concluded that
primary equine endothelial cells can serve as a very useful in vitro model for
characterizing the virulence of EAV (Moore et al. 2002; 2003b). It was found that
virulent and avirulent strains of EAV induced different quantities of proinflammatory
cytokines in alveolar and blood-derived equine macrophages (Moore et al. 2003a).
Persistent infection of Hela cells with EAV has been recently established (Chapter
3). It has been shown that EAV evolves during persistent infection with respect to its
growth properties, ability to initiate secondary persistent infection (Chapter 3), and its
genetic and neutralization phenotypic characteristics (Chapter 4). The objective of the
present study was to investigate whether the pathogenicity of EAV had changed in the
course of persistent infection in Hela cells. To achieve this goal, the in vitro assay
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described by Moore et al. (2002; 2003b) was used to investigate and estimate the
virulence of viruses recovered from persistently infected Hela cells. The actual
pathogenicity of these viruses will require challenge studies in horses.

MATERIALS AND METHODS
Cells and viruses. Rabbit kidney (RK-13, KY) cells and baby hamster kidney
(BHK-21) cells were maintained in Eagle’s medium (EMEM) with 10% ferritin
supplemented calf serum (FSCS), penicillin, streptomycin, fungizone, and sodium
bicarbonate. The isolation and purification of primary equine endothelial cells (EEC) has
been previously described in detail (Hedges et al. 2001; Moore et al. 2003b). Equine
endothelial cells were kindly provided by Drs. Udeni Balasuriya and James MacLachlan
at University of California, Davis. Equine endothelial cells were maintained in
Dulbecco’s modified essential medium (DMEM) with sodium pyruvate, 10% fetal bovine
serum, penicillin, streptomycin, non-essential amino acids, and L-glutamine. All
experiments were performed on EECs between passages 10 and 15. The VBS53 strain of
EAV was propagated twice in BHK-21 cells to produce virus stocks which were used to
establish persistent infection in the Hela ‘High’ cell line. Hela-EAVP10, Hela-EAVP20,
Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-EAVP80 are the viruses isolated
from the 10th, 20th, 35th, 50th, 60th, and 80th passage levels of the persistently infected Hela
‘High’ cell line, respectively.
Growth of various EAV strains in EECs and RK-13 cells. Each virus (VBS53,
Hela-EAVP10, Hela-EAVP20, Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and HelaEAVP80) was diluted to approximately 100 pfu per ml and inoculated onto confluent
monolayers of EECs or RK-13 cells. Each virus strain was inoculated into six T-25 flasks
with an inoculum of 1 ml of diluted virus per flask. After one hour’s incubation at 37ºC,
cell monolayers were overlaid with EMEM containing 0.75% carboxymethyl cellulose.
Inoculated cultures were incubated at 37ºC, and cytopathic effects were checked daily. At
each of the following time points, 48, 72, and 87 h post inoculation, duplicates of the
inoculated cell cultures were stained with 10% formalin buffered crystal violet. Of the
cultures stained at 87 h post inoculation, at least 50 plaques were measured to determine
mean plaque size.
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RESULTS AND DISCUSSION
Genetic variation and divergent phenotypic properties (e.g. neutralization and
virulence) have been repeatedly demonstrated among field isolates and laboratory
adapted strains of EAV. Persistently infected stallions (carrier stallions) are thought to be
a natural source of genetic and phenotypic diversity of EAV (Balasuriya et al. 2004a;
Balasuriya and MacLachlan 2004c; Hedges et al. 1999a). An in vitro model of EAV
persistence in Hela cells has been recently established (Chapter 3) to help characterize
virus evolution during persistent infection. It has been shown that EAV evolves during
persistent infection in cell culture with respect to its growth properties, ability to initiate
secondary persistent infection (Chapter 3), and genetic and neutralization phenotypic
characteristics (Chapter 4). In order to determine whether the pathogenicity of EAV had
changed during persistent infection of Hela cells, an in vitro assay described by Moore et
al. (2002; 2003b) was used to investigate the virulence of viruses recovered from
persistently infected Hela cells. All of the EAV strains (VBS53, Hela-EAVP10, HelaEAVP20, Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-EAVP80) caused lytic
infections in both RK-13 and primary equine endothelial cells. However, the onset of
cytopathic effect (CPE) differed in RK-13 and EECs. In EEC cells, CPE became evident
at 48 h post inoculation, and typical plaques could be observed after cells were stained.
However, in RK-13 cells, CPE was not apparent even at 72 h post inoculation, and
plaques were not clear after cells were stained at either 48 h or 72 h post inoculation. At
87 h post inoculation, CPE in both EECs and RK-13 cells was evident and plaques were
clearcut and readily measurable after staining. Therefore, it was decided to determine and
compare plaque size of each virus in RK-13 and EECs at 87 h post inoculation.
As shown in Table 5.1 and Fig 5.1, EAV strain VBS53 produced significantly
larger plaques in EECs than all of the other EAV strains evaluated (Hela-EAVP10, -P20,
-P35, -P50, -P60, and -P80; P < 0.002 between VBS53 EAV and Hela-EAVP10; P <
0.001 between VBS53 EAV and any other EAV strains); Hela-EAVP10 produced
significantly larger plaques in EECs than Hela-EAVP20, -P35, -P50, -P60, and -P80 did
(P < 0.001); Hela-EAVP20 produced significantly larger plaques in EECs than HelaEAVP35, -P50, -P60, and -P80 did (P < 0.001); Hela-EAVP35 produced significantly
larger plaques in EECs than did Hela-EAVP50 (P < 0.001), -P60 (P < 0.002), and -P80 (P
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<0.001); there was no significant difference in plaque size among Hela-EAVP50, -P60,
and -P80 strains (P > 0.1). In contrast, there was no significant difference in the size of
plaques produced by all seven of these EAV strains in RK-13 cells. If the size of plaques
produced by EAV in EECs truly reflects the virulence of a virus strain for horses, these
findings would suggest that EAV became progressively less virulent during the course of
persistent infection in Hela cells up to the 50th passage in cell culture after which there
did not appear to be any further reduction in viral virulence.
However, the actual pathogenicity of these EAV strains needs to be definitively
determined by challenge studies in horses. Determination of the pathogenicity of these
viruses recovered from persistently infected Hela cells for horses is currently in progress.
If EAV, by serial passage in persistently infected Hela cells, should prove to become
progressively less virulent for the horse, that is not without precedent. It has been
previously demonstrated that foot-and-mouth disease virus became progressively less
virulent for mice and cattle during the course of persistence in BHK-21 cells (Diez et al.
1990b). So far, the genetic determinants of EAV virulence have not been defined.
Alignment of available nucleotide and amino acid sequences of a variety of EAV strains
with varying virulence (e.g. EAV strains VBS53, KY84, CAN86, AZ87, IL93, SWZ64,
AUT68, IL94, CA97, KY63, PA76, KY77, CA95G, and ARVAC vaccine) failed to
identify a unique mutation that could possibly distinguish virulent strains from avirulent
strains (data not shown). It would suggest that virulence differences between EAV strains
are probably determined by a combination of multiple mutations or by mutation(s)
present in the fragment of the genome whose sequences are not available yet for most of
the aforementioned EAV strains. Therefore, comparison of the entire genomes of EAV
strains that differ in virulence for horses may be the appropriate way to identify the target
gene(s) responsible for EAV virulence. At this time, entire genome sequences are only
available for a few EAV strains, e.g. the VBS53 strain (Chapter 3), ARVAC vaccine
strain (Balasuriya et al., unpublished), EAV030 virus generated from the infectious
cDNA clone EAV030 (Balasuriya et al. 1999b; van Dinten et al. 1997), Hela-EAVP35
and Hela-EAVP80 (Chapter 3). Among these strains, VBS53 EAV has demonstrated
virulent properties (MacLachlan et al. 1996; McCollum et al. 1971); the ARVAC vaccine
strain and EAV030 virus have been demonstrated avirulent (Balasuriya et al. 1999b;
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McCollum 1986); the virulence of Hela-EAVP35 and Hela-EAVP80 for horses has not
been established. Determination of the in vivo virulence of Hela-EAVP35 and HelaEAVP80 should help to identify the genetic determinants of EAV virulence.
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Table 5.1 Plaque size of different EAV strains in RK-13 (KY) and EEC cells

Virus

Number of plaques measured

Plaque diameter (mm)
Mean ± SE
RK-13 (KY)
EEC

RK-13 (KY)

EEC

VBS53 EAV

81

59

2.12 ± 0.06

6.17 ± 0.13

Hela-EAVP10

79

63

2.03 ± 0.06

5.67 ± 0.09

Hela-EAVP20

85

60

1.99 ± 0.04

4.88 ± 0.12

Hela-EAVP35

95

98

2.07 ± 0.04

3.92 ± 0.07

Hela-EAVP50

85

83

2.16 ± 0.04

3.33 ± 0.08

Hela-EAVP60

90

55

2.05 ± 0.04

3.53 ± 0.09

Hela-EAVP80

90

58

2.00 ± 0.04

3.36 ± 0.11

RK-13 (KY) = Rabbit Kidney cells (KY); EEC = Equine endothelial cells;
SE = Standard error of the Mean.
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Equine Endothelial Cells (EEC)
Rabbit Kidney (RK-13 KY) Cells
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RK-13

Fig 5.1 Size of plaques produced by EAV strains VBS53, Hela-EAVP10, Hela-EAVP20,
Hela-EAVP35, Hela-EAVP50, Hela-EAVP60, and Hela-EAVP80 in equine endothelial
cells (EECs) and rabbit kidney (RK-13 KY) cells. Mean ± Standard Error is shown in (A).
In (B), pictures of plaques formed by three EAV strains VBS53, Hela-EAVP35, and
Hela-EAVP80 in EECs and RK-13 cells are shown.
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SUMMARY
Chapter 1 of this dissertation presents an overview of current knowledge of the
molecular biology of equine arteritis virus; EAV infection and persistently infected
stallions were briefly described; and persistent infection of cell cultures with RNA
viruses were reviewed.
Neither a virus attachment molecule nor a specific cell receptor has yet been
identified for equine arteritis virus. Identification of the receptor used by EAV for cell
attachment and entry has been hampered by the unavailability of a known cell line that
lacks the appropriate EAV receptor(s). In Chapter 2, a variety of cell lines of different
species and tissue origin were assessed for their permissiveness to infection with the
strain VBS53 of EAV and the mechanism that restricts EAV infection in the nonpermissive cell lines was investigated. The cell lines BHK-21, RK-13, and C2C12 were
found to support productive infection with EAV strain VBS53, whereas Hela, Hep-2, and
L-M cell lines exhibited limited susceptibility to infection with the virus. In the course of
the study, it was found that the Hela cell line became more susceptible to infection with
EAV strain VBS53 after extended serial passage. The respective cell lines were referred
to as Hela ‘High’ (passage 170-221) and Hela ‘Low’ (passage 95-115) lines. While the
Hela ‘High’ cell line was more susceptible than the Hela ‘Low’ cell line, it was still
considerably less susceptible than the BHK-21 cell line to EAV infection. Subsequent
studies demonstrated that infection with EAV strain VBS53 was restricted at the entry
step in Hela, Hep-2, and L-M cell lines. The availability of cells with varying
susceptibility to EAV infection should help to identify the cellular factor(s) involved in
EAV attachment and entry.
Up to 30% to 70% of stallions can subsequently become persistently infected
following natural infection with EAV. The detailed mechanism by which EAV
establishes persistent infection in stallions is unknown. Carrier stallions are not only a
natural reservoir of EAV responsible for maintenance and dissemination of EAV in
equine populations, but also a natural source of genetic and phenotypic diversity of EAV.
Persistent viral infections in cell culture have been demonstrated as a valuable tool to
study virus-host cell interactions, virus and host cell evolutions, and to elucidate the
mechanisms of viral persistence. In Chapter 3, an in vitro model of EAV persistence,
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namely persistently infected cultures of Hela cells, was established and characterized.
Virus evolution with respect to virus growth characteristics, ability of the virus to initiate
secondary persistent infection, and genetic changes during persistent EAV infection in
Hela cells was investigated. In Chapter 4, neutralization phenotypic changes of viruses
were observed during the course of persistent EAV infection in Hela cells. Subsequent
reverse genetics studies identified that amino acid 98 of the GP5 protein is a new
neutralization determinant of EAV. In Chapter 5, using an in vitro assay, it was found
that EAV probably became progressively less virulent during the course of persistent
infection in Hela cells. The potential changes in pathogenicity of EAV during persistent
infection of Hela cells need to be verified by inoculation of horses. The results in
Chapters 3, 4, and 5 have demonstrated that persistent EAV infection of Hela cells
provides a system to characterize genetic and phenotypic evolution of the virus.
Persistent EAV infection of Hela cells may also be a useful tool for investigating viral
and host cell factors involved in viral persistence and for elucidating virus-host cell
interactions, e.g. EAV-cell receptor interactions.
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Appendix 1. Primers used for RT-PCR amplification of the genome of EAV
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Fragment

Primer ID

Polarity

Nt position

Nucleotide sequence (5' to 3')

Primer Size (bp)

Frag 1
(1559 bp)

1P
1540N

+
-

1-30
1540-1559

GCT CGA AGT GTG TAT GGT GCC ATA TAC GGC
TTG AAG TCG CGT GCG CGG TG

30
20

Frag 2
(2191 bp)

947P
3118N

+
-

947-966
3118-3137

CTA CGT TTG TGA CAT CTC TG
GAA CAG ATT CAC AAA AAG CG

20
20

Frag 3
(2010 bp)

2610P
4600N

+
-

2610-2629
4600-4619

GAC CAT GCT CTT TAC AAC CG
GTC ATC ATC AGT GAG GGC AG

20
20

Frag 4
(2240 bp)

4357P
6577N

+
-

4357-4376
6577-6596

TCC TAG TGT ACC AGT TCC CC
TCT CCA GGT CTG TTT CAA GG

20
20

Frag 5
(949 bp)

5802P
6731N

+
-

5802-5821
6731-6750

ACG CTT TTC AAG GGT TCC AC
CCC CCG CGT TTG GTG AAT GC

20
20

Frag 6
(3284 bp)

6587P
9850N

+
-

6587-6606
9850-9870

GAC CTG GAG AGT TGT GAT CG
AGT AAC AAC AGC CAA TGC AAG

20
21

Frag 7
(2480 bp)

7391P
9850N

+
-

7391-7411
9850-9870

TGG TTC TGT GGC AAT TGT GTC
AGT AAC AAC AGC CAA TGC AAG

21
21

Frag 8
(1718 bp)

9745P
11442N

+
-

9745-9767
11442-11462

CGT GTG ATG GGC TTA GTG TGG TC
ATG TCA TCA AAC AGC GCA CTG

23
21

Frag 9
(1608 bp)

11097P
12681N

+
-

11097-11117
12681-12704

TTG TGG CTA TAG TTT ATG TTC
GGT TCC TGG GTG GCT AAT AAC TAC

21
24

Note: Nucleotides are numbered according to the published sequence of EAV030 virus (van Dinten et al., 1997).

Appendix 2. Optimized thermacycling protocols for PCR amplification of EAV
genome
Fragment

Primer
1P

Frag 1
1540N
947P
Frag 2
3118N
2610P
Frag 3
4600N
4357P
Frag 4
6577N
5802P
Frag 5
6731N
6587P
Frag 6
9850N
7391P
Frag 7
9850N
9745P
Frag 8
11442N
11097P
Frag 9
12681N

VBS53 EAV

Thermacycling Conditions
Hela-EAVP35

Hela-EAVP80

95ºC 30 sec
55ºC 30 sec
72ºC 2 min

95ºC 30 sec
55ºC 30 sec
72ºC 2 min

95ºC 30 sec
55ºC 30 sec
72ºC 2 min

95ºC 30 sec
42ºC 30 sec
72ºC 3 min

95ºC 30 sec
42ºC 30 sec
72ºC 3 min

95ºC 30 sec
40ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
49ºC 30 sec
72ºC 2 min

95ºC 30 sec
49ºC 30 sec
72ºC 2 min

95ºC 30 sec
47ºC 30 sec
72ºC 2 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
46ºC 30 sec
72ºC 3 min

95ºC 30 sec
47ºC 30 sec
72ºC 3 min

95ºC 30 sec
45ºC 30 sec
72ºC 3 min

95ºC 30 sec
45ºC 30 sec
72ºC 3 min

95ºC 30 sec
42ºC 30 sec
72ºC 3 min

95ºC 30 sec
45ºC 30 sec
72ºC 3 min

95ºC 30 sec
45ºC 30 sec
72ºC 3 min

Note:
1. PCR amplification of each fragment of each strain follows: 95ºC 2 min; 35 cycles
of amplification; 72ºC 10 min; 4ºC forever. Above table only shows the
thermacycling conditions for 35 cycles of amplification.
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Appendix 3. EAV sequencing primers list
Note: Nucleotides are numbered according to the published sequence of EAV030 virus
(van Dinten et al., 1997)

Fragment 1

Positve

(1-1559)

1P
457P
833P
947P

Fragment 2
(947-3137)

Fragment 3
(2610-4619)

Sequence (5'-3')
GCT CGA AGT GTG TAT GGT GCC ATA
TAC GGC
GGT ATC GAG CTG CCA AAG TC
AGA CCT GGG TTT GGG CAT CA
CTA CGT TTG TGA CAT CTC TG

Nt Position

Size (bp)

1--30
457--476
833--852
947--966

30
20
20
20

Negative
233N
548N
880N
1270N
1540N

Sequence (5'-3')
CAA ATC CAG TAG CGG AGA AG
CTT GCC TCT TCA ATG GCT AAC
AGG CGA ACC CCT CAT AAT GT
ATT GCA GAT GCC CCT GAA AC
TTG AAG TCG CGT GCG CGG TG

Nt Position
233--252
548--568
880-899
1270--1289
1540--1559

Size (bp)
20
21
20
20
20

Positive
1524P
1891P
2296P
2610P

Sequence (5'-3')
CAG GCG CCC ATC CCA GCA CC
TGG GCA ATA ATG TTG TTC TG
TCG ATG TTG TGG GCA TGG C
GAC CAT GCT CTT TAC AAC CG

Nt Position
1524--1543
1891--1910
2296--2314
2610--2629

Size (bp)
20
20
19
20

Negative
1540N
1836N
2106N
2508N
3118N

Sequence (5'-3')
TTG AAG TCG CGT GCG CGG TG
AAA GCA AGA GAT GGC CAT AT
ACA GTG CAA GGA ACA TAA GC
TCA CAA CAG CTC CTG TTT GTT C
GAA CAG ATT CAC AAA AAG CG

Nt Position
1540--1559
1836--1855
2106--2125
2508--2529
3118-3137

Size (bp)
20
20
20
22
20

Positive
2963P
3331P
3668P
4002P
4357P

Sequence (5'-3')
GAT CTT GTT GGT CTG CCA CC
ATT CAC TGC TTG GAG TGG CT
TTT CGC CCA ACC AAC AAC CG
CTG ATT GAT GGC TTA TCC AA
TCC TAG TGT ACC AGT TCC CC

Nt Position
2963--2982
3331-3350
3668--3687
4002--4021
4357--4376

Size (bp)
20
20
20
20
20

Negative
3485N
3832N
4472N
4600N

Sequence (5'-3')
TGT TCC TGG TCC ACA CTG AC
CAC GTA GGC AAC ACC ACT TG
AAG TCC TGT CAA AGC GAC CT
GTC ATC ATC AGT GAG GGC AG

Nt Position
3485--3504
3832--3851
4472--4491
4600--4619

Size (bp)
20
20
20
20
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Fragment 4
(4357-6596)

Fragment 5
(5802-6750)

Fragment 6
(6587-9870)

Fragment 7
(7391-9870)

Positive
4357P
4718P
5072P
5436P
5802P
6198P

Sequence (5'-3')
TCC TAG TGT ACC AGT TCC CC
CAT CCT TAA TGC ATC CTT GC
TGC GGT CTC GAA TGA TTA TG
TGG GGC GTC GGA CCT TTG CT
ACG CTT TTC AAG GGT TCC AC
GGG CGT ACT TAA AAG AGG AG

Nt Position
4357--4376
4718--4737
5072--5091
5436--5455
5802--5821
6198--6217

Size (bp)
20
20
20
20
20
20

Negative
4828N
5198N
5569N
5969N
6363N
6577N

Sequence (5'-3')
CAG ACC GTC GAT AAC CAC AA
CTT CCT GAT GCT CCA CGT AA
ACC CAA GCA GTG TGT CTT TT
GTA ACG GCC TCA CAT CCA GC
CAT GGT GGC GGT TTG TAG AT
TCT CCA GGT CTG TTT CAA GG

Nt Position
4828--4847
5198--5217
5569--5588
5969--5988
6363--6382
6577--6596

Size (bp)
20
20
20
20
20
20

Positive
6449P

Sequence (5'-3')
ATT GGC CTA GGT TTG CGT GCC TGC

Nt Position
6449--6472

Size (bp)
24

Negative
6731N

Sequence (5'-3')
CCC CCG CGT TTG GTG AAT GC

Nt Position
6731--6750

Size (bp)
20

Positive
6587P
6950P
7391P

Sequence (5'-3')
GAC CTG GAG AGT TGT GAT CG
ACA CCC AAC CAG CAT TAC GC
TGG TTC TGT GGC AAT TGT GT

Nt Position
6587--6606
6950--6969
7391--7411

Size (bp)
20
20
21

Negative
7111N
7468N

Sequence (5'-3')
GTG TAA CGC GGT CCT GAA GA
AAG TGG AGC GGT ACA TGA TG

Nt Position
7111--7130
7468--7487

Size (bp)
20
20

Positive
7720P
8107P
8493P
8842P
9206P
9570P

Sequence (5'-3')
CAT CGC AGT ACC ACT TCA GG
AGT CAA GGG TTA CGG TGA TT
ACA TCT ACG ACC CCT TTG AT
GCC CGT AGT GTC CAA TGA TA
GCC CTG GTA GGT GCT TCA TT
CAC CTG CTG GTT ATG CGA TC

Nt Position
7720--7739
8107--8126
8493--8512
8842--8861
9206--9225
9570--9589

Size (bp)
20
20
20
20
20
20

Negative
7831N
8177N
8543N
8907N
9299N
9614N
9850N

Sequence (5'-3')
GCA CAT CTT TGA CCA GGT GA
AGG CTG ACA AAA TGT CGG AG
AAG TCC TGC GCC TCT GCT TC
CGC TGA GCA CGG TTT ACT GA
ACG CGA CTC AGT GTC TCA GG
ACT TCT GTT GAG CTG AGG AG
AGT AAC AAC AGC CAA TGC AAG

Nt Position
7831--7850
8177--8196
8543--8562
8907--8926
9299--9318
9614--9633
9850--9870

Size (bp)
20
20
20
20
20
20
21
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Fragment 8
9745P-11442N

Fragment 9
11097P-12681N

Positive
9745P
10142P
10511P
10845P
11097P

Sequence (5'-3')
CGT GTG ATG GGC TTA GTG TGG TC
GAG TCT TCT AGC TAT GCT CC
ACA CGG GTT ATG AAT ATG CC
GGT GTA GGA ATT TTA TTA ATG
TTG TGG CTA TAG TTT ATG TTC

Nt Position
9745--9767
10142--10161
10511--10530
10845--10865
11097--11117

Size (bp)
23
20
20
21
21

Negative
10128N
10517N
10780N
11235N

Sequence (5'-3')
AAG ACT CCA GAT GGT CAA AGC
GAC CCC GGC ATA TTC ATA AC
TAA AAT TAC GAG CCT CTG CAG CG
CGT CAG CAT ACA CAA GGT GAA G

Nt Position
10128--10148
10517--10536
10780--10802
11235--11256

Size (bp)
21
20
23
22

Positive
11272P
11557P
11850P
12069P
12481P

Sequence (5'-3')
GCC AAT TTG CTG CGA TAT GAT G
CTA CCC TAT GCT ACG CTT ATT C
AGT GGC CTA CGG CAG CAA AGT C
TTT GTT ATA GTT GGA AGA GC
GAT TTA AAT CAA CAG GAG CG

Nt Position
11272--11293
11557--11578
11850--11871
12069--12088
12481--12500

Size (bp)
22
22
22
20
20

Negative
11442N
11691N
11995N
12370N
12681N

Sequence (5'-3')
ATG TCA TCA AAC AGC GCA CTG
CAG GCA TAA CCA CAG TAA TTG G
CTA ACC CAG ATG CTA CAT ACC
TCA TTG TAG CTT GTA GGC TG
GGT TCC TGG GTG GCT AAT AAC TAC

Nt Position
11442--11462
11691--11712
11995--12015
12370--12389
12681--12704

Size (bp)
21
22
21
20
24
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Appendix 4. Protocols of cycle sequencing
Reagent
BigDye Ready Reaction Mix (2.5X)
Half-Dye mix
EAV Sequencing Primer
(3.2 pmol/µl)
Template
Nuclease-free water
Final Volume

Volume Needed
1.5 µl
1.5 µl
1 µl
Variable, depends on template size
Variable
15 µl

Note: Perform cycle sequencing following the program below:
(1) Place the tubes in a thermal cycler and set to the correct volume.
(2) Perform an initial denaturation.
a. Rapid thermal ramp (1°C/second) to 96°C
b. 96°C for 1 min
(3) Repeat the following for 25 cycles:
• Rapid thermal ramp to 96°C
• 96°C for 10 seconds.
• Rapid thermal ramp to 50°C
• 50°C for 5 seconds.
• Rapid thermal ramp to 60°C
• 60°C for 4 minutes.
(4) Rapid thermal ramp to 4°C and hold until ready to purify.
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Appendix 5. Alignment of nucleotide sequences of VBS53 EAV (entire genome), Hela-EAVP10 (ORFs 2-7),
Hela-EAVP35 (entire genome), Hela-EAVP60 (ORFs 2-7) and Hela-EAVP80 (entire genome)
VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
100
GCTCGAAGTGTGTATGGTGCCATATACGGCTCACCACCATATACACTGCAAGAATTACTATTCTTGTGGGCCCCTCTCGGTAAATCCTAGAGGGCTTTCC
....................................................................................................
....................................................................................................
101
150
200
TCTCGTTATTGCGAGATTCGTCGTTAGATAACGGCAAGTTCCCTTTCTTACTATCCTATTTTCATCTTGTGGCTTGACGGGTCACTGCCATCGTCGTCGA
....................................................................................................
....................................................................................................
201
250
300
TCTCTATCAACTACCCTTGCGACTATGGCAACCTTCTCCGCTACTGGATTTGGAGGGAGTTTTGTTAGGGACTGGTCCCTGGACTTACCCGACGCTTGTG
....................................................................................................
....................................................................................................
301
350
400
AGCATGGCGCGGGATTGTGCTGTGAAGTGGACGGCTCCACCTTATGCGCCGAGTGTTTTCGCGGTTGCGAAGGAGTGGAGCAATGTCCTGGCTTGTTCAT
....................................................................................................
....................................................................................................
401
450
500
GGGACTGTTAAAACTGGCTTCGCCAGTTCCAGTGGGACATAAGTTCCTGATTGGTTGGTATCGAGCTGCCAAAGTCACCGGGCGTTACAATTTCCTTGAG
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

501
550
600
CTGTTGCAACACCCTGCTTTCGCCCAGCTGCGTGTGGTTGATGCTAGGTTAGCCATTGAAGAGGCAAGTGTGTTTATTTCCACTGACCACGCGTCTGCTA
....................................................................................................
....................................................................................................
601
650
700
AGCGTTTCCCTGGCGCTAGATTTGCGCTGACACCGGTGTATGCTAGCGCTTGGGTTGCGAGCCCGGCTGCTAACAGTTTGATAGTGACCATTGACCAGGA
.........................................................T....................................C.....
.........................................................T....................................T.....
701
750
800
ACAAGATGGGTTCTGCTGGTTAAAACTTTTGCCACCTGACCGCCGTGAGGCTGGTTTGCGGTTGTATTACAACCATTACCGCGAACAAAGGACCGGGTGG
....................................................................................................
....................................................................................................
801
850
900
CTGTCTAAAACAGGACTTCGCTTATGGCTTGGAGACCTGGGTTTGGGCATCAATGCGAGCTCTGGAGGGCTGAAATTCCACATTATGAGGGGTTCGCCTC
....................................................................................................
....................................................................................................
901
950
1000
AGCGAGCTTGGCATATCACAACACGCAGCTGCAAGCTGAAGAGCTACTACGTTTGTGACATCTCTGAAGCAGACTGGTCCTGTTTGCCTGCTGGCAACTA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1001
1050
1100
CGGCGGCTACAATCCACCAGGGGACGGAGCTTGCGGTTACAGGTGCTTGGCCTTCATGAATGGCGCCACTGTTGTGTCGGCTGGTTGCAGTTCTGACTTG
....................................................................................................
....................................................................................................
1101
1150
1200
TGGTGTGATGATGAGTTGGCTTATCGAGTCTTTCAATTGTCACCCACGTTCACGGTTACCATCCCAGGTGGGCGAGTTTGTCCGAATGCCAAGTACGCAA
....................................................................................................
....................................................................................................
1201
1250
1300
TGATTTGTGACAAGCAGCACTGGCGCGTCAAACGTGCAAAGGGCGTCGGCCTGTGTCTCGATGAAAGCTGTTTCAGGGGCACCTGCAATTGCCAACGCAT
...............................................................................C....................
...............................................................................T....................
1301
1350
1400
GAGTGGACCACCACCTGCACCCGTGTCAGCCGCCGTGTTAGATCACATACTGGAGGCGGCGACGTTTGGCAACGTTCGCGTGGTTACACCTGAAGGGCAG
....................................................................................................
....................................................................................................
1401
1450
1500
CCACGCCCCGTACCAGCGCCGCGAGTTCGTCCCAGCGCCAACTCTTCTGGAGATGTCAAAGATCCGGCGCCCGTTCCGCCAGTACCAAAACCAAGGACCA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1501
1550
1600
AGCTTGCCAAACCGAACCCAACTCAGGCGCCCATCCCAGCACCGCGCACGCGACTTCAAGGGGCCTCAACACAGGAGCCACTGGCGAGTGCAGGAGTTGC
....................................................................................................
....................................................................................................

1601
1650
1700
VBS53 EAV
TTCTGACTCGGCACCTAAATGGCGTGTGGCCAAAACTGTGTACAGCTCCGCGGAGCGCTTTCGGACCGAACTGGTACAACGTGCTCGGTCCGTTGGGGAC
Hela-EAVP10
Hela-EAVP35 ....................................................................................................
Hela-EAVP60
Hela-EAVP80 ....................................................................................................
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1701
1750
1800
GTTCTTGTTCAAGCGCTACCGCTCAAAACCCCAGCAGTGCAGCGGTATACCATGACTCTGAAGATGATGCGTTCACGCTTCAGTTGGCACTGCGACGTGT
....................................................................................................
....................................................................................................
1801
1850
1900
GGTACCCTTTGGCTGTAATCGCTTGTTTGCTCCCTATATGGCCATCTCTTGCTTTGCTCCTTAGCTTTGCCATTGGGTTGATACCCAGTGTGGGCAATAA
........................................................................................C...........
........................................................................................C...........
1901
1950
2000
TGTTGTTCTGACAGCGCTTCTGGTTTCATCAGCTAATTATGTTGCGTCAATGGACCATCAATGTGAAGGTGCGGCTTGCTTAGCCTTGCTGGAAGAAGAA
.....................................................G........................T.....................
.....................................................G........................T.....................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

2001
2050
2100
CACTATTATAGAGCGGTCCGTTGGCGCCCGATTACAGGCGCGCTGTCGCTTGTGCTCAATTTACTGGGGCAGGTAGGCTATGTAGCTCGTTCCACCTTTG
........................................................T...........................................
........................................................T...........................................
2101
2150
2200
ATGCAGCTTATGTTCCTTGCACTGTGTTCGATCTTTGCAGCTTTGCTATTCTGTACCTCTGCCGCAATCGTTGCTGGAGATGCTTCGGACGCTGTGTGCG
....................................................................................................
....................................................................................................
2201
2250
2300
AGTTGGGCCTGCCACGCATGTTTTGGGTTCCACCGGGCAACGAGTTTCCAAACTGGCGCTCATTGATTTGTGTGACCACTTTTCAAAGCCCACCATCGAT
....................................................................................................
....................................................................................................
2301
2350
2400
GTTGTGGGCATGGCAACTGGTTGGAGCGGATGTTACACAGGAACCGCCGCAATGGAGCGTCAGTGTGCCTCTACGGTGGACCCTCACTCGTTCGACCAGA
....................................................................................................
....................................................................................................
2401
2450
2500
AGAAGGCAGGAGCGATTGTTTACCTCACCCCCCCTGTCAACAGCGGGTCAGCGCTGCAGTGCCTCAATGTCATGTGGAAGCGACCAATTGGGTCCACTGT
..................................................................................A.................
..................................................................................T.................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

2501
2550
2600
CCTTGGGGAACAAACAGGAGCTGTTGTGACGGCGGTCAAGAGTATCTCTTTCTCACCTCCCTGCTGCGTCTCTACCACTTTGCCCACCCGACCCGGTGTG
....................................................................................................
....................................................................................................
2601
2650
2700
ACCGTTGTCGACCATGCTCTTTACAACCGGTTGACTGCTTCAGGGGTCGATCCCGCTTTATTGCGTGTTGGGCAAGGTGATTTTCTAAAACTTAATCCGG
....................................................................................................
....................................................................................................
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2701
2750
2800
VBS53 EAV
GGTTCCGGCTGATAGGTGGATGGATTTATGGGATATGCTATTTTGTGTTGGTGGTTGTGTCAACTTTTACCTGCTTACCTATCAAATGTGGCATTGGCAC
Hela-EAVP10
Hela-EAVP35 ....................................................................................................
Hela-EAVP60
Hela-EAVP80 ....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

2801
2850
2900
CCGCGACCCTTTCTGCCGCAGAGTGTTTTCTGTACCCGTCACCAAGACCCAAGAGCACTGCCATGCTGGAATGTGTGCTAGCGCTGAAGGCATCTCTCTG
.................................................................................................C..
.................................................................................................T..
2901
2950
3000
GACTCTCTGGGGTTAACTCAGTTACAAAGTTACTGGATCGCTGCCGTCACTAGCGGATTAGTGATCTTGTTGGTCTGCCACCGCCTGGCCATCAGCGCCT
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

3001
3050
3100
TGGACTTGTTGACTCTAGCTTCCCCTTTAGTGTTGCTTGTGTTCCCTTGGGCATCTGTGGGGCTTTTACTTGCTTGCAGTCTCGCTGGTGCTGCTGTGAA
..........G.........................................................................................
..........A.........................................................................................
3101
3150
3200
AATACAGTTGTTGGCGACGCTTTTTGTGAATCTGTTCTTTCCCCAAGCTACCCTTGTCACTATGGGATACTGGGCGTGCGTGGCGGCTTTGGCCGTTTAC
....................................................................................................
....................................................................................................
3201
3250
3300
AGTTTGATGGGCTTGCGAGTGAAAGTGAATGTGCCCATGTGTGTGACACCTGCCCATTTTCTGCTGCTGGCGAGGTCAGCTGGACAGTCAAGAGAGCAGA
....................................................................................................
....................................................................................................
3301
3350
3400
TGCTCCGGGTCAGCGCTGCTGCCCCCACCAATTCACTGCTTGGAGTGGCTCGTGATTGTTATGTCACAGGCACAACTCGGCTGTACATACCCAAGGAAGG
....................................................................................................
....................................................................................................
3401
3450
3500
CGGGATGGTGTTTGAAGGGCTATTCAGGTCACCGAAGGCGCGCGGCAACGTCGGCTTCGTGGCTGGTAGCAGCTACGGCACAGGGTCAGTGTGGACCAGG
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

3501
3550
3600
AACAACGAGGTCGTCGTACTGACAGCGTCACACGTGGTTGGCCGCGCTAACATGGCCACTCTGAAGATCGGTGACGCAATGCTGACTCTGACTTTCAAAA
....................................................................................................
....................................................................................................
3601
3650
3700
AGAATGGCGACTTCGCCGAGGCAGTGACGACACAGTCCGAGCTCCCAGGCAATTGGCCACAGTTGCATTTCGCCCAACCAACAACCGGGCCCGCTTCATG
....................................................................................................
....................................................................................................
3701
3750
3800
GTGCACYGCCACAGGAGATGAAGAAGGCTTGCTCAGTGGCGAGGTTTGTCTGGCGTGGACTACTAGTGGCGACTCTGGATCAGCAGTGGTTCAGGGTGAC
......C.........................................................................................T...
......C.........................................................................................C...
3801
3850
3900
GCTGTGGTAGGGGTCCACACCGGTTCGAACACAAGTGGTGTTGCCTACGTGACCACCCCAAGCGGAAAACTCCTTGGCGCCGACACCGTGACTTTGTCAT
....................................................................................................
....................................................................................................
3901
3950
4000
CACTGTCAAAGCATTTCACAGGCCCTTTGACATCAATCCCGAAGGACATCCCTGACAACATCATTGCCGATGTTGATGCTGTTCCTCGTTCTCTGGCCAT
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

4001
4050
4100
GCTGATTGATGGCTTATCCAATAGAGAGAGCAGCCTTTCTGGACCTCAGTTGTTGTTAATTGCTTGTTTTATGTGGTCTTATCTTAACCAACCTGCTTAC
....................................................................................................
....................................................................................................
4101
4150
4200
TTGCCTTATGTGCTGGGCTTCTTTGCCGCTAACTTCTTCCTGCCAAAAAGTGTTGGCCGCCCTGTGGTCACTGGGCTTCTATGGTTGTGCTGCCTCTTCA
....................................................................................................
....................................................................................................
4201
4250
4300
CACCGCTTTCCATGCGCTTGTGCTTGTTCCATCTGGTCTGTGCTACCGTCACGGGAAACGTGATATCTTTGTGGTTCTACATCACTGCCGCTGGCACGTC
....................................................................................................
....................................................................................................
4301
4350
4400
TTACCTTTCTGAGATGTGGTTCGGAGGCTATCCCACCATGTTGTTTGTGCCACGGTTCCTAGTGTACCAGTTCCCCGGCTGGGCTATTGGCACAGTACTA
................................................A...................................................
................................................A...................................................
4401
4450
4500
GCGGTATGCAGCATCACCATGCTGGCTGCTGCCCTCGGTCACACCCTGTTACTGGATGTGTTCTCCGCCTCAGGTCGCTTTGACAGGACTTTCATGATGA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

4501
4550
4600
AATACTTCCTGGAGGGAGGAGTGAAAGAGAGTGTCACCGCCTCAGTCACCCGCGCTTATGGCAAACCAATTACCCAGGAGAGTCTCACTGCAACATTGGC
....................................................................................................
....................................................................................................
4601
4650
4700
TGCCCTCACTGATGATGACTTCCAATTCCTCTCTGATGTGCTTGACTGTCGGGCCGTCCGATCGGCAATGAATCTGCGTGCCGCTCTCACAAGTTTTCAA
....................................................................................................
....................................................................................................
4701
4750
4800
GTGGCGCAGTATCGTAACATCCTTAATGCATCCTTGCAAGTCGATCGTGACGCTGCTCGTAGTCGCAGACTAATGGCAAAACTGGCTGATTTTGCGGTTG
....................................................................................................
....................................................................................................
4801
4850
4900
AACAAGAAGTAACAGCTGGAGACCGTGTTGTGGTTATCGACGGTCTGGACCGCATGGCTCACTTCAAAGACGATTTGGTGCTGGTTCCTTTGACCACCAA
...................................................................................................G
...................................................................................................G
4901
4950
5000
AGTAGTAGGCGGTTCTAGGTGCACCATTTGTGACGTCGTTAAGGAAGAAGCCAATGACACCCCAGTTAAGCCAATGCCCAGCAGGAGACGCCGCAAGGGC
............C.......................................................................................
............T.......................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

5001
5050
5100
CTGCCTAAAGGTGCTCAGTTGGAGTGGGACCGTCACCAGGAAGAGAAGAGGAACGCCGGTGATGATGATTTTGCGGTCTCGAATGATTATGTCAAGAGAG
....................................................................................................
....................................................................................................
5101
5150
5200
TGCCAAAGTACTGGGATCCCAGCGACACCCGAGGCACGACAGTGAAAATCGCCGGCACTACCTATCAGAAAGTGGTTGACTATTCAGGCAATGTGCATTA
....................................................................................................
....................................................................................................
5201
5250
5300
CGTGGAGCATCAGGAAGATCTGCTAGACTACGTGCTGGGCAAGGGGAGCTATGAAGGCCTAGATCAGGACAAAGTGTTGGACCTCACAAACATGCTTAAA
....................................................................................................
....................................................................................................
5301
5350
5400
GTGGACCCCACGGAGCTCTCCTCCAAAGACAAAGCCAAGGCGCGTCAGCTTGCTCATCTGCTGTTGGATCTGGCTAACCCAGTTGAGGCAGTGAATCAGT
....................................................................................................
....................................................................................................
5401
5450
5500
TAAACTGAGAGCGCCCCACATCTTTCCCGGCGATGTGGGGCGTCGGACCTTTGCTGACTCTAAAGACAAGGGTTTCGTGGCTCTACACAGTCGCACAATG
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

5501
5550
5600
TTTTTAGCTGCCCGGGACTTTTTATTTAACATCAAATTTGTGTGCGACGAAGAGTTCACAAAGACCCCAAAAGACACACTGCTTGGGTACGTACGCGCCT
....................................................................................................
....................................................................................................
5601
5650
5700
GCCCTGGTTACTGGTTTATTTTCCGTCGTACGCACCGGTCGCTGATTGATGCATACTGGGACAGTATGGAGTGCGTTTACGCGCTTCCCACCATATCTGA
....................................................................................................
....................................................................................................
5701
5750
5800
TTTTGATGTGAGCCCAGGTGACGTCGCAGTGACGGGTGAGCGATGGGATTTTGAATCTCCCGGAGGAGGCCGTGCAAAACGTCTCACAGCTGATCTGGTG
....................................................................................................
....................................................................................................
5801
5850
5900
CACGCTTTTCAAGGGTTCCACGGAGCCTCTTATTCCTATGATGACAAGGTGGCAGCTGCTGTCAGTGGTGACCCGTATCGGTCGGACGGCGTCTTGTATA
....................................................................................................
....................................................................................................
5901
5950
6000
ACACCCGTTGGGGCAACATTCCATATTCTGTCCCAACCAATGCTTTGGAAGCCACAGCTTGCTACCGTGCTGGATGTGAGGCCGTTACCGACGGGACCAA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

174

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

6001
6050
6100
CGTCATCGCAACAATTGGGCCCTTCCCGGAGCAACAACCCATACCGGACATCCCAAAAAGCGTGCTTGACAACTGCGCTGACATCAGCTGTGACGCTTTC
...................C................................................................................
...................T................................................................................
6101
6150
6200
ATAGCGCCCGCTGCAGAGACAGCCCTGTGTGATGATTTAGAGAAATACAACCTATCCACGCAGGGTTTTGTGTTGCCTAGTGTTTTCTCCATGGTGCGGG
....................................................................................................
....................................................................................................
6201
6250
6300
CGTACTTAAAAGAGGAGATTGGAGACGCTCCACCACTCTACTTGCCATCTACTGTACCATCTAAAAATTCACAAGCCGGAATTAACGGCGCTGAGTTTCC
....................................................................................................
....................................................................................................
6301
6350
6400
TACAAAGTCTTTACAGAGCTACTGTTTGATTGATGACATGGTGTCACAGTCCATGAAAAGCAATCTACAAACCGCCACCATGGCGACTTGTAAACGGCAG
....................................................................................................
....................................................................................................
6401
6450
6500
TACTGTTCCAAATACAAGATTAGGAGCATTCTGGGCACCAACAATTACATTGGCCTAGGTTTGCGTGCCTGCCTTTCGGGGGTTACGGCCGCATTCCAAA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

6501
6550
6600
AAGCTGGAAAGGATGGGTCACCGATTTATTTGGGCAAGTCAAAATTCGACCCGATACCAGCTCCTGACAAGTACTGCCTTGAAACAGACCTGGAGAGTTG
....................................................................................................
....................................................................................................
6601
6650
6700
TGATCGCTCCACCCCGGCTTTGGTGCGTTGGTTCGCTACTAATCTTATTTTTGAGCTAGCTGGCCAGCCCGAGTTGGTGCACAGCTACGTGTTGAATTGC
....................................................................................................
....................................................................................................
6701
6750
6800
TGTCACGATCTAGTTGTGGCGGGTAGTGTAGCATTCACCAAACGCGGGGGTTTGTCATCTGGAGACCCTATCACTTCCATTTCCAATACCATCTATTCAT
...................................................C................................................
...................................................C................................................
6801
6850
6900
TGGTGCTGTACACCCAGCACATGTTGCTATGTGGACTTGAAGGCTATTTCCCAGAGATTGCAGAAAAATATCTTGATGGCAGCCTGGAGCTGCGGGACAT
....................................................................................................
....................................................................................................
6901
6950
7000
GTTCAAGTACGTTCGAGTGTACATCTACTCGGACGATGTGGTTCTAACCACACCCAACCAGCATTACGCGGCCAGCTTTGACCGCTGGGTCCCCCACCTG
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

7001
7050
7100
CAGGCGCTGCTAGGTTTCAARGTTGACCCAAAGAAAACTGTGAACACCAGCTCCCCTTCCTTTTTGGGCTGCCGGTTCAAGCAAGTGGACGGCAAGTGTT
....................A...............................................................................
....................A...............................................................................
7101
7150
7200
ATCTAGCCAGTCTTCAGGACCGTGTTACACGCTCTCTGTTATACCACATTGGTGCAAAGAATCCCTCAGAGTACTATGAAGCTGCTGTTTCCATCTTTAA
....................................................................................................
....................................................................................................
7201
7250
7300
GGACTCCATTATCTGCTGTGATGAAGACTGGTGGACGGACCTCCATCGACGTATCAGTGGCGCTGCGCGTACTGACGGAGTTGAGTTCCCCACCATTGAA
....................................................................................................
....................................................................................................
7301
7350
7400
ATGTTAACATCCTTCCGCACCAAGCAGTATGAGAGTGCCGTGTGCACAGTTTGTGGGGCCGCCCCCGTGGCCAAGTCTGCTTGTGGAGGGTGGTTCTGTG
....................................................................................................
....................................................................................................
7401
7450
7500
GCAATTGTGTCCCGTACCACGTGGGTCATTGTCACACAACCTCGCTCTTCGCCAACTGCGGGCACGACATCATGTACCGCTCCACTTACTGCACAATGTG
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

7501
7550
7600
TGAGGGTTCCCCAAAACAGATGGTACCAAAAGTGCCTCACCCGATCCTGGATCATTTGCTGTGCCACATTGATTACGGCAGTAAAGAGGAACTAACTCTG
....................................................................................................
....................................................................................................
7601
7650
7700
GTAGTGGCGGATGGTCGAACAACATCACCGCCCGGGCGCTACAAAGTGGGTCACAAGGTAGTCGCCGTGGTTGCAGATGTGGGAGGCAACATTGTGTTTG
....................................................................................................
....................................................................................................
7701
7750
7800
GGTGCGGTCCTGGATCACACATCGCAGTACCACTTCAGGATACGCTCAAGGGCGTGGTGGTGAATAAAGCTCTGAAGAACGCCGCCGCCTCTGAGTACGT
....................................................................................................
....................................................................................................
7801
7850
7900
GGAAGGACCCCCTGGGAGTGGGAAGACTTTTCACCTGGTCAAAGATGTGCTAGCCGTGGTCGGTAGCGCGACCTTGGTTGTGCCCACCCACGCGTCCATG
....................................................................................................
....................................................................................................
7901
7950
8000
CTGGACTGCATCAACAAGCTCAAACAAGCGGGCGCCGATCCATACTTTGTGGTGCCCAAGTATACAGTTCTTGACTTTCCCCGGCCTGGCAGTGGAAACA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

8001
8050
8100
TCACAGTGCGACTGCCACAGGTCGGAACCAGTGAGGGAGAAACCTTTGTGGATGAGGTGGCCTACTTCTCACCAGTGGATCTGGCGCGCATTTTAACCCA
....................................................................................................
....................................................................................................
8101
8150
8200
GGGTCGAGTCAAGGGTTACGGTGATTTAAATCAGCTCGGGTGTGTCGGACCCGCGAGCGTGCCACGTAACCTTTGGCTCCGACATTTTGTCAGCCTGGAG
....................................................................................................
....................................................................................................
8201
8250
8300
CCCTTGCGAGTGTGCCATCGATTCGGCGCTGCTGTGTGTGATTTGATCAAGGGCATTTAYCCTTATTATGAGCCAGCTCCACATACCACYAAAGTGGTGT
...........................................................C.............................C..........
...........................................................C.............................C..........
8301
8350
8400
TTGTGCCAAATCCAGACTTTGAGAAAGGTGTAGTCATCACCGCCTACCACAAAGATCGCGGTCTTGGTCACCGCACAATTGATTCAATTCAAGGCTGTAC
.................................................................................................T..
.................................................................................................C..
8401
8450
8500
ATTCCCTGTTGTGACTCTTCGACTGCCCACACCCCAATCACTGACGCGCCCGCGCGCAGTTGTGGCGGTTACTAGGGCGTCTCAGGAATTATACATCTAC
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

8501
8550
8600
GACCCCTTTGATCAGCTTAGCGGGTTGTTGAAGTTCACCAAGGAAGCAGAGGCGCAGGACTTGATCCATGGCCCACCTACAGCATGCCACCTGGGCCAAG
....................................................................................................
....................................................................................................
8601
8650
8700
AAATTGACCTTTGGTCCAATGAGGGCCTCGAATATTACAAGGAAGTCAACCTGCTGTACACACACGTCCCCATCAAGGATGGTGTAATACACAGTTACCC
....................................................................................................
....................................................................................................
8701
8750
8800
TAATTGTGGCCCTGCCTGTGGCTGGGAAAAGCAATCCAACAAAATTTCGTGCCTCCCGAGAGTGGCACAAAATTTGGGCTACCACTATTCCCCAGACTTA
....................................................................................................
....................................................................................................
8801
8850
8900
CCAGGATTTTGCCCCATACCAAAAGAACTCGCTGAGCATTGGCCCGTAGTGTCCAATGATAGGTACCCGAATTGCTTGCAAATCACCTTACAGCAAGTAT
....................................................................................................
....................................................................................................
8901
8950
9000
GTGAACTCAGTAAACCGTGCTCAGCGGGCTATATGGTTGGACAATCTGTTTTCGTGCAGACGCCTGGTGTGACATCTTACTGGCTTACTGAATGGGTCGA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

9001
9050
9100
CGGCAAAGCGCGTGCTCTACCAGATTCCTTATTCTCGTCCGGTAGGTTCGAGACTAACAGCCGCGCTTTCCTCGATGAAGCCGAGGAAAAGTTTGCCGCC
....................................................................................................
....................................................................................................
9101
9150
9200
GCTCACCCTCATGCCTGTTTGGGAGAAATTAATAAGTCCACCGTGGGAGGATCCCACTTCATCTTTTCCCAATATTTACCACCATTGCTACCCGCAGACG
....................................................................................................
....................................................................................................
9201
9250
9300
CTGTTGCCCTGGTAGGTGCTTCATTGGCTGGGAAAGCTGCTAAAGCTGCTTGCAGCGTCGTTGACGTCTATGCTCCATCATTTGAACCTTATCTGCACCC
....................................................................................................
....................................................................................................
9301
9350
9400
TGAGACACTGAGTCGCGTGTACAAGATTATGATCGATTTCAAGCCGTGTAGGCTTATGGTGTGGAGAAACGCGACCTTTTATGTCCAAGAGGGTGTTGAT
....................................................................................................
....................................................................................................
9401
9450
9500
GCAGTTACATCAGCACTAGCAGCTGTGTCCAAACTCATCAAAGTGCCGGCCAATGAGCCTGTTTCATTCCATGTGGCATCAGGGTACAGAACCAACGCGC
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

9501
9550
9600
TGGTAGCGCCCCAGGCTAAAATTTCGATTGGAGCCTACGCCGCCGAGTGGGCACTGTCAACTGAACCGCCACCGGCTGGTTATGCGATCGTGCGGCGATA
....................................................................................................
....................................................................................................
9601
9650
9700
TATTGTAAAGAGGCTCCTCAGCTCAACAGAAGTGTTCTTGTGCCGCAGGGGTGTTGTGTCTTCCACCTCAGTGCAGACCATTTGTGCACTAGAGGGATGT
....................................................................................................
....................................................................................................
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

9701
9750
9800
AAACCTCTGTTCAACTTCTTACAAATTGGTTCAGTCATTGGGCCCGTGTGATGGGCTTAGTGTGGTCACTGATTTCAAATTCTATTCAGACTATTATTGC
..................................................
..........................C.........................................................................
..................................................
..........................T.........................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

9801
9850
9900
TGATTTTGCTATTTCTGTGATTGATGCAGCGCTTTTCTTTCTCATGCTACTTGCATTGGCTGTTGTTACTGTGTTTCTTTTCTGGCTCATTGTTGCCATC
..................................................................T.................................
..................................................................C.................................
..................................................................C.................................
..................................................................C.................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

9901
9950
10000
GGCCGCAGCTTGGTGGCGCGGTGTTCACGAGGTGCGCGTTACAGACCTGTTTAAGGATTTGCAGTGCGACAACCTGCGCGCGAAAGATGCCTTCCCGAGT
......A......T......................................................................................
......A......C......................................................................................
......T......C......................................................................................
......T......C......................................................................................
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10001
10050
10100
CTGGGATATGCTCTGTCGATTGGCCAGTCGAGGCTATCGTATATGCTGCAGGATTGGTTGCTTGCTGCGCACCGCAAGGAAGTTATGCCCTCCAATATCA
.................................................................................G..A...............
.................................................................................G..G...............
.................................................................................C..A...............
.................................................................................C..A...............

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10101
10150
10200
TGCCTATGCCCGGTCTTACTCCTGATTGCTTTGACCATCTGGAGTCTTCTAGCTATGCTCCATTTATCAATGCCTATCGGCAGGCAATTTTGAGTCAATA
........................................................G...............................C...........
........................................................A...............................C...........
........................................................A...............................C...........
........................................................A...............................C...........

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10201
10250
10300
CTCACAAGAGCTCCTGCTCGAAGCCATCAACTGTAAATTGCTTGCTGTGGTTGCACCGGCATTGTATCATAATTACCATCTAGCCAATTTGACCGGACCG
..................................................................T.................................
..................................................................T.................................
..................................................................C.................................
..................................................................T.................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10301
10350
10400
GCCACATGGGTCGTGCCTACAGTGGGCCAGTTGCACTATTATGCTTCTTCCTCTATTTTTGCTTCATCTGTGGAAGTGTTGGCAGCAATAATACTACTAT
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10401
10450
10500
TTGCATGCATACCACTAGTGACACGAGTGTACATCTCTTTTACGCGGCTAATGTCACCTTCCCGTCGCACTTCCAGCGGCACTTTGCCGCGGCGCAAGAT
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10501
10550
10600
TTTGTAGTGCACACGGGTTATGAATATGCCGGGGTCACTATGTTAGTGCACTTGTTTGCCAACTTGGTTCTGACATTTCCGAGCTTAGTTAATTGTTCCC
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10601
10650
10700
GCCCTGTGAATGTCTTTGCTAATGCTTCTTGCGTGCAAGTGGTTTGTAGTCATACCAACTCAACTACTGGCTTGGGTCAACTTTCTTTTTCCTTTGTAGA
...............................................A....................................................
...............................................G....................................................
...............................................G....................................................
...............................................G....................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10701
10750
10800
TGAAGATCTACGGCTGCATATYAGGCCTACTCTTATTTGTTGGTTTGCCTTGTTGTTGGTGCACTTTCTACCCATGCCACGCTGCAGAGGCTCGTAATTT
........T............T..............................................................................
........C............T..............................................................................
........C............T..............................................................................
........C............T..............................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10801
10850
10900
TACTTACATTAGTCATGGATTGGGCCACGTGCACGGTCATGAGGGGTGTAGGAATTTTATTAATGTCACTCATTCTGCATTTCTTTATCTTAATCCCACC
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

10901
10950
11000
ACTCTCACTGCGCCGGCTATAACTCATTGTTTACTTCTGGTTCTGGCAGCCAAAATGGAACACCCAAACGCTACTATCTGGCTGCAGCTGCAGCCGTTTG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

184

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11001
11050
11100
GGTATCATGTGGCTGGCGATGTCATTGTCAACTTGGAAGAGAATAAGAGGCATCCTTACTTTAAACTTTTGAGAGCGCCGGCTTTACCGCTTGGTTTTGT
.......................A............................................................................
.......................A............................................................................
.......................T............................................................................
.......................T............................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11101
11150
11200
GGCTATAGTTTATGTTCTTTTACGACTGGTACGTTGGGCTCAACAATGTTATCTATGATTGTATTGCTATTCTTGCTTTGGGGTGCGCCATCACATGCTT
......................................................................T.............................
......................................................................C.............................
......................................................................C.............................
......................................................................C.............................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11201
11250
11300
ACTTCTCATACTACACCGCTCAGCGCTTCACAGACTTCACCTTGTGTATGCTGACGGATCGCGGCGTTATTGCCAATTTGCTGCGATATGATGAGCACAC
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11301
11350
11400
TGCTTTGTACAATTGTTCCGCCAGTAAAACCTGTTGGTATTGCACATTCCTGGACGAACAGATTATCACGTTTGGAACCGATTGTAATGACACCTACGCG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11401
11450
11500
GTCCCAGTTGCTGAGGTCCTGGAACAGGCGCATGGACCGTACAGTGTGCTGTTTGATGACATGCCCCCTTTTATTTACTATGGCCGTGAATTCGGCATAG
.....................................C....................................T.........................
.....................................T....................................T.........................
.....................................T....................................C.........................
.....................................T....................................C.........................

185

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11501
11550
11600
TTGTGTTGGATGTGTTTATGTTCTATCCCGTTTTAGTTCTGTTTTTCTTATCAGTACTACCCTATGCTACGCTTATTCTTGAAATGTGTGTATCTATTCT
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11601
11650
11700
GTTTATAATCTATGGCATTTACAGCGGGGCCTACTTGGCCATGGGCATATTTGCGGCCACGCTTGCTATACATTCAATTGTGGTCCTCCGCCAATTACTG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11701
11750
11800
TGGTTATGCCTGGCTTGGCGATACCGCTGTACGCTTCACGCGTCCTTTATATCAGCTGAGGGGAAAGTGTACCCCGTAGACCCCGGACTCCCGGTTGCCG
...T............................................A...................................................
...C............................................A...................................................
...C............................................G...................................................
...C............................................A...................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11801
11850
11900
CCGCGGGCAATCGGTTGTTAGTCCCAGGTAGGCCCACTATCGATTATGCAGTGGCCTACGGCAGCAAAGTCAACCTTGTGAGGTTGGGGGCAGCTGAGGT
.................................................................................G..................
.................................................................................A..................
.................................................................................G..................
.................................................................................G..................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

11901
11950
12000
ATGGGAGCCATAGATTCATTTTGTGGTGACGGGATTTTAGGTGAGTATCTAGATTACTTTATTCTGTCCGTCCCACTCTTGCTGTTGCTTACTAGGTATG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................
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VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12001
12050
12100
TAGCATCTGGGTTAGTGTATGTTTTGACTGCCTTGTTCTATTCCTTTGTATTAGCAGCTTATATTTGGTTTGTTATAGTTGGAAGAGCCTTTTCTACTGC
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12101
12150
12200
TTATGCTTTTGTGCTTTTGGCTGCTTTTCTGTTATTAGTAATGAGGATGATTGTAGGTATGATGCCTCGTCTTCGGTCCATTTTCAACCATCGCCAACTG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12201
12250
12300
GTGGTAGCTGATTTTGTGGACACACCTAGTGGACCTGTTCCCATCCCCCGCTCAACTACTCAGATAGTGGTTCGCGGCAACGGGTACACCGCAGTTGGTA
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12301
12350
12400
ACAAGCTTGTCGATGGCGTCAAGACGATCACGTCCGCAGGCCGCCTCTTTTCGAAACGGGCGGCGGCGACAGCCTACAAGCTACAATGACCTACTGCGTA
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12401
12450
12500
TGTTTGGTCAGATGCGGGTCCGCAAACCGCCCGCGCAACCCACTCAGGCTATCATTGCAGAGCCTGGAGACCTTAGGCATGATTTAAATCAACAGGAGCG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

187

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12501
12550
12600
CGCCACCCTTTCGTCGAACGTACAACGGTTCTTCATGATTGGGCATGGTTCACTCACTGCAGATGCCGGAGGACTCACGTACACCGTCAGTTGGGTTCCT
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12601
12650
12700
ACCAAACAAATCCAGCGCAAAGTTGCGCCTCCAGCAGGGCCGTAAGACGTGGATATTCTCCTGTGTGGCGTCATGTTGAAGTAGTTATTAGCCACCCAGG
....................................................................................................
....................................................................................................
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

12701
AACC
....
....
....
....

Note:
1. The entire genome sequences (1-12704) of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80 were shown. The nucleotide
sequences (9751-12704, corresponding to ORFs 2-7 plus 3’ non-translated region) of Hela-EAVP10 and Hela-EAVP60 were
shown.
2. Y = T or C; R = A or G.

Appendix 6. Alignment of amino acid sequences of polyprotein 1ab of VBS53 EAV, Hela-EAVP35, and Hela-EAVP80
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VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1
50
100
MATFSATGFGGSFVRDWSLDLPDACEHGAGLCCEVDGSTLCAECFRGCEGVEQCPGLFMGLLKLASPVPVGHKFLIGWYRAAKVTGRYNFLELLQHPAFA
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

101
150
200
QLRVVDARLAIEEASVFISTDHASAKRFPGARFALTPVYASAWVASPAANSLIVTIDQEQDGFCWLKLLPPDRREAGLRLYYNHYREQRTGWLSKTGLRL
............................................V.......................................................
............................................V.......................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

201
250
300
WLGDLGLGINASSGGLKFHIMRGSPQRAWHITTRSCKLKSYYVCDISEADWSCLPAGNYGGYNPPGDGACGYRCLAFMNGATVVSAGCSSDLWCDDELAY
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

301
350
400
RVFQLSPTFTVTIPGGRVCPNAKYAMICDKQHWRVKRAKGVGLCLDESCFRGTCNCQRMSGPPPAPVSAAVLDHILEAATFGNVRVVTPEGQPRPVPAPR
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

401
450
500
VRPSANSSGDVKDPAPVPPVPKPRTKLAKPNPTQAPIPAPRTRLQGASTQEPLASAGVASDSAPKWRVAKTVYSSAERFRTELVQRARSVGDVLVQALPL
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

501
550
600
KTPAVQRYTMTLKMMRSRFSWHCDVWYPLAVIACLLPIWPSLALLLSFAIGLIPSVGNNVVLTALLVSSANYVASMDHQCEGAACLALLEEEHYYRAVRW
............................................................................G.......................
............................................................................G.......................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

601
650
700
RPITGALSLVLNLLGQVGYVARSTFDAAYVPCTVFDLCSFAILYLCRNRCWRCFGRCVRVGPATHVLGSTGQRVSKLALIDLCDHFSKPTIDVVGMATGW
....................................................................................................
....................................................................................................

701
750
800
SGCYTGTAAMERQCASTVDPHSFDQKKAGAIVYLTPPVNSGSALQCLNVMWKRPIGSTVLGEQTGAVVTAVKSISFSPPCCVSTTLPTRPGVTVVDHALY
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

801
850
900
NRLTASGVDPALLRVGQGDFLKLNPGFRLIGGWIYGICYFVLVVVSTFTCLPIKCGIGTRDPFCRRVFSVPVTKTQEHCHAGMCASAEGISLDSLGLTQL
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

901
950
1000
QSYWIAAVTSGLVILLVCHRLAISALDLLTLASPLVLLVFPWASVGLLLACSLAGAAVKIQLLATLFVNLFFPQATLVTMGYWACVAALAVYSLMGLRVK
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1001
1050
1100
VNVPMCVTPAHFLLLARSAGQSREQMLRVSAAAPTNSLLGVARDCYVTGTTRLYIPKEGGMVFEGLFRSPKARGNVGFVAGSSYGTGSVWTRNNEVVVLT
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1101
1150
1200
ASHVVGRANMATLKIGDAMLTLTFKKNGDFAEAVTTQSELPGNWPQLHFAQPTTGPASWCTATGDEEGLLSGEVCLAWTTSGDSGSAVVQGDAVVGVHTG
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1201
1250
1300
SNTSGVAYVTTPSGKLLGADTVTLSSLSKHFTGPLTSIPKDIPDNIIADVDAVPRSLAMLIDGLSNRESSLSGPQLLLIACFMWSYLNQPAYLPYVLGFF
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1301
1350
1400
AANFFLPKSVGRPVVTGLLWLCCLFTPLSMRLCLFHLVCATVTGNVISLWFYITAAGTSYLSEMWFGGYPTMLFVPRFLVYQFPGWAIGTVLAVCSITML
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1401
1450
1500
AAALGHTLLLDVFSASGRFDRTFMMKYFLEGGVKESVTASVTRAYGKPITQESLTATLAALTDDDFQFLSDVLDCRAVRSAMNLRAALTSFQVAQYRNIL
....................................................................................................
....................................................................................................
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VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1501
1550
1600
NASLQVDRDAARSRRLMAKLADFAVEQEVTAGDRVVVIDGLDRMAHFKDDLVLVPLTTKVVGGSRCTICDVVKEEANDTPVKPMPSRRRRKGLPKGAQLE
..........................................................R.........................................
..........................................................R.........................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1601
1650
1700
WDRHQEEKRNAGDDDFAVSNDYVKRVPKYWDPSDTRGTTVKIAGTTYQKVVDYSGNVHYVEHQEDLLDYVLGKGSYEGLDQDKVLDLTNMLKVDPTELSS
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1701
1750
1800
KDKAKARQLAHLLLDLANPVEAVNQLNLRAPHIFPGDVGRRTFADSKDKGFVALHSRTMFLAARDFLFNIKFVCDEEFTKTPKDTLLGYVRACPGYWFIF
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1801
1850
1900
RRTHRSLIDAYWDSMECVYALPTISDFDVSPGDVAVTGERWDFESPGGGRAKRLTADLVHAFQGFHGASYSYDDKVAAAVSGDPYRSDGVLYNTRWGNIP
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

1901
1950
2000
YSVPTNALEATACYRAGCEAVTDGTNVIATIGPFPEQQPIPDIPKSVLDNCADISCDAFIAPAAETALCDDLEKYNLSTQGFVLPSVFSMVRAYLKEEIG
................................P...................................................................
................................S...................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2001
2050
2100
DAPPLYLPSTVPSKNSQAGINGAEFPTKSLQSYCLIDDMVSQSMKSNLQTATMATCKRQYCSKYKIRSILGTNNYIGLGLRACLSGVTAAFQKAGKDGSP
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2101
2150
2200
IYLGKSKFDPIPAPDKYCLETDLESCDRSTPALVRWFATNLIFELAGQPELVHSYVLNCCHDLVVAGSVAFTKRGGLSSGDPITSISNTIYSLVLYTQHM
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2201
2250
2300
LLCGLEGYFPEIAEKYLDGSLELRDMFKYVRVYIYSDDVVLTTPNQHYAASFDRWVPHLQALLGFKVDPKKTVNTSSPSFLGCRFKQVDGKCYLASLQDR
....................................................................................................
....................................................................................................

190

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2301
2350
2400
VTRSLLYHIGAKNPSEYYEAAVSIFKDSIICCDEDWWTDLHRRISGAARTDGVEFPTIEMLTSFRTKQYESAVCTVCGAAPVAKSACGGWFCGNCVPYHV
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2401
2450
2500
GHCHTTSLFANCGHDIMYRSTYCTMCEGSPKQMVPKVPHPILDHLLCHIDYGSKEELTLVVADGRTTSPPGRYKVGHKVVAVVADVGGNIVFGCGPGSHI
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2501
2550
2600
AVPLQDTLKGVVVNKALKNAAASEYVEGPPGSGKTFHLVKDVLAVVGSATLVVPTHASMLDCINKLKQAGADPYFVVPKYTVLDFPRPGSGNITVRLPQV
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2601
2650
2700
GTSEGETFVDEVAYFSPVDLARILTQGRVKGYGDLNQLGCVGPASVPRNLWLRHFVSLEPLRVCHRFGAAVCDLIKGIYPYYEPAPHTTKVVFVPNPDFE
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2701
2750
2800
KGVVITAYHKDRGLGHRTIDSIQGCTFPVVTLRLPTPQSLTRPRAVVAVTRASQELYIYDPFDQLSGLLKFTKEAEAQDLIHGPPTACHLGQEIDLWSNE
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2801
2850
2900
GLEYYKEVNLLYTHVPIKDGVIHSYPNCGPACGWEKQSNKISCLPRVAQNLGYHYSPDLPGFCPIPKELAEHWPVVSNDRYPNCLQITLQQVCELSKPCS
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

2901
2950
3000
AGYMVGQSVFVQTPGVTSYWLTEWVDGKARALPDSLFSSGRFETNSRAFLDEAEEKFAAAHPHACLGEINKSTVGGSHFIFSQYLPPLLPADAVALVGAS
....................................................................................................
....................................................................................................

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

3001
3050
3100
LAGKAAKAACSVVDVYAPSFEPYLHPETLSRVYKIMIDFKPCRLMVWRNATFYVQEGVDAVTSALAAVSKLIKVPANEPVSFHVASGYRTNALVAPQAKI
....................................................................................................
....................................................................................................

191

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

VBS53 EAV
Hela-EAVP35
Hela-EAVP80

3101
3150
3176
SIGAYAAEWALSTEPPPAGYAIVRRYIVKRLLSSTEVFLCRRGVVSSTSVQTICALEGCKPLFNFLQIGSVIGPV......................................................................................................................................................-

192

Appendix 7. Alignment of amino acid sequences of E protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
E
E
E
E
E

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MGLVWSLISNSIQTIIADFAISVIDAALFFLMLLALAVVTVFLFWLIVAI
..................................................
..................................................
..................................................
..................................................

E
E
E
E
E

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
68
GRSLVARCSRGARYRPV..S.V..............S.A..............C.A..............C.A............-

Appendix 8. Alignment of amino acid sequences of GP2b protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
GP2b
GP2b
GP2b
GP2b
GP2b

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MQRFSFSCYLHWLLLLCFFSGSLLPSAAAWWRGVHEVRVTDLFKDLQCDN
..............L...............W...................
..............S...............R...................
..............S...............R...................
..............S...............R...................

GP2b
GP2b
GP2b
GP2b
GP2b

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
100
LRAKDAFPSLGYALSIGQSRLSYMLQDWLLAAHRKEVMPSNIMPMPGLTP
....................................VM............
....................................VV............
....................................LM............
....................................LM............

GP2b
GP2b
GP2b
GP2b
GP2b

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

101
150
DCFDHLESSSYAPFINAYRQAILSQYSQELLLEAINCKLLAVVAPALYHN
...........A......................................
...........T......................................
...........T......................................
...........T......................................

GP2b
GP2b
GP2b
GP2b
GP2b

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

151
200
YHLANLTGPATWVVPTVGQLHYYASSSIFASSVEVLAAIILLFACIPLVT
..................................................
..................................................
..................................................
..................................................

GP2b
GP2b
GP2b
GP2b
GP2b

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

201
228
RVYISFTRLMSPSRRTSSGTLPRRKIL............................................................................................................-
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Appendix 9. Alignment of amino acid sequences of GP3 protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
GP3
GP3
GP3
GP3
GP3

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MGRAYSGPVALLCFFLYFCFICGSVGSNNTTICMHTTSDTSVHLFYAANV
..................................................
..................................................
..................................................
..................................................

GP3
GP3
GP3
GP3
GP3

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
100
TFPSHFQRHFAAAQDFVVHTGYEYAGVTMLVHLFANLVLTFPSLVNCSRP
..................................................
..................................................
..................................................
..................................................

GP3
GP3
GP3
GP3
GP3

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

101
150
VNVFANASCVQVVCSHTNSTTGLGQLSFSFVDEDLRLHIRPTLICWFALL
..............S...................L...............
..............G...................P...............
..............G...................P...............
..............G...................P...............

GP3
GP3
GP3
GP3
GP3

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

151
164
LVHFLPMPRCRGS....................................................-
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Appendix 10. Alignment of amino acid sequences of GP4 protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
GP4
GP4
GP4
GP4
GP4

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MKIYGCIXGLLLFVGLPCCWCTFYPCHAAEARNFTYISHGLGHVHGHEGC
...Y...L..........................................
...H...L..........................................
...H...L..........................................
...H...L..........................................

GP4
GP4
GP4
GP4
GP4

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
100
RNFINVTHSAFLYLNPTTLTAPAITHCLLLVLAAKMEHPNATIWLQLQPF
..................................................
..................................................
..................................................
..................................................

GP4
GP4
GP4
GP4
GP4

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

101
150
GYHVAGDVIVNLEENKRHPYFKLLRAPALPLGFVAIVYVLLRLVRWAQQC
........I.........................................
........I.........................................
........F.........................................
........F.........................................

GP4
GP4
GP4
GP4
GP4

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

151
YL........-

Note: At position 8, X represents amino acid L (Leucine) or S (Serine).
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Appendix 11. Alignment of amino acid sequences of GP5 protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
GP5
GP5
GP5
GP5
GP5

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MLSMIVLLFLLWGAPSHAYFSYYTAQRFTDFTLCMLTDRGVIANLLRYDE
........F.........................................
........S.........................................
........S.........................................
........S.........................................

GP5
GP5
GP5
GP5
GP5

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
100
HTALYNCSASKTCWYCTFLDEQIITFGTDCNDTYAVPVAEVLEQAHGPYS
...............................................P..
...............................................L..
...............................................L..
...............................................L..

GP5
GP5
GP5
GP5
GP5

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

101
150
VLFDDMPPFIYYGREFGIVVLDVFMFYPVLVLFFLSVLPYATLILEMCVS
..................................................
..................................................
..................................................
..................................................

GP5
GP5
GP5
GP5
GP5

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

151
200
ILFIIYGIYSGAYLAMGIFAATLAIHSIVVLRQLLWLCLAWRYRCTLHAS
..................................................
..................................................
..................................................
..................................................

GP5
GP5
GP5
GP5
GP5

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

201
250
FISAEGKVYPVDPGLPVAAAGNRLLVPGRPTIDYAVAYGSKVNLVRLGAA
.I...........................................R....
.I...........................................K....
.V...........................................R....
.I...........................................R....

GP5
GP5
GP5
GP5
GP5

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

251
EVWEP....................-
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Appendix 12. Alignment of amino acid sequences of M protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
M
M
M
M
M

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MGAIDSFCGDGILGEYLDYFILSVPLLLLLTRYVASGLVYVLTALFYSFV
..................................................
..................................................
..................................................
..................................................

M
M
M
M
M

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
100
LAAYIWFVIVGRAFSTAYAFVLLAAFLLLVMRMIVGMMPRLRSIFNHRQL
..................................................
..................................................
..................................................
..................................................

M
M
M
M
M

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

101
150
VVADFVDTPSGPVPIPRSTTQIVVRGNGYTAVGNKLVDGVKTITSAGRLF
..................................................
..................................................
..................................................
..................................................

M
M
M
M
M

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

151
163
SKRAAATAYKLQ................................................-
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Appendix 13. Alignment of amino acid sequences of N protein of VBS53 EAV,
Hela-EAVP10, Hela-EAVP35, Hela-EAVP60, and Hela-EAVP80
N
N
N
N
N

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

1
50
MASRRSRPQAASFRNGRRRQPTSYNDLLRMFGQMRVRKPPAQPTQAIIAE
..................................................
..................................................
..................................................
..................................................

N
N
N
N
N

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

51
100
PGDLRHDLNQQERATLSSNVQRFFMIGHGSLTADAGGLTYTVSWVPTKQI
..................................................
..................................................
..................................................
..................................................

N
N
N
N
N

of
of
of
of
of

VBS53 EAV
Hela-EAVP10
Hela-EAVP35
Hela-EAVP60
Hela-EAVP80

101
111
QRKVAPPAGP........................................-
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Appendix 14. Thermacycling conditions for site-directed mutagenesis PCR reactions
1st mutagenesis PCR reaction
Component
Nuclease free water
10 × cloned Pfu reaction buffer
dNTPs (25 mM each dNTP)
pS45VBS53 DNA (1:20 dilution)
Positive primer C211156P (20 µM)
Negative mutagenic primer 11443N (20 µM)
Pfu Turbo DNA polymerase (2.5 U/µl)
Total reaction volume

Amount per reaction
40.6 µl
5.0 µl
0.4 µl
1.0 µl
1.0 µl
1.0 µl
1.0 µl
50 µl

2nd mutagenesis PCR reaction
Component
Nuclease free water
10 × cloned Pfu reaction buffer
dNTPs (25 mM each dNTP)
pS45VBS53 DNA (1:20 dilution)
1st mutagenesis PCR mixture
Reverse primer 11515N (20 µM)
Pfu Turbo DNA polymerase (2.5 U/µl)
Total reaction volume

Amount per reaction
36.6 µl
5.0 µl
0.4 µl
1.0 µl
5.0 µl
1.0 µl
1.0 µl
50 µl

Thermacycling conditions for both 1st and 2nd mutagenesis PCR
Seg 1

Seg 2

Seg 3
Seg 4
Seg 5

95ºC
40ºC
72ºC
95ºC
40ºC
72ºC
95ºC
50ºC
72ºC
72ºC
4ºC

2 min
1.5 min
6 min
45 sec
1.5 min
6 min
45 sec
45 sec
6 min
10 min
8
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1 cycle

5 cycles

34 cycles
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